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English Summary
The universe of small molecules is huge. Small molecules characterize organic chemical compounds, which are of
a much lower molecular weight than macromolecules like proteins or DNA. Small molecules are grouped into di erent
families according to their physico-chemical or functional properties, and they can be either natural (like lipids) or
synthetic (like drugs). Only a staggeringly low fraction of the small molecule universe has been characterize, and
very little is known about it. For instance, we know that lipids can play the role of sca olding and energy storage
compounds, and that they di erently compose biological membranes. However, we don’t know if it influences some
biological functions, including protein recruitment to membranes and cellular transport.
Chemical biology aims at utilizing chemicals in order to explore biological systems. Advances in synthesizing big
chemical libraries as well as in high-throughput screenings have led to technologies capable of studying protein-lipid
interactions at large scale and in physiological conditions. Therefore, answering such questions has become possible, but
it presents many new computational challenges. For instance, establishing methods capable of automatically classifying
interactions as binding or non-binding requiring a minimal interaction with human experts. Making use of unsupervised
clustering methods to identify clusters of lipids and proteins exhibiting similar patterns and linking them to similar
biological functions.
To tackle these challenges, I have developed a computational pipeline performing a technical and functional analysis
on the readouts produced by the high-throughput technology LiMA. Applied to a screen focusing on 94 proteins and 122
lipid combinations yielding more than 10,000 interactions, I have demonstrated that cooperativity was a key mechanism
for membrane recruitment and that it could be applied to most PH domains. Furthermore, I have identified a conserved
motif conferring PH domains the ability to be recruited to organellar membranes and which is linked to cellular transport
functions. Two amino acids of this motif are found mutated in some human cancer, and we predicted and confirmed
that these mutations could induce discrete changes in binding a nities in vitro and protein mis-localization in vivo.
These results represent milestones in the field of protein-lipid interactions.
While we are progressing toward a global understanding of protein-lipid interactions, data on the bioactivities of
small molecules is accumulating at a tremendous speed. In vitro data on interactions with targets are complemented
by other molecular and phenotypic readouts, such as gene expression profiles or toxicity readouts. The diversity
of screening technologies accompanied by big e orts to collect the resulting data in public databases have created
unprecedented opportunities for chemo-informatics work to integrate these data and make new inferences. For instance,
is the protein target profile of a drug correlated with a given phenotype? Can we predict the side e ects of a drug
based on its toxicology readouts? In this context, I have developed CART: a computational platform with which
we address major chemo-informatics challenges to answer such questions. CART integrates many resources covering
molecular and phenotypical readouts, and annotates sets of chemical names with these integrated resources. CART
includes state-of-the-art full-text search engine technologies in order to match chemical names at a very high speed
and accuracy. Importantly, CART is a scalable resource that can cope with the increasing number of new chemical
annotation resources, and therefore, constitutes a major contribution to chemical biology.
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Zusammenfassung
Das Universum von niedermolekularen Substanzen, sogenannter kleiner Moleküle, ist riesig. Kleine Moleküle charak-
terisieren organische chemische Substanzen, die ein sehr viel geringeres Molekulargewicht besitzen als Proteine oder
DNA. Kleine Moleküle sind anhand ihrer physikalisch-chemischen oder funktionellen Eigenschaften in verschiedene
Familien gruppiert und können entweder natürlichen (z.B. Lipide) oder synthetischen (z.B. Medikamente) Ursprungs
sein. Nur ein äußerst geringer Teil des Universums kleiner Moleküle wurde bis jetzt charakterisiert und das Wissen
darüber ist noch sehr begrenzt. Man weiß zum Beispiel, dass Lipide die Rolle von Gerüst- und Energiespeicher-
sto en übernehmen können und dass sie biologische Membranen in unterschiedlicher Art zusammensetzen. Es ist
jedoch nicht bekannt, ob dies in irgendeiner Weise biologische Funktionen beeinflusst, wie etwa die Rekrutierung
von Proteinen zur Membran oder den zellulären Transport. Chemische Biologie zielt darauf ab Chemikalien zu be-
nutzen, um biologische Systeme zu erforschen. Fortschritte in der Synthese großer chemischer Bibliotheken, sowie
in Hochdurchsatz-Screenings haben zu Technologien geführt, die in der Lage sind Protein-Lipid Interaktionen im
großen Maßstab und unter physiologischen Bedingungen zu untersuchen. Dadurch ist es ermöglicht worden der-
artige Fragen zu beantworten, dies bedeutet allerdings gleichzeitig neue computergestützte Herausforderungen, wie
z.B. die Einführung von Methoden, die automatisch Interaktionen als bindend oder nicht-bindend klassifizieren kön-
nen und dabei nur einen geringen Austausch mit Experten benötigen. Oder auch die Anwendung unüberwachter
Clustertechniken zur Identifizierung von Lipid- und Proteinclustern, die ähnliche Eigenschaften aufweisen und die
Verknüpfung dieser mit ähnlichen biologischen Funktionen. Um diese Herausforderungen in Angri  zu nehmen, habe
ich eine computergestützte Pipeline entwickelt, die technische und funktionelle Analysen von experimentellen Ausle-
seergebnissen durchführt, die mit Hilfe der Hochdursatz-Technologie LIMA gewonnen wurden. Angewandt auf einen
Screen, der 94 Protein- und 122 Lipidkombinationen aufweist und mehr als 10.000 Interaktionen umfasst, haben
wir Kooperativität als Schlüsselmechanismus für Membranrekrutierung nachgewiesen sowie, dass dies auf die meisten
PH-Domänen zutri t. Weitergehend habe ich ein konserviertes Motiv bestimmt, dass PH-Domänen die Fähigkeit
verleiht zu Organellenmembranen rekrutiert zu werden und mit zellulären Transportfunktionen verbunden ist. Zwei
Aminosäuren dieses Motivs wurden in Patienten einiger Krebsarten mutiert vorgefunden. Wir haben vorausgesagt
und bestätigt, dass diese Mutationen in vitro bestimmte Veränderungen der Bindungsa nität und in vivo falsche
Lokalisierungen von Proteinen verursachen können. Diese Ergebnisse stellen einen Meilenstein im Feld der Protein-
Lipid Interaktionen dar. Während wir uns immer mehr einem globalen Verständnis von Protein-Lipid Interaktionen
nähern, nehmen Daten über bioaktive kleine Moleküle in einer enormen Geschwindigkeit zu. In vitro-Daten über In-
teraktionen mit Zielmolekülen werden mit anderen molekularen und phänotypischen Ausleseergebnissen ergänzt, wie
z.B. Genexpressionsprofilen oder Toxizitätsausleseergebnissen. Die Vielfalt von Screening-Technologien zusammen mit
einem großen Bestreben vorhandene Daten in ö entlichen Datenbanken zusammenzuführen, haben bislang unbekannte
Möglichkeiten für chemo-informatische Arbeiten gescha en diese Daten zu integrieren und neue Erkenntnisse aus ihnen
zu gewinnen. Korreliert beispielsweise das Proteinzielprofil eines Medikaments mit dem Auftreten eines bestimmten
Phänotyps? Ist es möglich die Nebenwirkungen eines Medikaments anhand seiner toxikologischen Ausleseergebnisse
vorherzusagen? In diesem Zusammenhang habe ich CART entwickelt: eine computergestützte Plattform, mit der
großen chemo-informatischen Herausforderungen begegnet werden kann, um derartige Fragen zu beantworten. CART
integriert viele Datenbanken die molekulare und phänotypische Ausleseergebnisse umfassen und annotiert chemische
Namenslisten mit diesen integrierten Datenbanken. CART besitzt eine sich auf dem neusten Stand der Technik befind-
ende Volltext-Suchmaschinentechnologie, um chemische Namen mit einer sehr schnellen Geschwindigkeit und großen
Genauigkeit zuzuordnen. CART ist eine skalierbare Ressource, die für die zunehmende Anzahl neuer chemischer
Annotationsquellen ausgerichtet ist und somit einen wichtigen Beitrag in der chemischen Biologie leistet.
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Part I
Summary
In this part, I will introduce the importance of chemicals as tools for learning about
biological systems. I will describe how chemical biology and high-throughput technologies
have led to the generation of massive amounts of chemical screening data and I will
explain how computational analyses have helped to get a deeper understanding of
chemical e ects on biological systems.
xi
Introduction
Chemicals
T he set of all existing small molecules is colossus. Some estimates of this number approach 1060[1]. On average, one novel substance has been synthesized or isolated every 2.6 seconds since 2008
[2]. At the time when this thesis was written, over 91 millions of unique small molecules were registered
in a database maintained by the American Chemical Society [3], making it the most comprehensive
chemical repository. Small molecules are chemical substances that may be natural or synthetic and
some of them can modulate biological processes [4]. While they are of much lower weight than organic
macromolecules like DNA or proteins, lipids and most drugs fall within the definition of small molecules[5].
Only a tiny fraction of the universe of small molecules is characterized, and these have been grouped into
di erent families based on either their physico-chemical or functional properties. The physico-chemical
properties of amphiphilic chemicals, a class that includes lipids, force them in aqueous environments to
assemble into bilayers, which also form the sca olds for biological membranes and thus delineate biological
organelles and organisms. More than sca olding compounds, lipids also act as mediators and regulators
of many physiological functions, such as energy storage or cell signalling [6]. Another class of chemicals
defined both by its functional and physico-chemical properties is the class of drugs. Natural products
extracted from plants or bacteria have been used since the dawn of time by healers because of their
specific e ects on the human organism. As a result of modern pharmacology and medicinal chemistry
research, high-throughput technologies have increased the number of potentially bioactive compounds to
another dimension [7] [8]. Aside from their value as healing compounds, these small molecules can also
be used to perturb physiologically normal organisms, so they can be systematically applied as tools to
unravel the molecular responses and ultimately the wiring diagrams of living systems [4] [9].
Chemical biology
The foundations
T he twentieth century has seen the raise of molecular biology approaches, which allowed us to under-stand the chemical reactions fundamentals to living organisms down to the underlying mechanistic
principles [10]. Specific knock-outs of certain genes as a means of perturbing a biological system have
been pivotal in understanding the role of those genes in the physiology of the genetically altered organism
[11]. In the last decade, chemicals have been increasingly used to perturb biological systems [4] [9] [12]
as an alternative method to genetic engineering. One advantage of using chemicals over genetic engi-
neering is that it is easier to maintain the temporal control of the system’s physiology, as the incubated
perturbing chemicals can be washed away to return to an unperturbed state. Pioneer studies have shown
that small molecules extracted from coal-tar could interact with specific cells and tissues [13]. Based on
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this observation, Paul Ehrlich discovered that another small molecule (methylene blue) was capable of
selectively staining nerve cells [14] and postulated for the first time that small molecules could be of great
value to study membrane receptors specific to cell types and tissues [15]. By demonstrating that small
molecules are endowed with a biological activity, and that they interact with specific targets within an
organism, these studies have set the foundations of modern chemical biology. It became clear that small
molecules could also help unraveling many other aspects of biological systems, yet it took several years
before some of the chemical diversity was gathered in the first chemical libraries. While the first estab-
lished chemical libraries were the propriety of pharmaceutical companies, later ones became available to
academic researchers at the end of the twentieth century, when rapid synthesis of small molecules was
invented [16] [17]. Chemical libraries size grew, and with that the hope of getting a more comprehensive
understanding of biological systems. However, testing the e ects of these chemical libraries, some of
which contain up to millions of small molecules, required new high throughput screens performing many
assays in parallel[18].
High-throughput screens
H igh-throughput screening is a technical advance that has made it possible to move beyond studyingisolated biological phenomena using a reductionist approach to the comprehensive investigation
of biological systems as a whole [19]. This paradigm has been fuelled by advances, mostly in the indus-
trial sector, which enabled the rapid synthesis and screening of big chemical libraries. High-throughput
screens of chemical libraries are often divided in two categories, depending on the nature of the readout.
High-throughput screens yielding molecular readouts are often referred as target-based screens, and those
yielding phenotypic readouts as phenotypic-based screens [4]. These screening e orts engendered a colos-
sus amount of data on chemical interaction profiles and phenotypic e ects. While most of the data is still
kept proprietary [20], in recent years, high-throughput screening technologies have also been adopted by
academic researchers [21], who deposited their data in public databases. For instance, two years after the
creation of the Molecular Libraries Screening Centers Network (MLSCN), 256 MLSCN assays spanning
more than 140,000 chemicals have been deposited in PubChem [22]. In addition to this, there exist at
least 17 publicly available databases focused on biological activities of chemicals [23] [Supplementary
Table V.1].
Computational analysis of target-based screens
T arget-based screens are utilized to identify ligands of a protein or a group of proteins. A numberof techniques have been developed to that purpose and make use of immobilized ligands on solid
surface [24]. For instance, Birk et al. successfully utilized such an approach to measure the binding profile
of many antibodies to immobilized triazines and screened for 384 compounds to look for those acting as
thrombin inhibitors. Other screening setups tend to invert the surface-based method and make use of
immobilized proteins [25]. Studies based on these protein arrays have globally mapped interactions in the
yeast proteome or discovered novel human protein-protein interactions [26]. Such target-based screens
have also led to the postulation of new hypotheses. For instance, are there rules governing the binding of
these proteins to the screened chemicals? How do these interactions take part in a particular biological
process? Are some proteins more important than others? Are some of these interactions a ected in
a certain disease? Target-based screens focusing on protein-lipid interactions and yielding quantitative
readouts already exist [27] [28] at a throughput suitable for answering such questions. Therefore, there
is an immediate need for computational analysis to pair with these technologies in order to address these
questions. These analyses encompass assessing the reproducibility of such screens and of detecting possible
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bias in the measurement of protein-chemical interactions. Often protein (or lipid) concentration used can
vary from one replicate to the other and a precise quantification of the influence of this parameter on
the measured readout is essential, as well as a normalization method if any concentration e ect is found.
Another computational challenge associated with such screens is the automatic classification of interaction
as a binding or a non-binding event, ideally requiring minimal interaction with human experts. Automatic
analysis assigning a quality index to each interaction has the advantage that subsequent analysis can be
restricted to the subset of bona fide interactions. The biggest computational challenge however lies
in the functional analysis of such readouts. To identify groups of proteins or lipids exhibiting similar
binding patterns, which result in similar biological functions, unsupervised learning methods including
hierarchical clustering analysis or principal component analysis can be used. Finding sequence motifs
in proteins characteristic of certain binding properties requires sequence analysis of protein clusters.
However, this can be a daunting computational task given the low sequence identity of some protein
families [29]. As a specific example for the analysis of one such protein lipid interaction screen, I describe
in part II of this dissertation how I have addressed these challenges in analysing a novel high-throughput
protein-lipid interaction screen.
Data integration in chemo-informatics
W hile our understanding of protein-lipid interactions is still very incomplete, data on the bioac-tivities of small drug-like molecules is accumulating at a tremendous speed. In vitro data on
interactions with protein targets, including therapeutic targets, o -targets and metabolizing enzymes,
are complemented by phenotypic-based screens including multivariate cell-based and in vivo assays, such
as expression response of cell lines and animal models to chemical perturbations [30]. The diversity of
screening technologies accompanied by big e orts to collect the resulting data in public repositories [31]
[32], have created unprecedented opportunities for chemo-informatics work aiming at integrating these
heterogeneous data in order to make inferences on the complex e ects of chemicals on biological systems.
For instance, if each compound of a chemical family or library is annotated on one side in terms of
proteins it binds to, and on the other side in terms of phenotypes it induces, then one can attempt to
predict whether the recruitment to any specific protein or group of proteins is correlated with a particular
propensity to induce a given phenotype, or vice versa (conceptually illustrated in Figure 1). In applying
this logic, Rihel et al. brought phenotypic-based screens to the whole-organism level, and demonstrated
that clustering chemicals according to their behavioural phenotypes observed in zebrafish was highly cor-
related of drug’s bioactivity in higher organisms including mouse or humans [33]. In applying a similar
logic, Fliri et al made use of hierarchical clustering analysis to show that the target profile of some drugs
was highly predictive of their side e ects [34]. Campillos, Kuhn et al. have demonstrated that the side
e ect similarity of two drugs could be utilized to predict whether they share a target, which has important
implications in drug repurposing [35]. By integrating phenotypic data to known drug-target interactions,
Kuhn et al revealed that a substantial proportion of drug side e ects are primarily caused by interac-
tions with specific proteins [36]. Associated with the opportunities to integrate these various chemical
databases are the big chemo-informatics challenges to develop tools for linking disparate chemical iden-
tifiers and naming conventions in order to bridge multiple databases containing information of chemical
actions at various scales. These form the basis for subsequent data mining, clustering and visualization.
Together integrative computational analysis tools will help pave the way forward to acquiring a better
systemic understanding of chemicals’ e ects on living systems [23].
In this context I present work (in part III of this dissertation) on a software tool developed for the
purpose of integrating diverse information on chemical properties collected from various databases with
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Figure 1: Hypothetical illustration of a biological activity matrice . The matrice represents
six PH domains whose binding properties have been measured against ten chemicals. A
number above 1 implies an interaction between the PH domain and the chemical. If
the chemicals highlighted in gray are all capable of inducing a particular phenotype, the
PH domain PH1 and PH2 are most likeley responsible for those chemicals to induce this
particular phenotype: they are the only PH domain capable of binding all four chemicals.
Such biological activity matrices can thus be used to determine which proteins are involved
in specific biological processes.
the goal of enabling multi-faceted annotation and enrichment analysis of chemicals. With this work
we have addressed a major chemo-informatics challenge related to data on chemical bioactivities being
scattered across many di erent databases. There exists no central repository, in which each chemical
substance is referred to by a unique and universally accepted identifier, but there is rather many names
for each chemical entity (including brand names) and structural identifiers are generally also not free
of ambiguities. Therefore, matching chemical names into a common universe that spans most chemical
annotation databases, is a major hurdle for integrative analysis and ideally a name matching algorithm
should be accurate and fast enough to handle large sets of chemicals. Importantly, this framework needs
to be scalable to cope with the constantly increasing number of new chemical annotations resources.
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Summary
T echnological advances have led to high-throughput technologies, which when applied to chemicallibraries can generate a myriad of multi-parametric readouts, from target profiles to phenotypic
outcomes. The availability of these data in public repositories have opened a new area of research in
chemical biology, largely driven by computational analysis aiming to unravel the roles played by the
plethora of chemical compounds in the context of physiology and diseases of living organisms.
Thesis outline
A s such, two layers are being analyzed during this PhD. A first project on large-scale chemicalbiology was initiated in collaboration with the experimental group of Dr. Anne-Claude Gavin.
Her team invented a high-throughput technology systematically charting tens of thousands of protein-lipid
interactions in a physiological context [28]. My first contribution was to develop a computational pipeline
realizing a technical assessment of this new method by working on a dataset produced by Dr Antoine-
Emmanuel Saliba and Dr Ivana Vonkova [28] [37]. Namely, this technical analysis pipeline is meant to
calibrate and evaluate the di erent readouts produced by this technology. My second implication aimed
at coupling computational biology approaches to the readouts produced by this technology, in order to
establish a lipid-binding landscape of PH domains and to get a deeper understanding of their biology and
how lipid regulate cell physiology. A second project focused data integration in the context of chemical-
biology and how to make sense of chemical sets [38]. Chemical high-throughput screens are flowering
and the need for a computational framework capitalizing chemical resources that can identify common
biological themes amongst chemicals urges, which is the focus of the second project [39].
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Part II
Development of a computational
pipeline to analyze readouts from a
high-throughput protein-lipid
interaction screen
1

Part II
Summary
In this part, I present the results of a computational analysis pipeline developed to
process and analyze readouts from LiMA [28], a platform enabling the high-throughput
study of protein-lipid interactions in physiological conditions. This project contributes to
the field of large-scale chemical biology in the sense that it provides a reusable [37]
computational platform analyzing readouts produced by a high-throughput technology
aiming at understanding how chemicals a ect biological systems through their
interactions with proteins. The first part of the results focuses on the the technical part
of the computational analysis pipeline. These results are published in the LiMA
publication Saliba,Vonkova, Deghou et al [28]. The second part of the results focuses on
the functional part of the computational analysis pipeline. I applied it to a screen
performed by Dr Ivana Vonkova and Dr Antoine-Emmanuel Saliba. The results of this
analysis are currently in review in Science (Vonkova, Saliba, Deghou et al [38]). All the
data used for this analysis as well as the experimental validations results have been
produced by Dr Ivana Vonkova and Dr Antoine-Emmanuel Saliba. I conceived and wrote
the entire computational analysis pipeline and produced the results presented here, which
were then discussed and confirmed with Dr Ivana Vonkova, Dr Anne-Claude Gavin, Dr
Antoine-Emmanuel Saliba and Dr Peer Bork. Lastly, the entire computational analysis
pipeline itself will be published as part of the LiMA experiment and analysis workflow
publication currently in preparation for Nature Protocol and for which I am writing the
computational part.
A quantitative liposome microarray to systematically characterize protein-lipid interactions
Saliba, A.E., Vonkova, I, Deghou, SL et al Nature methods, 2014
Lipid cooperativity as a general membrane-recruitment principle of PH domains
Vonkova, I, Saliba, A.E., Deghou, SL et al Science, In review
A protocol for the systematic and quantitative measurement of protein-lipid interaction
using the liposome microarray-based assay (LiMA)
Saliba, A.E., Vonkova, I, Deghou, SL et al Nature protocols, Manuscript
(First author(s) to be decided)
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Chapter 1
Introduction
1.1 Lipids
L ipids are chemicals that constitute the keystones of every biological compartment. Eukaryoticcells are composed of thousands of structurally di erent lipids and 5% of the average Eurkaryotic
genome comprises of genes involved in lipid biosynthesis [40]. Biological membranes contain lipids of var-
ious size and charge that are organized into a bilayer comprising a hydrophobic core and highly polarized
interfacial region [41]. The membranes of cellular organelles are primarily composed of phospholipids
(PIPs), glycerolipids, sphingolipids, sterols, and other lipid species in varying concentrations.
Many lipids are produced in the endoplasmic reticulum including; PIPs, glycerol, cholesterol as well as
precursors of sphingolipids including ceramide (Cer). Once synthesized these lipids are exported to other
organelles, in which they will be modified or directed to the plasma membrane. In the Golgi apparatus
other sphingolipids including sphingomyeline, lactoglyceramide and glycosphingolipids are synthesized
and transported to the plasma membrane. Phopshatidylinositols (PIPs) head groups contain several
phosphorylation sites giving birth to mono, bi and tri phosphorylated PIPs. The diversity of the PIPs
and their cellular repartitions make them very good markers of organellar and plasmic membranes.
DOPI45P2 is the most abundant PIP and is characteristics of the plasma membrane. DOPI4P is the
second most abundant PIP and is located in the membranes of the Golgi apparatus as well as in the
plasmic membrane. DOPI35P2 and DOPI3P are on the other side scarcer and solely present in the
membranes of lysozomes/endomes and early endosomes, respectively [42].
Eukaryotics cells possess an enormous catalogue of lipids with an almost unique repartition across mem-
branes, which is far away from being completely depicted. It is still very unclear how the lipid composition
is maintained and what implications it has on the global organization of the proteome and subsequent
cellular functions mediated through protein-lipid interaction, including signalization and protein trans-
port.
1.2 Lipid Binding Domains
A plurality of biological processes, crucial for the cell including cell signaling, vesicle budding, andmembrane tra cking occur at the biological membranes. The attention paid to the critical role
played by membrane-protein interactions in these processes has become more obvious in the past decade
[43] [44]. The first lipid binding domain (LBD) has been discovered in 1989 and since then structural first
and then computational analysis have identified at least 10 additional domains conferring to a protein the
ability to bind lipids [45] [46]. The di erent families of LBDs have developed di erent ways to selectively
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target membranes, but most of them must contend with the lipid content and physicochemical properties
of plasmic and organellar phospholipid bilayers. Some LBDs like C2 domains and MARCKS ED domains
have evolved to selectively target membrane based on their bulk electrostatic properties. Others including
PH domains require stereospecific mode of lipid recognition and have a high a nity and selectivity for
particular lipid head groups. Finally, some LBDs including FYVE, P40-PX pr P47-PX can also display
multivalent lipid head group binding properties, also known as cooperative binding (Figure 1). Proteins
capable of targeting membranes often possess more than one LBD in their sequence sand are thus subject
to combine several ways of selectively target membranes, could it be via protein-protein interactions
(Figure 1) [47] [45].
Figure 1: LBDs mode of recruitment to biological membranes (a) Some LBDs can recog-
nize in a specific or unspecific way particular physical or chemical features that charac-
terize the variety of biological membranes. (b) Other LBDs bind membranes by synergis-
tically cooperating with other LBDs.
1.3 PH domains
P H domains are one of the most studied lipid binding domains [48] [49] [50]. They were identifiedin 1993 as conserved modules of 120 amino acids with a weak degree of homology to a protein
kinase C substrate in platelets, the pleckstrin [51] [52]. There are about 250 human proteins known to
contain at least one PH domain, making them the most common LBD in the human genome, but also in
yeast [53]. PH domains share a common structural core, despite a very high sequence variability (20%
sequence identity, [50]). It consists of seven-stranded — cylinders capped at the C-terminal end by an –
helix (Figure 3). The loops, which correspond to the regions located within the — strands are extremely
variable within subfamilies of PH domains in their structure, length and composition. Many studies have
demonstrated that PH domains preferentially bind PIPs [54] [55] [56] [57] [58] [59] and more recent studies
have shown their lack of specificity [60] [61] [62]. Their exacerbated binding towards PIPs over other lipid
families is thought to be driven by the higher negative charge of the PIPs head groups [60], and even if
some PH domains-PIPs interactions appear to be driven by stereospecific interactions, the neighboring
electrostatic potential is thought to be primordial in orientating the PH domain toward the membrane
[63]. The existence of di erent modes of interaction and determinism for binding specificities has been
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proposed for a handful of PH domains. Namely, the crystal structures of some PH domains including
PLCDELTA, PKB, Dapp1, and Grp have led to the identification of residues conferring PH domains the
ability to bind certain PIPs. Those residues were baptized “signature motif” Figure 2 [64] [65] [66] [67].
Mutational analyses have indicated that (with the exception of PLCDELTA) the vast majority of the
interactions with PIPs head groups are mediated by the signature motif.
Figure 2: Schematic representation of the Basic Sequence Motif (BSM) required for PH
domain to be able to bind PM PIPs.
PH domains have also been shown to cooperatively bind lipids and proteins. The PH domain of
the protein —-ARK was shown to hold two binding sites through which the protein could simultaneously
and e ectively interact with DOPI45P2 and G—“ in order to be recruited at the plasmic membrane [68].
Few instances of PH domains have also been demonstrated as being able to simultaneously bind two
lipids belonging to two di erent families (PIPs and sphingolipids) [27]. Namely, the interaction strength
between the PH domain of Slm1 and the two lipids DOPI45P2 and DHS1P was much higher than what
one could have expected from the two individual binding event to DOPI45P2 and DHS1P. The PH
domains of the proteins PDK1 and AKT1 also displayed similar cooperative binding mechanisms to the
pair of lipids DOPI345P3 and PS [69] [70]. PH domains contain two known binding sites, the canonical
and non-canonical binding site. They both flank the —1-—2 loop and are rich in basic amino acids favoring
interactions with PIPs head groups (negatively charged) capable of recruiting many lipid ligands [64] [65]
[71]. The existence of two binding sites capable of accommodating several ligands could probably explain
the three instances of cooperative binding mechanisms that have been observed. PH domains are involved
in a myriad of biological processes, including cell signaling, cytoskeletal rearrangements, lipid transport,
metabolic processes, protein oligomerization and many others [48]. The binding mechanisms ruling PH
domain recruitment to PIPs and cellular membranes is crucial for the fine regulation of these biological
processes and the unperturbed continuation of a cell physiology. As a matter of fact, many proteins
involved in diseases including diabetes, cardiovascular diseases and cancer are found mutated within
their PH domain. In most of these cases, the mutations leads to natural variants either unable to bind a
membrane it is supposed to or dramatically increase the binding to a particular membrane [72] [73] [74]
[75] [76] [77]. The binding mechanisms dictating the recruitment of PH domains to biological membranes
are more complex than what has already been postulated. The small number of proteins that was used
to extract the signature motif needs to be increased in order to include PH domains displaying other
binding properties. Mutations a ecting or changing the membrane specificity of a PH domain clearly
point towards residues that are not part of the signature motif and that account for a certain membrane
specificity that still remain to be unraveled. PH domains capability to cooperatively bind two di erent
lipids has indeed been mentioned, yet its incidence and implication in terms of biological processes are
question that cannot be addressed with the current experimental and computational methods.
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Figure 3: The cartoon structure represents the structure of the Osh3 PH domain (PDB
ID: 2D9X), which is composed of seven — sheets and one – helix. The —1-—2 loop delimits
the two known binding pockets.
1.4 Studying protein-lipid interactions
M ost of what is known in the field of protein-lipid interaction comes from single case study to whichall PH domains have been generalized. These findings are based on a very small subset of PH
domains. The discovery of the signature motif is a prime example in which the authors used a handful of
proteins to extract a motif that they subsequently generalized to all PH domains [78]. Plenty of methods
have been developed since then in order to study more specific protein-lipid interactions (Figure 4). None
of them fulfill though the criteria of studying them at large-scale, in conditions close to physiological
concentrations and with a membrane lipid constitution similar to that of a cell. Moreover, there exist
no computational analysis methods for analyzing readouts from protein-lipid interaction screens that
could answer some of the questions posed in the introduction. Current in vitro and in vivo methods
make use of fluorescent microscopy coupled to mass spectrometry readouts. These methods are known to
produce a lot of noise and are not very reproducible. Methods making use of microarrays are well suited
to study protein-lipid interactions at large scale. The first study probed the entire yeast proteome [79]
and incubated the microarray with five di erent liposomes containing members of the PIP lipid family.
This study represented a first tour de force in which many lipid binding proteins deprived from any
known LBD were found, including the Kinase associated domain. This microarray technique o ered the
possibility to study an entire proteome from one sample, but was extremely restricted with regards to
the possible number of testable lipids. Other techniques making use of microarrays directly spotted lipids
(PIPS) and to study the P binding properties of yeast PH domains [62]. This analysis unexpectedly
showed that few PH domains were capable of binding PIPs. Those that could target PIPs would show no
particular specificity. The main weakness of this assay lied in the absence of a quantitative readout and
therefore in the impossibility of undertaking any quantitative or statistical analysis of the PH domain’s
PIPs binding profile. Recently, Gallego et al developed a lipid array accommodating more lipids [27] with
the help of which they measured the lipid binding profile of 172 proteins. This high-throughput screen
identified a new lipid binding domain, the CRAL-TRIO (cryptic lipid-binding). Additionally, this screen
demonstrated that one PH domain (Slm1) was capable to cooperatively bind to DOPI45P2 and DHS1P.
The main drawback of this assay lied in the high concentration of lipid of interest, which probably yielded
7
Part II Chapter 1 – Introduction Chapter 1 – Introduction
a very high rate of false positive interactions. Regardless of the inherent drawbacks of each systematic
method employed to study protein-lipid interactions, they have all contributed to the discovery of new
interactions, new binding domains, or binding properties. However, there exist no technology enabling the
precise measurement of lipid-protein interactions under physiological conditions at large scale and mixing
several lipid of interest into a single liposome. Such a technology would need to output a quantitative
readout representative of the protein dissociation constant, comparable between proteins. Only under
these conditions could we conceive statistical and computational methods drawing a precise picture of
the PH domain-lipid interaction landscape.
Figure 4: High-throughput assays utilized to study protein-lipid interactions
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Chapter 2
Results
2.1 LiMA
2.1.1 concept
The amount of systematic studies mentioning the importance of high-throughput approaches in the field
of protein-lipid interactions grows rapidly [27] [80] [81]. Yet, protein-lipid interactions remain still poorly
characterized on a systematic level because of the lack of methods capable of detecting interactions on a
large-scale. We recently introduced Liposome Microarray-based Assay (LiMA) Figure 1 that allows the
capture of more than 700 protein lipid interactions per day in a quantitative, automated, multiplexed
and high-throughput manner. The core technology of LiMA relies on the in vitro parallel production of
artificial membranes, the integration in a microfluidic format and the use of high-throughput fluorescence
microscopy to quantify protein recruitment to membranes. LiMA increases by several orders of magnitude
the throughput of protein-lipid interaction methods and allows with its paired computational analysis
pipeline to envision proteome-wide protein-lipid interaction screens.
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Figure 1: Principle of LiMA (a) The core of LiMA lies in the thin agarose layer containing
120 slots onto which lipid mixtures are automatically spotted. (b) Liposome are composed
of the same lipids and di er only in their lipid(s) of interest (characterizing the liposome).
The formation of giant liposomes is subsequent to this spotting. The extract containing
the tagged protein of interest is then incubated. (c) The automated image analysis follows
the incubation and compute one NBI per interaction.
2.1.2 Array design
Artificial liposomes enable the study of lipids under physiological concentrations and within membrane
bilayers, but they have many drawbacks, making them di cult to use in a high-throughput manner.
They are di cult to scale up [82], unstable and are known to oxidate quickly [83]. LiMA uses some of
the liposome preparation methods described by Horger et al., a method enabling the formation of giant
liposomes [84]. A defined lipid mixture is applied on a cover glass covered with a thin layer of agarose
(TAL), onto which lipid mixtures are spotted. A lipid mixture contains a carrier lipid, the lipid(s) of
interest, (characterized the liposome itself ) as well as PE linked to poly(ethylene glycol) to help the
formation of the liposomes. Finally, each liposome contained a lipid fluorescently labeled (PE-Atto 647)
to help during the image-processing step. The detail composition of each mixture used during the screen
is available in Supplementary Table V.3. Subsequent to this spotting the TAL is hydrated inducing quick
formation of liposomes containing the lipid mixture applied beforehand (Figure 2). The diameter of the
liposomes can be adjusted by varying the thickness of the TAL (Figure 1). The geometrical characteristic
of the liposomes are stable for a period of 6 hours and they do not di use to neighboring spots of the array,
thus reducing the risk of cross-contamination (Figure 1). We have applied 110 di erent lipid mixtures,
spanning all principal families and all of them successfully were incorporated into liposomes of equal
quality (Figure 3).
2.1.3 Detection of interactions
We produced a miniaturized array containing multiple spots, each holding a particular lipid mixture.
We made use of microfluidics techniques in order to streamline the array with automated fluorescence
10
Chapter 2 – Results 2.1. LiMA
!
Figure 2: Liposome formation (a) Giant liposome formation time (<2 minutes). (b)
TAL height grows with agarose concentration. (c) Liposome diameter grows with agarose
concentration. (d) Pictures of giant liposome formed from neighboring spotting points.
The enlarged squats (bottom) show that liposomes maintain their position within the
spotting area. Cross contamination risks are thus minimized.
microscopy. The lipid mixtures were spotted on the TAL with a Camag thin-layer chromatography
spotter. The liposomes were formed upon hydratation of spotted TAL by injecting the assay bu er in
to the microfluidic chambers. The liposomes were then incubated with the GFP-tagged protein for 20
minutes. Subsequently, the unbound material was washed away. The amount of GFP-tagged protein
recruited by liposomes was characteristic of the interaction between the protein and the lipid of interest
of the liposome. This ratio was automatically computed by high-content fluorescent microscopy [85].
11
Part II Chapter 2 – Results Chapter 2 – Results
Figure 3: Liposome number (left) Boxplots representing the number of liposome observed
for each liposome type and per mm2. (Right) Boxplots representing the liposome fluores-
cence intensity per liposome type.
2.1.4 Readout
To quantitatively characterize the recruitment of proteins to the formed liposomes, we have developed
the normalized binding intensity. Each spot of the array onto which a lipid mixture had been spotted was
automatically acquired on two channels: PE-Atto 647, the liposomal marker and GFP, characterizing the
amount of protein bound to the liposome. Additionally, several exposure times were acquired in order
to detect binders with di erent a nities and only pixels corresponding to the position of the liposome
membranes were retained for the computation of the NBI. The GFP intensities represented the number
of proteins recruited to the liposomes and the Addo-647 the available surface for proteins to bind to.
The NBI was computed as the ratio of GFP to Atto-647 [See Materials and Methods 2.5.1]. The NBI
can be used as a quantitative measure of protein-lipid interactions. LiMA was found to be sensitive to
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changes in lipid or protein concentrations, and this was well reflected by the NBI (Figure 4). Protein
a nities are also well represented by the NBI. For instance, the ph domain of the protein kinase AKT1
is known to specifically bind to DOPI345P3 and DOPI34P2, and binds to DOPI45P2 with less a nity
[86]. The NBI measured with the technology LiMA very well reflected these specificities (Figure 4). The
NBI is a quantitative readout that can be sensitive to protein concentration and lipid concentration.
Furthermore, it can be used to to compare a nities between di erent proteins. As a proof of principle,
we have measured the NBIs of the two variants of the PH domain of the protein SOS1 (SOS1-HF-WT
and SOS1-HF-E108K) to DOPI45P2 and PA. This mutation is linked to the Noonan syndrome [87] and
known to increase the a nity to PA [88]. The sensitivity of the technology to detect these slight changes
was reflected in the NBIs measured. Surprisingly, an equally important increase of a nity to DOPI45P2
was observed, which was not known before. This might suggest that the two lipid ligands are recruited
on the same binding sites (Figure 4).
Figure 4: Sensitivity and Specificity of LiMA (a) Sensitivity of LiMA with regard to the
lipid concentration : the NBI of a given interaction increases when the concentration of
lipid of interest increases. (b) Sensitivity of LiMA with regard to the protein concentration
: the NBI of a given interaction increases when the concentration of protein increases.
(c) The NBI is directly proportional to the Kd of a protein. (d-e) Sensitivity of LiMA
to detect fine alterations of a protein a nity caused by diverse mutations: the disease-
associated mutation E108K substantially increased the a nity oft he protein SOS for
both PA and DOPI45P2.
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2.1.5 Performance in high-throughput
In order to evaluate how well LiMA can perform in a high-throughput screening, we probed seven proteins
belonging to the most frequent lipid binding domains encountered in eukaryotes and measured their
lipid binding preferences to 30 di erent liposomes. In total, we measured 300 di erent protein-lipid
combinations (Figure 5). This pilot screen yielded an excellent reproducibility (Figure 5). NBIs reflected
small changes in lipid concentrations as well as protein’s specificities (Figure 5).
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Figure 5: Performance in high-throughput (a) Scatter plot illustrating quantitative re-
producibility of NBIs measured on pilot screen interactions (8 LBDs and 30 di erent
liposomes). (b) Heatmap displaying PH domains binding profiles.
2.1.6 Summary
The first step of the computational analysis pipeline have shown that LiMA is a technology that can be
applied to tens of thousands of protein-lipid interactions and provides a quantitative readout capable of
reflecting protein’s specificities. This information is essential to address some of the problems posed in
the introduction.
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2.2 Dataset
2.2.1 Lipids
This array was further designed to accommodate 122 di erent types of liposomes. The liposomes contain
between one and four lipid of interest selected from a pool of 26 di erent signalling lipids (Figure 6).
For comparison purposes, we decided to include non-physiological analogues that are not synthesized in
yeasts or higher eukaryotes [Supplementary Table V.2]. Additionally, given that the exact in vivo lipid
concentration is not known [89], we chose to use in vitro concentrations found in other studies studies
[90] [91]. Biotinylated phosphatidylethanolamine (PE) was chosen as control lipids and was placed at ten
specific positions on the array in order to served as an indicator for the assay quality (Figure 7).
Figure 6: Matrix representing (gray) the lipid combinations selected to compose the 122
liposomes studied along with their concentration in mol % (number written next to the
lipid).
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Figure 7: Schematic representation of LiMA’s chip. The green spots represent positions
onto which control liposomes (with PE-biotin as lipid of interest) were automatically
spotted. These liposomes were always spotted on these positions (as opposed to the other
liposomes whose positions were shu ed between replicates). The number indicate the
concentration of the lipid of interest within the liposome (mol %).
2.2.2 Proteins
This screen focused on all known and predicted PH domains in Saccharomyces cerevisiae (58 PH domains
from 49 proteins) and their orthologues in a thermophilic fungus, Chaetomium thermophilum as identified
in [92] (27 PH domains from 24 proteins). We additionally selected six mammalian PH domains and, for
comparison purposes, four unrelated LBDs with known and distinct lipid-binding specificities (Figure 8).
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Figure 8: Presentation of the dataset (A) Upper panel: Selection of lipid-binding do-
mains (LBDs, number of sourceproteins in parenthesis) and liposomes covered in the
study. Middle panel: Summary of experimental success rate. Lower panel: Summary
of PH domain–liposome interactions detected. Inner circles are liposomes, outer circles
are PH domains and lines represent high confidence binding events. (B) Quantitative
reproducibility of the screen. The Pearson correlation of NBI values is measured for all
corresponding replicates for each LBD–liposome experiment. Counts represent the num-
ber of measurements per each hexagon in the matrix. (C) Correlation of lipid-binding
profiles of 27 pairs of orthologous PH domains from S.cerevisiae and C.thermophilum.
The Pearson correlation of all corresponding normalized binding intensity (NBI) values
measured for all orthologous PH domains.
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2.2.3 Interactions
The experimentalists yielded 11,386 unique domain-liposome experiments in biological replicates. They
have acquired and processed a total of 229,880 images corresponding to 32,840 domain-liposome experi-
ments. They processed a total of 229,880 images that were visually inspected and experiments that were
unsuccessful – for example, because of protein precipitation, failure to produce liposomes or to acquire
focused images – were labeld as such. This constitutes the unfiltered dataset that still remained to be
filtered from the unsuccessful experiments.
2.3 Preprocessing of LiMA readouts
2.3.1 Filtering
All images were visually inspected and unsuccessful experiments – e.g., protein precipitation, failure to
produce liposomes or to acquire focused images – were accordingly annotated and removed from the
dataset. To facilitate the annotation process, all images were displayed on an internal web page, thanks
to kind help of Dr Karl Kugler. Altogether, 29.8% (9,771) of collected data was removed. The final
dataset consists of 10,514 unique protein–liposome experiments (92.3% of those designed), comprising
23,069 replicates (i.e. on average 2.7 replicates per protein–liposome pair, Figure 8). The subsequent
analysis was based on this final dataset
2.3.2 Reproducibility of the assay
Quantitative reproducibility
The first step of the technical analysis pipeline consists in computing the quantitative reproducibility
of the screen. The qualitative reproducibility was measured by plotting the NBIs of the replicates of
each interaction against each other and by measuring their correlation. It yielded a pearson correlation
coe cient of 0.67 with a P value < 2.2.10≠16. This indicates a very strong and significant correlation
of the NBIs outputted by LiMA which nonetheless seem to display quite a bit of variability (Figure
8). To know whether this variability is synonyms with variability in the biological interpretation of the
interactions, we performed a qualitative reproducibility of the assay.
Qualitative reproducibility
The screen benefits from manual annotations that have the advantage of assessing the true value of an
interaction regardless of it s associated NBI. The annotator cannot take the replicate variability into
account and thus, the annotation is very likely to reflect the true biological information of the picture,
that is, if it is a binding event or not. Thus, the qualitative reproducibility assesses the propensity
of LiMA to reproducibly output the same biological information for a given interaction regardless of
the NBI variation that might be observed between replicates and that could be caused by numerous
factors (detailed in paragraph 2.3.3). The overall reproducibility was 91.2% for distinguishing between
interacting and non-interacting LBD–liposome pairs, measured on the set of 8,148 experiments for which
replicates were available (Figure 9).
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Figure 9: The big pie chart represents how often an interaction yielded NBIs above or
below the binding threshold. The small pie charts assesses how often inconsistent NBI
derived interpretation of the binding event were in fact reproducibly manually annotated.
2.3.3 Possible bias
The NBI is subject to be influenced by many di erent parameters, such as the protein concentration, the
liposome number per well, the chip itself or the time spent between two spotting. The technical analysis
pipeline considers these parameters and alert if one parameter is found to correlate with or to influence
the NBI.
Protein concentration e ects
For each interaction, the replicate of one protein have been incubated at di erent concentrations. The
protein concentrations used for this screen ranged from 1 to 100 µM [Supplementary Table V.4]. The
protein concentration e ects were assessed in two di erent ways. First, we looked at the global correlation
between the protein concentration and the NBI collected for all of the screen data (Figure 10). Second,
we zoomed in and analyzed the protein concentration e ect for each individual interaction (See Materials
and Methods 2.5.2 and Figure 11). We found that the majority (92.4%) of these substantial concentration
changes did not significantly a ect the NBI measured. This indicates that proteins were present in the
assay at saturating concentration (or for the proteins that did not show any binding event, that the protein
concentration used was inferior to the one required to detect any possible binding event detection). As
such, the measured NBIs were mainly dependent on their binding constant and were not influenced by
the protein concentration.
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Figure 10: Correlation analysis of LBDs concentration versus NBIs of all experiments
performed in the screen.
Lipid concentration e ects
Some lipids were present in liposomes at two di erent concentrations (7 and 10 mol %) : DHS-1P,
DOPI45P2, DOPI45P2:DHS-1p and DOPI45P2:DOPS. In order to assess the lipid concentration e ects,
we collected the NBI values measured for each of each of these lipids (Figure 12). We then computed
a Wilcoxon test followed by a Benjamini-Hochberg correction test to assess if the NBI collected at the
di erent lipid concentrations for each of these lipids was statistically significant.
Liposome number e ects
The assay comprises 122 liposomes, including 94 mixtures made out of 27 lipids [Supplementary Table
V.3]. The formation of liposomes is known to be di cult with certain lipids including DOPI345P3, which
is shown in the figure (Figure 3). Given that the number of liposomes obtained can be significantly
di erent from one mixtures to another, we also checked whether these di erences also influenced the NBI
measured by plotting the NBIs against the liposome numbers(Figure 13). No significant correlation was
found, which implied that the NBI did not need to be normalized with regard to the liposome number.
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Figure 11: Protein concentration e ects (a) Pairwise correlation analysis of NBIs for LBDs
with more than 1.5 fold di erence in protein concentration between replicates. The NBIs
from the corresponding replicates were compared pairwise (Wilcoxon test followed by
Bonferroni correction) and corrected P values, reflecting statistical significance of di er-
ence in NBIs, were plotted for each pair. P value 0.05 (solid line) was used as a threshold
for statistically significant di erence. The domain name together with the concentration
(µM) of the two corresponding replicates (Repl.) is given. (b) Number of interactions
detected per PH domain. The proteins for which data from only one replicate are avail-
able are labeled in red, the proteins for which the mean TI of the interactions was Ø 2
are marked in blue.
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Figure 12: Boxplot representing the influence of the increased concentration of the lipid
of interest within four di erent liposomes on the NBI measured.
Spatial e ects
Chip based experiments provide a huge amount of data that can sometimes embody a significant amount of
measurement error or bias due to technical issues directly tied to the chip itself. The scientific community
has already reported various sources of spatial artifacts [93] [94] [95] which include for instance droplets,
scratches, uneven washing or non randomization of the chip [93] [94] [96] [97] [98]. The technical analysis
pipeline includes a module to check whether the chips used for the assay are spatially biased. The Figure
14 illustrates the mean NBI collected on each spot of the chip used and demonstrate that chip used were
not spatially biased, which implied that no spatial normalization was required.
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Figure 13: Correlation analysis of liposome number versus NBIs of all experiments per-
formed in the screen.
E ect of the spotting time on the NBIs measured
The placement of the majority of liposome used in this assay was randomly shu ed as suggested in
[99], in order to control for spatial bias. Besides, PIPs are known to hydrolyse quickly and the time
spent between the measurements of two consecutive replicates could in theory have had an impact on the
protein recruitment and hence the NBI measured. We measured the importance of this e ect as explained
in the paragraph 2.5.2 of Materials and Methods and found that there was no correlation whatsoever
between the time spent between the spotting of two replicates and the NBI measured (Figure 15).
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Figure 14: Control for potential position-dependent artifacts on the liposome array. Each
cell of the heatmap corresponds to a position on the liposome array and indicates the
logarithmic value of the ratio between the number of experiments of NBI > 0.037 (i.e.,
interactions) and the total number of experiments measured at the particular coordinate.
Squared cells represent the positions of the positive control (liposomes containing a PE-
biotin lipid), which remained fixed across all replicates.
2.3.4 Extraction of a binding threshold
In order to define a binding event based on the NBI, we performed a ROC analysis using the manual
annotation as “golden standard” [100] in order to extract an NBI threshold above which an interaction is
predicted as binding event. This threshold is used as interaction predictor for the rest of the data analysis.
The binding threshold extraction module allows to select the NBI threshold either by maximizing accuracy
(Figure 16) or by maximizing the sum of sensitivity and speficitity(Figure 16). The threshold was set to
the NBI value of 0.037 according to the extraction method algorithm chosen [see Materials and Methods
paragraph 2.5.2]. This chosen ratio yielded a 75.2% TPR and 3.4% FPR and a recall of 86%, with an
AUC of 0.95 (Figure 16). The final NBI value for each domain-liposome experiment was calculated as a
mean NBI from all available replicates. The mean NBI values were used for further analysis.
2.3.5 Assessment of binding quality
The assay yields very reproducible readouts (Figure 9) which display nonetheless quite a bit of variability
(Figure 10) . Some interactions yielded replicates whose standard error was almost three quarters their
mean values. This needed to be taken into account. To this aim, we have developed a Trust Index. The
trust index (TI) is computed for each interaction that was measured at least twice. For each interaction
between a protein domain and a liposome type, we calculated the mean NBI of the replicates (NBI) as
well as the associated standard error (SENBI). We then calculated the TI of the interaction as such,
where Th is the binding threshold (0.037):
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Figure 15: Visualization of the relationship between the time delay in the imaging (x
axis)and NBI measurements between replicates (y axis)
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Figure 16: Background estimation and threshold extraction (a) Density plot showing the
repartition of NBI of the three population of interactions.(b) Extraction of threshold by
maximization of the accuracy. (c) Extraction of threshold by maximization of the sum
of sensitivity and specificity. (d,e) ROC curve and precision-recall curve analyses of the
NBIs of the screen dataset. The NBI cuto  extracted by maximization of the accuracy
yielded an NBI of 0.037. This cuto  yields a true positive rate (recall) of 75.2%, a false
positive rate of 3.4%, precision of 86% (dashed lines). AUC (area under curve) of ROC
curve was 0.95.
• if NBI > Th : TI =
Ò
SENBI
NBI≠Th
• if NBI < Th : TI = ≠
Ò
SENBI
Th≠NBI
Based on the TI calculation, the experiments have been assigned to four categories:
• TI œ ]0;2[ : high confidence binder
• TI œ ]2;inf[ : low confidence binder
• TI œ ]-2;0[ : high confidence non binder
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• TI œ ]≠ inf;-2[ : low confidence non binder
The Figure 17 illustrates the computation of the TI. and the We provide the table of computed TIs for
all the interactions that we probe [Supplementary Table ??].
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Figure 17: Determination of the trust index (TI) for each domain-liposome type exper-
iment studied. (a) Scatter plot representing the standard error (SENBI) as a function
of the NBI (log10 transformed). (b)Scatter plot represents the TI as a function of the
NBI (log10 transformed). Interactions yield a positive TI while no binding events yield a
negative TI. The closer the TI is to 0, the more confident is the datapoint (interaction or
no binding). (c) Boxplot representing randomly picked examples of PH domain-liposomes
type experiments which yielded di erent ranges of TI.
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2.3.6 Sensitivty and specificity assessment
The definition of a binding threshold coupled to the TI allows us to make use of our controls by verifying
their binding specificities to their known lipids. These should be both the strongest (in terms of NBI)
and the best (in terms of TI) binder. The known specific interactions are listed in the supplementary
information [Supplementary Table V.6, Supplementary Table V.7, Supplementary Table V.8, ]. The
Figure 18 confirms that the control proteins do preferably bind their known specific ligands and thereby,
confirm that the technology LiMA reproduce very precisely the true biological binding properties of the
probed proteins.
Figure 18: Sensitivity evaluation (a) Assessment of the ability of LiMA to recover the spe-
cific lipid-binding profile of four positive control LBDs (EEA1-FYVE, Hsv2, Lactadherin-
C2, p40phox-PX). The numbers behind the lipid names indicate lipid concentration (mol
%). (b) For the four positive controls shown in panel (a), the boxplots show the NBI and
1/TI for the known specific lipid(s) partners and all the other lipids and lipid mixtures.
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2.3.7 Number of required manual annotations
The extraction of the binding threshold has been based on the manual annotation of the entire dataset.
Three weeks were necessary to annotate the entire dataset (each annotator approximately annotated 7000
images per day). Screens including more replicates, proteins or liposomes could easily generate millions
of pictures and this daunting manual annotation task could then rapidly become unfeasible. To avoid this
fastidious task, we show that 500 randomly annotated pictures are enough in order to extract a binding
threshold that yields a su ciently high precision and sensitivity. Beyond this number, the precision and
the sensitivity of the extracted binding threshold do not significantly increase (Figure 19).
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Figure 19: Estimation of the minimal number of annotated pictures required to extract
an NBI binding threshold. For each number of picture, an NBI threshold is extracted in
order to maximize the accuracy . The rest of the pictures are classified accordingly (as
binder or non binder) and those classifications are compared with the manual annotations
in order in order to compute the precision yielded by the selected threshold. The precision
increases with the number of pictures used in order to extract the NBI binding threshold,
but above 500 pictures, the confidence interval of the precision does not seem to increase
anymore. Therefore, 500 manual annotations would su ce in order to extract a binding
threshold that can be used for the rest of the dataset.
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2.4 Functional analysis of LiMA readouts
2.4.1 Clustering analysis
Every PH domain studied in this screen was tested against an array of 122 liposomes. Thus, each PH
domain had a fingerprint, characterizing its binding preferences to the universe of lipid tested. Corol-
larily, every liposome was tested against an array of 94 PH domains, and thus, each liposome had a
fingerprint characterizing its binding preferences to the universe of PH domains tested. This screen,
making use of LiMA, is the first high-throughput study focusing on protein lipid interactions under phys-
iological concentration and capable of producing a quantitative readout that can be exploited in order
to understand PH domains lipid ligand preferences, that is, the basic features giving them the ability to
bind particular membranes, otherwise known as the “phosphoinositide code” [60]. The clustering anal-
ysis of single lipids of interest liposomes revealed that many more PH domains were capable of binding
PIPs containing liposomes as single lipid of interest and with a higher intensity (higher NBI) as well as
specificity (lower TI) compared to non PIPs containing liposomes(Figure 20). The clustering analysis of
mixture liposomes revealed that PIPs are indeed the dominant PH domains ligands when present in an
environment containing multiple lipids that the PH domains can potentially bind. Liposome mixtures
containing identical PIPs members displayed a strong propensity to cluster together. This implied that
they had a more similar PH domain binding profile (Figure 21 and Figure 22). More noticeably, two
clusters seemed to stand out pretty clearly, which respectively contained either liposomes made out of
PM PIPs and the other one, liposomes made out of Org. PIPs . The robustness of these clusters has
been ascertained by various methods (Figure 22) which all led to the conclusion that these clusters were
not random. This undoubtedly suggested that the nature of the recruited PH domains between those
two types of liposomes was di erent. At last, the secondary lipid present in the mixtures also appeared
to influence the protein binding profile of the liposome. The hierarchical clustering analysis displayed
branches that were enriched in the presence of charged secondary lipids. These formation of sub-clusters
did not perturb though the main clusters triggered by the presence of organellar and plasma membrane
PIPs. This led to the conclusion that PIPs are the main lipids targeted by PH domains, but that the
recruitment can be refined when put in the context of other charged lipids (secondary lipids).
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Figure 20: PIPs based liposomes are the preferred ligands (Top) hierarchical clustering
of single signalling lipid- containing liposomes according to the similarities in their PH
domain-binding profiles. Colours refer to the lipid family. The lipids that are not physi-
ological in S.cerevisiae are marked with §. (Middle) barplot represents the total number
of PH domains which bound to the liposome whose name is written on the leaf corre-
sponding. (Bottom) boxplot shows the intensity with which the PH domain bound that
liposome. The numbers behind the lipid names indicate lipid concentration (mol %) used
for each signalling lipid.
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Figure 21: Clustering analysis of liposomes based on similarities in the recruitment of
PH domains. (a) Hierarchical clustering of 90 liposome containing at least two lipids of
interests.The color of the leaves refers to the PIP contained in the liposome. The pie charts
illustrate the representation of charges of the secondary lipids. # indicates an inactive (in
our assay) dipalmitoyl variant of DOPI35P2. (b) E ect of the auxilliary lipid’s charges on
the PH domains-liposomes interactome within the clades highlighted in panel (a). PCer,
phytoceramide; DHCer, dihydroceramide. (c), Principal coordinates analysis of the same
90 liposomes mixtures used in (a). The PCoA was performed using the pearson metric
based on their their PH domain binding profile using the NBI as a readout. Red dots
represent liposome in which the PIP is known to locate in an organellar membrane. Blue
dots represent liposomes in which the PIP is known to locate in the plasmic membrane.
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2.4.2 A new motif behind the recruitment to Organellar PIPs
The results of the hierarchical clustering analysis concluded that PIPs were the lipid contributing the
most to the recruitment of PH domains. This conclusion was supported by the fact that that ORG
PIPs based liposomes [DOPI3P, DOPI4P, DOPI5P and DOPI35P2] displayed a completely distinct PH
domain binding profile as PM PIPs based liposomes [DOPI34P2, DOPI45P2 and DOPI345P3], and that
the presence of other charged lipids did not alter the structure of the observed clusters. A glance at
the PIPs binding profile (Figure 24) of the 90 PH domains exhibited a group of 16 proteins capable of
binding both ORG PIPs and PM PIPs based liposomes as opposed to another group of proteins that was
solely capable of binding PM PIPs based liposomes. In order to find out which amino-acids or positions
within the sequence of PH domain could explain the specific binding of ORG PIPs, we first performed
a multiple alignment of the 90 PH domains. The sequences were labeled according to their ability to
bind ORG PIPs based liposomes. We subsequently employed an algorithm optimized for the detection
of sub-family specific residues. In brief, the algorithm loops over every position of the multiple alignment
and identifies residues that are di erent amongst the sub-families present in the alignment, which in this
case are the proteins di erently labeled according to their ability to bind ORG PIPs based liposomes
[101] The algorithm scored every position of the multiple-alignment (Figure 23) and nine positions were
retained. More precisely, two positions were located in the —1-—2 loop, three at the end of the —7 strand,
and four in the –-helix. These nine positions were those that explained most of the di erence between the
two groups of labeled proteins in terms of amino-acids content and were thus assumed to be responsible
for the specific binding of ORGs PIPs liposomes. This constituted the organellar PIP recognition motif
(ORPM) (Figure 24) which were not overlapping with the already described BSM. The BSM (Figure 24)
was described as being the Sine qua non condition for PH domains to be able to bind PIPs in general
[102].
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Figure 22: Evaluation of cluster’s robustness (a) Detailed Hierarchical clustering analysis
of the 90 liposomes containing at least two lipids of interest as described in Figure 25a.
The barplot represents the total number of PH domains which bound to the liposome
whose name is written on the corresponding leaf. The boxplot shows the intensity with
which the PH domain bound that liposome. The numbers behind the lipid names in-
dicate lipid concentration (mol %) used for each signalling lipid. (b) Cluster robustness
assessment with k-medoids clustering of the same 90 liposomes using the partition around
medoids algorithm. The triangles represent ORG PIPs liposomes and the circles PM PIPs
liposomes. (c) Cluster robustness assessment computing silhouette index. Each bar cor-
responds to a liposome and the group of bar labeled as n=55 corresponds to the ORG
PIPs liposomes. Only two liposomes have been found in the wrong cluster.
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Figure 23: Scatter plot representing the results outputted by the multi harmony algorithm
used for the motif extraction. The x axis is the sequence harmony (SH) score, which
evaluates how conserved are the residue within each group. It ranges from 0 for completely
non-overlapping residue compositions to 1 for identical compositions (in other words, the
lower the better). The second statistic is a measure of statistical significance of the
SH score (the ZSH score). The ZSH score is calculated by permuting the group labels
and running the sequence harmony algorithm for 100 randomizations. The mean and
standard deviations of these permuted groups are calculated. A ZSH score of 1 means
that the SH score is 1 standard deviation below the random mean (the more negative the
ZSH score, the better). The y axis the multi-relief weight (MR score), which evaluates
how discriminatory are residues between each group. It ranges from 1 for completely
discriminatory residues to 0 for non discriminatory residues (so the higher the better).
The fourth statistics is a measure of statistical significance of the MR score (ZMR). The
ZMR is calculated by permuting the group labels and running the multi-relief algorithm
for 100 randomizations. The mean and standard deviation for these permuted groups
are calculated. A ZMR score of 1 means that the MR score is one standard deviation
above the random mean (the more positive the ZMR score, the better). At the end, each
position of the multiple sequence alignment these four statistics assigned.
37
Part II Chapter 2 – Results Chapter 2 – Results
The residues are conserved
The identification of the OPRM involved a group of 16 PH domains that all belong either to S.cerevisiea
or C.thermophilum. In order to claim that this motif was universal, we checked for its presence within
the entire annotated and reviewed PH domains universe, that is, 1216 PH domains that belong to 72
di erent species [103]. We performed a multiple alignment of these 1216 sequences as we did for the 90 PH
domains and applied a scoring scheme to each PH domain based on the presence or absence of the residues
belonging to both motifs (BSM and OPRM) (Figure 24). In order to confirm that the presence of the
OPRM amino acids is linked to the propensity of PH domains to bind ORG PIPs, we randomly selected
ten PH domains that yielded di erent scores from the species Homo Sapiens. Five of these PH domains
yielded contained most of the twelve amino-acids belonging to both motifs (OSBP1, OSBP2, OSBPL3,
OSBPL7, FAPP1), three yielded a medium score (CERT, OSBPL11, OSBPL10), and two with almost
no amino-acids belonging to the motifs (OSBPL8, OSBPL5). The confirmatory experiments validated
the role of the amino-acids present in both motifs (BSM and OPRM) in the respective recognition of PM
PIPs based liposomes and ORG PIPs based liposomes (Figure 24)
Making sense of the motif
In order to make sense of the two described motifs (BSM and ORPM) and understand what were their
biological implications, we performed an enrichment analysis on the 50 proteins that yielded the highest
score (Figure 24). The most enriched function found was transport between di erent cellular compart-
ments. This further validates the implication of the ORPM in the specific recognition of ORG PIPs based
liposomes (and thus organellar membranes) as proteins required for the non-vesicular transport of lipids,
are known to be found at various membrane contact sites and are responsible for the transport of lipids
from one membrane to the next ([104] [105] [106] [107])
In vivo validation
In order to confirm the implication of the OPRM in the specific recognition of organellar membranes
in vivo, we selected PH domains which yielded di erent scores (Figure 25) and marked them with a
fluoerescent tag (mCherry). As expected, FAPP1 and Swh1 (which both yielded a very high score) did
locate at the intracellular membranes, and notably at the Golgi apparatus. These results confirm what
has been long observed about lipid transporters, that is, that they are often found to locate to Golgi
membranes [105] [108] [109]. PH domains like CERT and Opy1c (which yielded low scores due to the lack
of OPRM, but nonetheless presence of BSM) did not –as expected- locate to the organellar membranes
but to the plasma membrane.
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Figure 24: Motif confirmation (a) Heatmap representing the PH domains PIP binding
profiles. Columns represent seven liposomes containing one lipid of interest. The four on
the left contain lipid of interests that are located in organellar membranes. The three
on the right contain lipid of interests that are located in the plasmic membrane. The
line delimitates PH domain capable of binding ORG PIPs (foreground) as opposed to
those which cannot bind ORG PIPs (background) (b) Representation of a part of the PH
domain secondary structure as well as (blue) the BSM and (red) the motif derived from
the foreground (c) Ranking of the entire PH domain universe based on the presence or
absence of the residues displayed in panel (b). The higher the score, the more residues are
found in a given PH domain (d) The boxplot shows NBI values measured for experiments
of 72 PH domains (10 human, red dots; 62 yeast, black dots) with either organellar PIPs
(pink) or PM PIPs (blue). The PH domains are separated into 3 groups based on the
score shown in the plot on the left. n indicates the number of PH domain in each group.
The darkness of the dots indicated their annotation as interaction (dark) or no binding
(light). ** P value < 9.10≠11, * P value < 4.10≠5 (e) Functional enrichment analysis of
Group 1 (from panel(c)) using gene ontology annotations.
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Figure 25: In vivo validation of the motif part 1. The selected PH domains were expressed
as mCherry-fusions in yeast strain with endogenously expressed trans-Golgi marker Kex2-
GFP. The left column shows localization of the PH domains, middle column the localiza-
tion of Kex2 protein and right column shows both images merged. The PH domains are
separated into three groups that correspond to their scoring in 24. Scale bar, 3µm.
To validate further the role linked to the OPRM, we performed point mutations. We first selected
an amino acid located in the —7 strand (lysine), as it appeared to be one of the most conserved amino
acids of the OPRM (it was the second most conserved amino acid within the group of 16 proteins of
our screen which were capable of binding ORG PIPs based liposomes) (Figure 26). Additionally, the
3D simulations indicated that this amino acid could be directly in contact with the lipid ligand. Lastly,
the HMM corresponding to the PH domain family found in the Pfam database indicated that the most
common amino acid present at this position is a glutamine. As a consequence, we decided to mutate this
amino acid to a glutamine in three di erent PH domains (Swh1, FAPP1, CERT) and to measure the
impact this mutation had on the binding to PIPs-containing membranes [Supplementary Table V.9]. As
expected, the mutated proteins lost their ability to strongly bind ORG PIPs based liposomes, whereas
the interaction with PM PIPs based liposomes was not a ected (Figure 26). The second mutated amino
acid was located in the —1- —2 loop, and corresponds to the position which was the most conserved
within the group of 16 proteins mentioned earlier (threonine). This amino acid is found mutated in the
protein FAPP1 in colorectal carcinoma [110]. This threonine was mutated to an alanine and specifically
a ected the recruitment to DOPI4P containing liposomes. The recruitment to DOPI45P2 containing
liposomes remained unchanged (Figure 26). The third mutated amino acid was an arginine found in the
–-Helix. This residue is found mutated in the protein OSBP2 in lung adenocarcinoma [111]. Intriguingly,
this residue is located far away from the two possible binding sites and consequently does not appear
to be directly involved in the contact with the lipid ligand. Yet, this residue was the most statistically
significant residue found by the multi-harmony algorithm [101]. The mutation did though specifically and
significantly perturbed the binding of OSBP2 to ORG PIPs based liposomes whereas the recruitment to
PM PIPs based liposomes remained unchanged (Figure 26).
All in all, this supports the notion that the recruitment of PH domains to membranes implies the
selective recognition of PIP species which is important for the protein function [65] [112].
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Figure 26: In vivo validation of the motif part 2 (a) Schematic representation of the PH
domains secondary structures holding the motif along with five proteins chosen for the
point mutation experiments. Highlighted residues represent the mutated residues. (b)
Box plot showing the impact of the R262L (in the alpha helix of OSB2-PH) on Org PIPs
liposomes (red) and PM PIPs liposomes (blue). (c) Impact of the T9A mutation (in the
beta1-beta2 loop of FAPP1) on a PM PIP liposome (DOPI45)P2) (left) and on an ORG
PIP liposome (DOPI4P2) (right) (d) Box plot showing the impact of the R98Q (in the
beta 7 strand of CERT-PH) on Org PIPs liposomes (red) and PM PIPs liposomes (blue).
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2.4.3 Lipid cooperativity
PH domains can bind cooperatively
The data collected from our screen, added to those from anterior studies [27], indicate that the presence
or absence of particular lipids around of PIPs within biological membranes can a ect the recruitment
of PH domains to these membranes. Furthermore, our data indicate that a quarter of the screened PH
domains necessitated the presence of several lipids in order to be able to bind these liposomes(Figure 27).
Figure 27: Summary of PH domain–liposome interactions detected. Inner circles are
liposomes, outer circles are PH domains and lines represent the 1628 high confidence
binding events. The PH domains from which red edges are drawn represent PH domains
that could only interact with liposomes containing at least two lipids of interest.
An interaction between a protein and a group of lipid is defined as being cooperative, when the
presence of a particular lipid increases the a nity of the binding event between a protein and its lipid
ligand. This screen o ers thanks to its quantitativeness and physiological conditions the first opportunity
to assess whether principles of cooperative binding apply to PH domains. To answer this question, we
have developed an algorithm in order to predict if an interaction between a PH domain and a mixture
liposome is likely to be of a cooperative nature or not, that is, if the interaction with the mixture liposome
is higher than what could have been expected from the two individual signaling lipids. We have focused
the data analysis on PIP, sphingolipids and PS based liposomes, and restricted the prediction event to
all pairs of physiological interactions. The algorithm predicted that the majority of PH domains was
capable of cooperatively bind mixture liposomes (Figure 28) with a high associated trust index. The sen-
sitivity and the specificity of these prediction was assessed by selecting 36 random interactions (predicted
as being cooperative or not), we performed dose-response experiments (Figure 28 and Supplementary
Table 2), from which 20 out of 25 predicted cooperative interactions were confirmed, and only 2 out of
11 predicted non cooperative interactions were confirmed. The reason that high false negative rate is
explained by the screen settings, namely, that most of the lipids were tested at one concentration (10
mol %), which probably was under the threshold of any detectable interaction, or already at saturating
concentration. As a matter of fact, the dose-response experiments reveals that 5 out of 9 of the falsely
predicted cooperative events behave cooperatively at lower concentrations (< 10 %mol). The incidence
of cooperative recruitment of PH domains to liposomes occurred with both PM and ORG PIPs based
liposomes, but PM PIPs based liposomes displayed twice as more cooperative binding events. (Figure
28).
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Figure 28: Cooperativity landscape of PH domains (a) Heatmap of cooperative indexes
(CI) calculated for PH domains (columns) and membranes containing combinations of
physiological signaling lipids (rows; the wedge indicates low and high lipid concentra-
tions, respectively). Only 50 PH domains with high confidence CI > 1 for at least one
liposome type are shown. (b) Dose-responses measured for the PH-domain interaction
with liposomes containing the indicated concentration of signaling lipids. Values are
means (n Ø 2). (c) The summary of the propensity of di erent driver lipids (PIPs, right)
and auxiliary lipids (left) to cooperate based on data shown in panel (a) Organelle PIPs
and PM PIPs: as in Figure 2; Ceramides: Cer, Cer1P, Phytocer, Dihydrocer; LCB1Ps:
S1P, DHS1P, PHS1P; LCBs: Sphingosine, DHS, PHS. (d) Cooperative interactions with
regard to secondary lipids encountered. The bar plot gives the proportion of cooperative
interactions of all experiments performed for each group of auxiliary lipids. LCB1Ps,
LCBs and ceramides as in (c).
Impact on membrane recruitment of PH domains
This screen shows for the first time that the incidence of cooperative sensing of lipids is not a sporadic
event but an inherent characteristic proper to PH domains, and this has many consequences. We have
established a classification with regard to the e ects induced in terms of specificity changes by the
cooperative binding. The class 1 corresponds to an exacerbation of the PIP specificity induced by the
presence of a secondary lipid. The class 2 corresponds to cases in which the presence of a secondary lipid
induces a switch in the PIP specificity of the PH domains and 19 PH domains fell into that category
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(Figure 29 and Supplementary Table 2). As an example, the PH domain of the kinase AKT1 was very
specifically recruited by either DOPI345P3 or DOPI342 based liposomes. The a nity of AKT was yet
switched to DOPI45P2 when this lipid was together in a liposome with LCBs ( 5 folds NBI) (Figure
29). This exacerbated a nity towards DOPI45P2 has already been observed for oncogenic variant of
AKT1 carrying a mutation within the —1-—2 loop of its PH domain, triggering a targeting to the plasma
membrane [113] and subsequently to its unregulated activation [73]. The PH domain of Bem3 – a GTPase-
activating protein (GAP) for Cdc42, a key regulator of polarized cell growth [114] – is not found to be
recruited by pure PIPs based liposomes [115]. However, it was found to strongly bind DOPI45P2 or
DOPI345P2 based liposomes when a secondary lipid was present, e.g. phosphatidylserine (Figure 29).
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Figure 29: Biological implications of cooperativity binding mechanisms (a) Classification
of PH domains in di erent cooperativity classes according to their cooperativity profile
(as illustrated by the surrounding barplots). The number in the pie charts represent how
many PH domains belong to the class The surrounding bar plots show the NBIs measured
for liposomes containing PIPs alone or mixtures of PIPs with auxiliary lipids. The order
of auxiliary lipids in the mixtures is (left to right): PS, DHS, PHS, Sphingosine, DHS1P,
PHS1P, S1P, Cer, Cer1P, Dihydrocer, Phytocer . (b) Influence of lipid cooperativity on
membrane recruitment of AKT1-PH. Comparison of AKT1-H wild type (wt) and E17K
NBIs to membranes of various lipid ompositions. The NBI values for each AKT1 variant
are normalized to the value of DOPI34P2 only (relative NBI = 1). Stars indicate cooper-
ative interactions. (c) Principal component analysis of the S.cerevisiae PH domains with
at least one CI > 1 (n =37). Only CI values for liposomes containing DOPI45P2 with
PS/DHS1P/PHS1P were considered. The box plots represent the di erence between nu-
cleus and non-nucleus groups (bottom, PC1; right, PC2), and Cdc42-interacting and non-
interacting groups (right, PC2). (d) Box plots of the CI values of DOPI45P2:PS (top) or
DOPI45P2:DHS1P/PHS1P (bottom) liposomes calculated for the groups of PH domains
defined in (c) (e) Proteins targeted by the same cooperating lipid pairs are functionally
related. Histograms show NBIs for DOPI45P2 alone or in the presence of cooperating
auxiliary lipids (CI > 1). Bars are normalized to the highest value for each individual PH
domain. (f) Impact of phosphatidylserine and DOPI45P2 metabolism on the localization
of selected GFP fusions in S.cerevisiae. ” cho1, phospahtidylserine synthase deletion and
mss4ts, thermosentsitive mutant of the phosphatidylinositol-4-phosphate 5-kinase. All
scale bars, 3 µm.
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Biological impact of cooperativity
So far, we have demonstrated that the majority of PH domains is capable of cooperatively being recruited
to lipid membranes, and that the presence of secondary lipids has indeed an implication on the increased
or switched PIPs specificity of PH domains. The biological implications of these cooperative mechanisms
in terms of cellular location, biological process or molecular mechanism remains yet to be answered.
Biological membranes are rich in lipids, and we have seen PH domains recruitment to membranes is finely
tunes and determined by the presence of particular lipids. Specific combination of lipids within membrane
might as such be good determinant in the exact location of a PH domain in the cell. There exist many
biological processes (bud assembly, cell polarization) in yeast which imply the reshu ing, modification
and enrichment of particular lipid species in particular cellular component in order to recruit the required
protein for that particular process to happen. Corrolarily, some lipids are more prone to be relocated
than others, which are more abundant and evenly distributed. DOPI45P2 is for instance continuously
and equally dispersed throughout the plasma membrane during the process of cell polarization, whereas
PS will be found enriched in areas of polarized growth [116]. The high concentration of PS at polarized
growth site is mandatory for the polarization to happen, as it specifically contributes to the binding of
Cdc42, which act as chief controller of cell polarity [117]. Cdc42 itself is not known to contain any known
lipid binding domain, yet plenty of its interacting partner do. The PH domain analysed in this screen
include nine proteins that are known to directly interact with Cdc42, which are all found to locate in
the bud compartment (in vivo). For six of these Cdc42 interacting partners, the a nity for DOPI45P2
based liposome was increased when those liposomes also included PS. Remarkably, other PH domains
tested known to locate to the bud without being known to directly interact with Cdc42 did not display an
increased specificity towards DOPI45P2 based liposomes when put together with PS. Those observations
suggested that the specific cooperative binding to DOPI45P2;PS based liposomes is not inherent to bud
locating proteins, but appear to be inherent to proteins sharing a particular function. In order to more
systematically assess the relevance of the predicted cooperating lipid partners, i.e. if they contribute to
a physiological membrane code, we compared the in vitro cooperative profile to physiologically derived
in vivo data. We first annotation data on protein–protein interactions provided by STRING [118] and
localization SGD [119]. We observed that the proteins displaying similar cooperativity profile with
regards to certain lipids are functionally related, or co-localize with their recruiting lipids (Figure 29).
For instance, DOPI45P2 and PS – two lipids that accumulate at the sites of polarized growth [116] –
most frequently cooperate to recruit PH domains that are known to be part of the Cdc42 interaction
network (Figure 29). We additionally made use of live-cell imaging data in order to assess the e ect of
perturbation of DOPI45P2 or PS metabolism on the cellular localization of Bem3, Boi1, Boi2, Cdc24
and Cla4 fused to GFP (Figure 29). As expected, the results suggested that both lipids are required
for the association of Cdc24, Boi2, Cla4, Bem3, and Boi1 with the sites of bud growth and confirms
that both lipids might as well cooperate in vivo. Similarly, PH domains present in nuclear proteins also
displayed more similar cooperative profile towards combinations of phosphoinositides and phosphorylated
LCBs (e.g. DHS1P and/or PHS1P) (Figure 29). These results confirm recent evidences proposing that
a nuclear pool of these lipids plays a role in various nuclear functions [120] [121] [122] [123]. Our results
confirms that the ability of PH domains to cooperatively bind several lipids and extends it to the majority
of PH domains and as being an important of this family. Cooperativity mechanisms can increase or alter
the a nity and specificity of PH domains toward PIPs and is linked to the biological function of PH
domains.
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2.5 Material and Methods
2.5.1 Screen settings
Protein selection and expression
The protein used in the screen were selected using Hidden Markov Models (HMMs) from the Pfam
database [124]. Only the species C.thermophilum and S.cerevisiae were considered. The position of the
PH domains within the protein sequences was performed with secondary and 3D structure predictions
[125]. Finally, the amino-acid sequences of all PH domains were run through SMART [126] in order to
give them an e-value indicating the quality of the PH domain [Supplementary Table V.4]. The lipid
binding domains were cloned into a vector (pETM11) and subsequently expressed as N-terminal His6-
SUMO3 and C-terminal sfGFP fusions in E.coli (BL21 STAR, Invitrogen). Cells were grown at 37¶C
and proteins were produced over night for 14.5 h before being lysed by sonication.
Liposome preparation
The mixtures used to assemble the liposomes were all composed of one or several lipid of interest, (concen-
tration 10 mol%), a carrier carrier lipid (PC, concentration 95 mol%), a lipid facilitating the autofocusing
of the camera during the image acquisition step (PE-Atto 647, concentration 0.1 mol%) and a lipid help-
ing the formation of the liposome (PE-PEG350, concentration 0.5 mol%). The lipid of interest selected
for this screen belonged to four di erent lipid families: DAG, sphingolipids, glycerophospholipids and
phosphoinositides. In total, 122 di erent liposomes containing di erent lipids of interest were utilized
[Supplementary Table V.3]. For technical reasons, two forms of DOPI35P2 di ering in their fatty acid
tail were used (dioleylphosphate (DOPI3P2) and dipalmitoylphosphate (DPPI35P2). The palmitoyl form
was not bound by the specific DOPI35P2 sensor (hsv2). Thus, we solely took into account the results
obtained with DOPI35P2 for the rest of the analysis.
Microarray preparation
Lipid mixtures were automatically spotted on the thin agarose layer (TAL). The array was design to hold
120 spots. The spot were all equally sized (800 µm x 800 µm) and equally distant from one another (200
µm ). The liposomes (> 5 µm) were fully assembled within 5 minutes following the automatic spotting
of the lipid mixtures. Protein extracts were incubated and after 20 minutes washed in order to get rid
of unbound proteins. Each protein was tested in three replicate. To this end, three microarrays were
prepared and the position of the liposomes was shu ed in order to control for positional and time bias.
Image acquisition
In order to acquire the position of the liposomes as well as the LBDs, the microarray spots were auto-
matically imaged on two di erent channels. The fluorescent channels Atto547 was meant to acquire the
position of the liposomes and was exposed at a single exposure time (3ms). The fluorescent channel GFP,
was meant to acquire the position of the LBDs and was imaged at six di erent exposure times
Image processing
The image processing pipeline relied on the image analysis software Cellprofiler [127]. For each image, the
background was removed and the remaining Atto 647 signal was used to delimitate liposome membranes
as well as the center of each liposome. The overexposed pixels within the pair GFP/Atto 647 were filtered
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out from both images were located in all images and then each image was assigned a mean GFP and a
mean Atto647 intensity.
Readout extraction
For each image corresponding to each exposure time, we computed the normalized binding intensity,
that is, the ratio GFP/Atto647 divided by the exposure time. This led to constant NBIs over time and
constituted our final readout. The computation of the NBIs for each image was performed on a cluster
(LSF).
2.5.2 Technical analysis pipeline
Reproducibility
In order to assess the quantitative reproducibility, we plotted the replicates of each interaction against
each other (replicate 1 vs replicate 2, replicate 1 vs replicate 3, replicate 2 vs replicate 3). Given that we
do not have rank data and are not trying to look for a monotonic relationship but rather a linear relation-
ship between related variables, we have log transformed the NBI and measured the pearson correlation
coe cient which yielded 0.67 with a P value < 2,2.10≠16. Two experimentalist as being a binding event,
a non-binding event, or a dubious event annotated each image. In total, 229,880 images were flagged
as non-binding events, binding eventsor as dubious event. The replicates of each interaction were not
necessarily annotated by di erent experimentalists, which might bias the objectiveness of judgment. To
avoid this annotation bias and thus an artificially high qualitative reproducibility, the replicates of an
interaction were not annotated at the same time so that the experimentalist does not know what anno-
tation was assigned to the previous image corresponding to the previous replicate. Lastly, the images
did not contain any information related to the NBI, so that the experimentalists’ judgment can be as
independent as possible from parameters proper to the image.
Threshold extraction
Given that each image benefited from a manual annotation (qualitative readout or “golden standard”) and
a quantitative readout (NBI), we used these two criteria in order to extract an NBI threshold above which
an interaction will be classified as binding event. We first draw a ROC curve as well as a precision-recall
curve in order to measure what would be the sensitivity, specificity, precision and recall of the threshold
chosen. In order to extract a particular threshold, we have chosen to minimize the classification error
rate and thus to maximize the accuracy of the prediction. As such, the extracted NBI threshold value
was set to 0.037, yielding a sensitivity of 75.2 %, a specificity of 96.6 %, a recall of 81 % and an accuracy
of 86 % (Figure 16). The technical analysis pipeline includes the R package Optimal Cutpoints ][100]
and thus leave to the data analysis the choice of how to select the threshold (that is, maximizing the
specificity, maximizing the sensitivity, maximizing the sum of the sensitivity or the specificity etc.)
Number of required annotations
Let N be the total number of interactions and n an integer. For each n that belong to [10;1000], we
defined the training set as being the set of n interactions randomly selected from N. We also defined
the test set of size m = N-n. For each training set, a binding threshold X was extract as explained in
paragraph 2.3.7 and the m interactions of the test set were classified according to that binding threshold
: interactions yielding an NBI > X were classified as binders, and interactions yielding an NBI < X were
classified as non binders. We then compared those classifications with the actual manual annotations and
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computed the precision of the classifications as being the ratio between correctly classified interactions
divided by non-correctly classified interactions.
Protein concentration e ects
Each interaction was tested in replicates and each replicate was performed at a di erent protein con-
centration. Therefore, we could assess the protein concentration e ects in two di erent ways. First, we
analyzed if there was a global correlation between the protein concentration and the NBI measured by
plotting the NBI collected for each protein concentration probed (Figure 10 and Figure 11). We then
measured the pearson correlation between these two hypothetically related variables. Secondly, we ana-
lyzed for each interaction if the NBI measured at two di erent concentrations were significantly di erent
(Figure 10 and Figure 11). In order to assess the statistical significance of these di erence, we performed
a Kruskal-Wallist one-way analysis of variance test, given that we do not have normally distributed data.
Spatial bias
In this screen, three microarrays were used in order to study the interactions in triplicates. The position
of the liposomes was shu ed each time in order to check for spatial bias. The NBI measured at each
position of the microarrays were collected and we computed the proportion of binding events measured
at this particular spot according to the binding threshold set earlier in the technical analysis pipeline
(NBI = 0.037) and represented the microarray as a heatmap (Figure 14). For each row and column we
computed a Kruskal-Wallis one-way analysis of variance test to verify some row (or column) significantly
contained more binding events than another row (or column).
E ect of the spotting time on the NBIs measured
The experimental time needed to complete the measurement of an array was 3 hours. To assess potential
bias in the results due to the imaging time, we took advantage of the fact that we reshu ed all the lipid
positions between the replicates. We plotted the di erence of NBI measured between the di erent pairs
of replicates, which were measured at di erent location on the microarray (and thus at di erent time).
We iterated over all interaction and plotted the NBI di erences observed vs the time elapsed between
two measurements (Figure 15). We also performed an experiment in which we imaged the same liposome
array twice, once at time 0 and then two hours later. We did not observe significant changes between the
NBIs measured at time 0 and two hours later.
Sensitivity and specificity assessment
In order to assess the sensitivity and the specificity of the binding events, we made used of the proteins
(EEA1-FYVE, P40PHOX,HSV2,LACT-C2) for which we know which liposomes they are supposed to
bind. For each of these proteins, we measured the NBI and TI collected for their physiological lipids
(lipids they are supposed to bind) and non physiological lipids (lipids they are not supposed to bind). We
then computed a wilcoxon test in order to evaluate if the NBI and the TI collected for the physiological
lipids were respectively significantly higher than the one collected for the non physiological lipids.
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2.5.3 Functional analysis pipeline
Clustering analysis
Hierarchical clustering In order to perform a hierarchical clustering analysis of the 122 liposomes
based on their protein binding profile using the NBI readout, we proceeded as follow. We first compared
the protein binding profile of the heterogeneous liposomes by setting a a matrix Mhet(dimension PxLhet)
(where P equates the number of proteins and Lhet the number of heterogeneous liposomes) whose elements
correspond to the average NBI of the replicates measured for the interaction <pi,lj>. The missing data
that were replaced by the average NBI the column they belong to. The second step consisted in applying
a log transformation (base 1) ofMhet. The third step of the clustering analysis consisted in computing the
distance matrix Mdhet of Mhet. The distance measure chosen in order to compute the distances between
each pair of heterogeneous liposomes (the columns of Mhet) was the uncentered pearson metric (Figure
22). The R package "dist" was used to this matter [128]. The last step of the hierarchical clustering was
to apply an agglomerative algorithm (‘complete’ algorithm) on Mdhet. A second matrix Mhom PXLhom
(P equates the number of proteins and Lhom the number of homogeneous liposomes) was set and an
identical approach employed in order to perform a hierarchical analysis of the homogeneous liposomes
based on their protein binding profile (Figure 20).
Principal coordinate analysis To verify wether the two main clusters engendered by the PIPs
could also be obtained with another method, we performed a principal coordinate analysis. We applied
an implementation of the statistical procedure on the same distance matrix Mdhet. We quantified the
statistical significance of the clusters by performing a Wilcoxon test on their cumulated MDS1 and
MDS2 values (Figure 21). The PCoA analysis confirmed the first branching observed in the hierarchical
clustering analysis in Mdhet separating two clades; one containing exclusively heterogeneous liposomes
containing PM PIPs and another clade containing exclusively heterogeneous liposomes containing ORG
PIPs.
Cluster validation In order to validate the observed cluster and determine the optimal number of
clusters (in other words, to test if these two clusters are not random), we employed two methods. We
first used a portioning around medoids algorithm in order to determine the optimal number of cluster
using the pam function from the cluster package [129] (Figure 22). We then validated the robustness of
these two clusters by computing the their silhouette index using the silhouette function from the cluster
package [129](Figure 22).
Sub cluster validation In order to confirm that the secondary lipids could engender sub-clusters
within the cluster triggered by the ORG PIPs containing liposomes, we performed a fisher test on the
di erential content in negative charges within certain clades of the ORG PIPs generated cluster (Figure
21).
Motif search
Definition of foreground and background In order to look for an amino acid sequence
that could explain why some PH domains can bind ORG PIPs containing liposomes and other cannot,
we first draw the PIPs binding profile of the 90 PH domains 24. We subsequently defined two groups.
PH domains capable of interacting at least with one pure ORG PIPs liposome regardless of its TI (the
foreground, 16 PH domains) and those which could not (the background, 74 PH domains).
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Multiple-alignment and filtering We then performed a multiple sequence alignment of the
amino acid sequences of these 90 labeled PH domains (depending on their belonging to the foreground
or background). We used the hidden markov model for PH domains in order to align the PH domain
sequences with the software HMMER 3 [130] and filtered out two PH domains belonging to the foreground
based on their misalignment and high e-value prediction score (PDK1 and Avo1).
Position scoring Given that we wanted to detect amino-acids that could explain binding specifici-
ties of proteins within the same protein family, we employed a method which accurately detects subfamily
specific residues from a multiple sequence alignment [101]. The algorithm scores compositional di er-
ences between n groups of proteins without imposing a high degree of sequence conservation, which is
an advantage in our case given that PH domains have less then 25% of sequence identity). In brief, the
algorithm loops over each position of the multiple sequence alignment and computes four statistics per
position. The first statistics is the sequence harmony (SH) score, which evaluates how conserved are
the residue within each group. It ranges from0 for completely non-overlapping residue compositions to
1 for identical compositions (in other words, the lower the better). The second statistic is a measure
of statistical significance of the SH score (the ZSH score). The ZSH score is calculated by permutating
the group labels and running the sequence harmony algorithm for 100 randomizations. The mean and
standard deviations of these permutated groups are calculated. A ZSH score of 1 means that the SH score
is 1 standard deviation below the random mean (the more negative the ZSH score, the better). The third
statistics is the multi relief weight (MR score), which evaluates how discriminatory are residues between
each group. It ranges from 1 for completely discriminatory residues to 0 for non discriminatory residues
(so the higher the better). The fourth statistics is a measure of statistical significance of the MR score
(ZMR). The ZNR is calculated by permutating the group labels and running the multi-relief algorithm
for 100 randomizations. The mean and standard deviation for these permutated groups are calculated.
A ZMR score of 1 means that the MR score is one standard deviation above the random mean (the more
positive the ZMR score, the better). At the end, each position of the multiple sequence alignment had
these four statistics assigned.
Positions selection The computed statistics of all the positions of the multiple alignment were
represented in the 4 dimentional scatter plot 2. We selected the positions that yielded a ZSH score <
3, and a ZMR score > 1. These criteria retained 17 positions, which we further filtered. We filtered
out positions which show an overlap in overrepresented amino acids in both groups (foreground and
background). We also filtered out positions which were not part of the predicted PH domain secondary
structure. At the end, we had nine positions which defined the organellar PIP motif (OPM)
Scoring of the 1216 PH domains We downloaded the amino-acid sequences oft he 1,216
reviewed PH domains from the uniprot database. We scored each PH domain according to the presence
or absence of the residues present in the newly defined organellar PIP motif (OPM) and those present in
the basic sequence motif (BSM). The scoring scheme was the following :
• OPM residues : Three points for the most conserved residues (the threonine residue located in
the —1-—2 loop and the lysine residue located at the end oft he —7 strand). All the other residues
received one point.
• BSM residues : one point per residue.
Each PH domain could in theory have a maximal score of 16 (maximal score of 13 if the PH domain
sequence contained the entire OPM and 3 if it contained the entire BSM).
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cooperativity events prediction
Prediction of cooperativity events For each interaction between a protein P and a hetero-
geneous liposome Lab (with a and b being two lipids of interest), we define NBIa the NBI observed
between P and La, NBIb the NBI observed between P and Lb, NBIabo the NBI observed between P and
Lab, and NBIabe the expected NBIab, that is, the sum of NBIa and NBIb. NBIa, NBIb, NBIabo and
NBIabe have at least two replicate each. For an interaction to be predicted as positively cooperative, the
following conditions must be fulfilled (Figure 30):
• NBIabo > NBIabe
• The NBIabo has to be superior to the highest NBI observed for NBIabe
For an interaction to be predicted as negatively cooperative, the following conditions must be fulfilled:
• NBIabo < maxNBIa;NBIb, provided that NBIa > 0.037 or NBIb > 0.037
• The NBIabo has to be inferior to the lowest NBI observed for maxNBIa;NBIb
Interactions that did not fulfill these criteria were classified as non-cooperative. The computed ratio
NBIabo/NBIabe (or NBIabo/maxNBIa;NBIb in the case of a negative cooperativity) defines the coop-
erativity index (CI). This index is completed with the TI computed for the interaction between P and
Lab (or between P and La or Lb in the case of a negative cooperativity)
Validation of cooperativity events We randomly selected 36 interactions that were classi-
fied as positive, negative and non cooperative in order to assess the sensitivity and specificity of these
predictions. To do so, we used LiMA In order to assemble liposomes of various concentrations (0,3,6,10
mol%) containing two lipids of interest (DOPI45P2 or DOPI35P2 and DHS1P or PHS1P or PS). Lipo-
somes containing DOPI45P2 and DHS1P as lipid of interest were assemble at a DOPI45P2 concentration
of 6 mol %. The PH domain concentration used in the validation experiments were identical to those
measured in the screen.
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Figure 30: Cooperativity prediction: scheme illustrating the heuristic chosen for the
prediction of cooperative binding.
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2.6 Discussion
M any cellular processes require the recruitment of protein to specific membranes, which are deco-rated with distinctive lipids that act as docking sites. In particular, the phosphoinositides (PIPs)
form signalling hubs, yet the underlying mechanisms remain elusive. A eukaryotic cell usually process
more than 1,000 di erent lipid species that bear structural, physical and biochemical properties. This
field of chemical biology lacks standardized experimental and computational methods that would allow
having a comprehensive view of the PH domain binding landscape and to unravel regulatory mechanisms
orchestrated by lipids. In this study, I present a new computational analysis pipeline, which in a first time
performs a technical assessment of the readouts outputted by the novel liposome microarray-based assay
(LiMA). We demonstrate that LiMA produces high quality and quantitative readouts that can be used
to capture and compare protein-lipid interactions. In a second time, it performs a functional assessment
of the same readouts. We applied this technology to a set of 91 PH domains selected from two species :
C.thermophilum and S.cerevisiae. We designed the LiMA to study a wide range of liposomes containing
the main lipid families. We applied the computational analysis pipeline to the readouts collected from
this screen and validated the postulate that PIPs are the preferred PH domains ligands and that these
binding events are dictated by particular sequence attributes proper to certain PH domains. Moreover,
we have generalized the concept of cooperativity as binding principle applied to the majority of PH
domains.
2.6.1 LiMA, a novel tool for high throughput screening of pro-
tein lipid interactions
To this day, many technologies have been developed in order to study protein-lipid interactions. Some
of these methods rely on liposomes and thus imitate very precisely physiological conditions. These
approaches usually yield very few false positive or negative interactions but are very di cult to setup
and are inconvenient for high-throughput screening . More recent improvements have led to a technology
making use of fixed lipids. This method, known as the lipid overlay assay is –as opposed to liposome
based assay- easy to setup and can be applied for high throughput screening [27] [60] [62] [131]. However,
this method usually yields a high number of false positive interactions due to the very high concentration
of lipid of interest, thus creating a non-physiological environment for the studied proteins.
LiMA is a technology marrying both characteristics: high-throughput and physiological conditions.
The technology makes use of liposomes in which the lipid(s) of interest studied are within a membrane
bilayer. Besides, LiMA makes use of a chip containing 120 spots onto which lipid(s) of interest can be
automatically spotted and this at di erent concentrations, and is thus easy to setup for high-throughput
studies. LiMA also sets a quantitative readout (NBI), which is proportional to the dissociation constants
(Kd) of a protein to a given ligand. In the future, other readouts could be envisioned and these Kds could
even be directly measured by making use of fluorescence imaging technique like two-photon excitation
microscopy or by using a di erent microscope like the total internal reflection fluorescence microscope.
In study, the chip settings we chose enabled the study of 120 liposomes. With the proper chip one could
assay the protein binding profile of thousands of lipids and screen the entire lipidome and proteome.
Future improvements of the technology could also enable the study of curvature sensing by proteins and
how it influences their recruitment to biological membranes. Additional adaptations of the protocol could
allow the insertion of protein into the liposomes and thereby represent an excellent method to study the
recruitment of protein requiring both protein and lipid partners at large scale.
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2.6.2 Systematic analysis of PH domains confirms their ability
to interact with membranes
In this study, we have made used of the technology LiMA in order the protein-lipid interactions between
91 PH domains and four other LBDs belonging to four species and 122 liposomes covering the most
frequent lipid families. We measured more than 11.000 experiments in replicates, which consist in one
of the biggest protein-lipid screen. Making use of manual annotation, we have extracted a threshold
allowing to distinguish binding events from non binding events. For this study, we used all annotations
in order to extract the binding threshold. This has the drawback of having to annotate every single
experiment, which cannot be conducted for screens containing hundreds of thousand of interactions.
However, the conducted analysis shows that 500 annotated interactions are enough in order to extract
a binding threshold yielding an excellent sensitivity and specificity. In this dataset, we have detected
2415 interactions, including 2269 physiological and 1628 of high confidence, capturing interactions with
a known Kd ranging from the nanomolar to the micromolar. We chose to focus on PH domains because
they are considered as good examples of LBDs. Besides, they have already been used in various studies
and this constitutes a good comparison basis for our results. The majority of the previous studies focused
on the so called “classical” PH domains, as opposed to PH-like domains. The group to which a PH domain
belong depends on the ability of the searching algorithms to recognize them. In this study, we focuse
on both types of PH domain and have found that 69 PH domains can bind at least one liposomes. In
most of the case, the binding event required the presence of several lipids of interest. Within the PH-like
PH domain category, many of them did unexpectedly manage to bind several liposomes (Figure 11 and
Figure 27). The binding events found in this study contain a big part of novelty. Indeed, we screened for
the first time 20 PH domains belonging to S.cerevisiae and 27 belonging to C.thermophilum. Another 5
were not found to interact with any lipid in previous studies. 75% of these 52 PH domains managed to
bind at least one liposome with a high confidence index, implying that a big fraction of the interaction
observed in this screen were novel.
2.6.3 Only fraction of PH domains interacts with PIPs localized
in ORG membranes
Our dataset supports the notion that the specificities of the PH domains encompass all seven phospho-
inositide species [131] (Figure 24). When clustering liposomes according to their PH domain binding
profiles, we observed that those containing phosphoinosidites known to predominantly localize in the PM
(DOPI45P2, DOPI34P2, DOPI345P3) and those containing phosphoinositide present in the orga nelles
(DOPI3P, DOPI4P, DOPI5P, DOPI35P2) [132] form two clusters that determine the propensity of the
two types of membranes to recruit PH domains (Figure 21). The first branching observed in the hier-
archical clustering engenders two main clusters. The first one exclusively contains liposomes mixtures
containing PIP species found on the plasma membrane. The second one contains PIP which are found on
various organellar membranes (but not in the plasma membrane). Those two clusters being driven by the
PIPs lipid suggest first that the PIPs lipid is the preferred ligand, and second that lipids located at the
plasma membranes and within organellar membranes recruit di erent sets of proteins. Additionally, we
the PM PIPs clade seems to display sub-clusters that are enriched in specific PM PIPs family members
(DOPI45P2, DOPI34P2, DOPI345P3). This corroborates the fact that di erent PM PIPs recruit di er-
ent PH domains [58] [64] [133]. This observation does not hold for the ORG PIPs cluster. Sub-clusters
seemed to be more influenced by the presence of secondary lipids enriched in negative charges. Consis-
tently with earlier findings, many more PH domains were able to bind PM PIPs than ORG PIPs [109]
[134] [135] [136] [137]. Noticeably, we have not found a PH domain capable of binding ORG PIPs without
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being able of binding PM PIPs, whereas some PH domains were able of exclusively bind members of the
PM PIPs family (Figure 24). All in all, most of PH domains can bind PM PIPs and only a subset can
recognize ORG PIPs.
2.6.4 PH domains interacting with ORG PIPs share common
sequence motif
The PH domains capable of binding ORG PIPs were not probed at a higher concentration than those only
capable of binding PM PIPs. Besides, none of the 16 ORG PIPs binders preferentially bound a member
of the ORG PIPs. This means that these proteins probably have some attributes conferring them the
ability of on top of binding PM PIPs, to also bind ORG PIPs. These attributes (e.g, amino acids) should
expectedly be absent from the group of PH domains that can only bind PM PIPs. Some studies have in
the past attempted to identify particular amino acids within PH domains responsible for some functions
(e.g, binding of particular lipids). These studies su ered from many flaws, which makes the veracity of the
proposed amino acids questionable. In some cases, the dataset used considered to few ligands [78] [112],
in others, the studies focused datasets including too few PH domains[71]. The small numbers of proteins
or lipids used in these studies did not confer them enough statistical power to generalize the function
associated with these amino acids to the entire PH domain family. Besides, PH domains are known to have
less than 20% of sequence identity, which makes the search of a consensus motif particularly hard without
a comprehensive view of the PH domain binding landscape. In this study, we have found nine positions
that contains amino-acids enriched in the group of PH domains capable of binding ORG PIPs. Amongst
these nine positions, eight are completely new and have never been mentioned in previous studies. Some
of these positions are close to the known binding pockets (—1-—2 loop) and others far away (—7 strand
and –-helix) and all of them were experimentally confirmed, in vitro and in vivo. Interestingly, two of
these positions are found to be mutated in human cancer samples [110] [111]. The human PH domain
OSBP2 has a natural variant found at the beginning of the C-terminal –-helix of its PH domain (R262L).
This particular position is part of the nine positions we have found and is distant from any reported PH
domain’s binding pocket. Interestingly, the in vitro and in vivo validation experiments showed that
mutations of this position specifically a ected the binding to ORG PIPs. The second natural variant
found is often mutated within the —1-—2 loop of the FAPP1 PH domain (T9A). This region is known to be
involved in the bindinf of DOPI4P [138]. The validation experiments confirmed what was already known.
The mutation specifically a ected the binding to the DOPI4P liposome in vitro and the localization to
the trans Golgi in vivo (Figure 27). Few studies have already mentioned the role that could play amino
acids located in the in the —7 strand or in the – helix [136]. For the first time, we confirm this hypothesis
but the exact mechanistic implications of these residues remain unknown. One hypothesis is that proteins
containing PH domains can form homodimers. It has been shown that some PH domains locate much
more at some membranes in dermic forms. Thus, it is assumable that perturbing the homodimerization
impacts the recruitment to organellar membranes. An enrichment analysis of proteins showing a high
conservation of the OPRN residues indicate that these proteins tend to be involved in oligomerization
process much more than other PH domain (deprived from OPRM residues) (Figure 24). If we assume
that the PIPs bound by a PH domain is a good marker of its in vivo localization, than the attributes
conferring the ability to PH domains to bind these di erent lipids are primordial for the fulfillment of
their cellular functions. When we performed a multiple sequence alignment of the entire PH domain
universe and looked for the presence of the 12 residues (BSM and OPRM residues), we found that the
OPRM reisdues are found in a much smaller set of PH domains than the BSM. Interestingly, not a single
PH domain contained the OPRM residues without containing the BSM residues, whereas the many PH
domains solely contained BSM residues. An enrichment analysis revealed that OPRM reidues containing
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PH domains were significantly more involved in cellular transport activities compared to the other PH
domains (Figure 24). The PH domains enriched in cellular transport activsities typically carry ligands
(lipids) from one donor compartment to another acceptor. The fulfillment of this activity require to be
able to bind di erent membranes containing di erent lipids, even though the exact binding mechanism
are still unknown. Some studies pointed out that particular residues might be responsible for the specific
recruitment of PH domains to biological membranes, and our data indicate that a single motif might be
able to sense both PM and organellar membranes [139]. A question that still remains to be answered is
why some PH domains can bind PM membranes without being able to bind organellar membranes, but
the other way around does not hold.
2.6.5 Interactions of PH domains with membranes are modu-
lated by cooperation between PIPs and other lipid species
Several studies which focused on a small set of PH domains have already postulated non PIPs lipids
can be bound by PH domains. The presence of these “secondary lipids” in the neighborhood of PIPs is
assumed in some cases to stabilize the interaction between the PH domains and the PIP. This concept
of synergetic binding between a PH domain and several lipids is known as cooperativity [69] [140] [141].
Our data o er for the first time the chance of assessing the occurrence of cooperative events in the PH
domain binding landscape. We have demonstrated that cooperative binding is not anecdotal, but rather
a general binding principle of PH domains. As several studies in the past have shown, we have found that
negatively charged secondary lipids (predominantly LCBP1) account for most of the cooperative events.
More than a finely tuned binding, 19 PH domains required the presence of two lipids in a liposomes
in order to be able bind them, implying that many PH domains require these cooperative mechanisms
in order to bind PIPs containing membranes. Noticeably, the presence of these secondary lipids can
sometime confer a particular specificity to a PIPs which the PH domain did not have otherwise. Given
that most of previous study were performed with liposomes containing a single lipid of interests, our
results answer the long lasting mystery why most PH domains lacked specificity.
The concentration of the lipids of interest in the liposomes most probably plays a role in the amount
of false negative cooperative events yielded in our predictions. Most lipids of interest were at high
concentration (10 mol %), which is a saturating concentration for many protein-lipid pairs of our screen.
Many interactions we classified as non cooperative were contradicted by the validation experiments we
performed. In those cases, cooperativity was observed at lower concentration, which we were not able to
capture [Supplementary Table 2].
2.6.6 Recognition of the same cooperating lipids is shared by
functionnally linked PH domain-containing proteins
Biological membranes are complex and contain a myriad of lipids. Their content is dynamic and varies
from one organelle to the next. Although the exact content of each biological membrane has not been
entirely depicted yet, one can assume that they fulfill both a structural and a functional role by recruiting
particular proteins. In this study, we have used cooperativity profiles as mean of understanding biological
function and cellular localization of PH domains. Many proteins studied in this screen are found to locate
in vivo the bud and bud neck [142] or to interact with the protein Cdc42, an important actor the the
bud formation [117]. Noticeably, most of the PH domains tested interacting with the protein Cdc42
display a very similar cooperativity profile compared with other proteins. They show indeed a stronger
binding to DOPI45P2-PS containing liposomes which is in accordance with PS in vivo location, that
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is, in areas of polarized growth [116]. Suprisingly, PH domains which were not found to interact with
Cdc42 but nonetheless locate to the bud did not exhibit any cooperative event with DOPI45P2-PS. This
observation indicates that a strong cooperativity with the pair DOPI45P2-PS seems to be a marker of
biological function, that is, Cdc42-regulated cellular functions. In agreement with this hypothesis, we
observed that many PH domains from protein locating elsewhere in the cell but still linked to the same
biological process also were able to cooperatively bind the pair DOPI45P2-PS. For instance, the PH
domain belonging to Slm2 –which was demonstrated to be an actor of the polarized actin assembly-
did not bind the liposome containing DOPI45P2 as single lipid of interest. However, the presence of
PS induced a binding event [143]. The same observation did not hold for the PH domains belonging to
the Osh proteins (Swh1, Swh1-ct, osh2, osh3, osh3-ct). In those cases, the presence of PS only slightly
increased the a nity to the liposomes. Additional experiments confirmed that this might be due to an
already saturating concentration of DOPI45P2.
The protein Cdc24 contains itself a PH domain and act as chief regulator of Cdc24 activity. Cdc24
locates at two di erent places: in the nucleus, and in areas of polarized growth. The nuclear membrane
contains many lipid species, including PIPs and sphingolipids [122] [144] [145]. Noticeably, most of the PH
domains from our screen which are known to locate in the nucleus displayed an exacerbated cooperativity
with the liposome containing DOPI45P2-LCB1Ps as lipids of interest.This suggests that the cooperative
binding of PH domains to lipids may serve various functions. Lastly, even though C.thermophilum and
S.cerevisiae displayed on average a similar binding landscape (Figure 8), they strongly di ered in terms
of cooperative landscape. Given that these two organisms are very distinct, we can imagine that these
organisms have evolved to contain di erent lipid mixtures in their biological membranes in order to face
di erent thermic conditions. Alternatively, orthologous proteins probably evolved towards di erent sets
of functions, which could explain the weak sequence identity that orthologous proteins share. These
assumptions would require additional analysis regarding the exact lipid compositions of each organism
and the implication it has in terms of biological function served, which is not the scope of this study.
2.6.7 A new path for drug discovery
Many lipid binding domains are enzymes, and their specific recruitment to lipids have biological impli-
cations, which are often linked to diseases when those binding events are abrogated [73]. Our data have
been able to reveal the consequences of many disease-associated mutations on the binding specificities
of PH domains. This suggests that protein-lipid interactions are of a great interest for the comprehen-
sion of mechanisms underlying certain diseases and that the developed computational methods analysing
readouts from such high-throughput chemical biology assays can be employed to aid this understanding.
Regardless of the nature of the interaction, lipid-binding domains constitute a relatively new niche to
be exploited in drug development. Some lipid binding domains have already been shown to contain a
druggable pocket that can be used to perturb protein-lipid interactions [146] and [147]. The discovery of
the lipid-binding domain C1 as a druggable target lead to the development of small molecules that are
now close to clinical trial [148]. Deregulations in the phosphoinositide-3-kinase pathway have often been
encountered in many diseases and represent an attractive set of targets for drug development. Typically,
hyperactivations of the PI3K pathway have been linked to cancer, whereas hypoactivation plays an im-
portant role in the development of type II diabetes [148]. Many compounds targeting the PI3K pathways
have been developed to inhibit downstream targets (typically, Akt1). A recent study has identified two
molecules altering interactions between DOPI345P3 and its pleckstrin homology domain containing part-
ners. To do so, the authors screened 50,000 molecules in order to indentify these two molecules, and have
tested the anticancer activities of one of these compound (PIT1) in vitro and in vivo. PIT1 revealed to
be a good candidate in the treatment of glioblastomas (which show elevated levels of DOPI345P3).
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2.6.8 Conclusion
The group of Dr Gavin has created LiMA, the first technology enabling the study of protein lipid in-
teractions under physiological conditions and in a high throughput manner. The computational meth-
ods developed here have proved that this technology could produce readouts of high quality for large
scale studies. It has also shown that the recruitment of proteins (PH domains) is largely influenced
by dominants lipids (PIPs) and that biding a nities and specificities are also frequently determined by
the presence of additional lipids. The analysis also revealed cooperativity as a general key mechanism
for membrane recruitment and showed that proteins displaying a similar cooperativity profiles do have
common biological functions or cellular localizations. The developed methods have also led to the iden-
tification of a motif shared by proteins displaying a similar binding profile containing amino-acids found
mutated in some human cancer, and thereby enable the interpretation of disease-associated mutations.
This opens a new door to identify new classes of drugs specifically perturbing some protein-lipid inter-
actions given that they constitute attractive targets for pharmaceutical drug development. This work
provides some milestones in the field of protein-lipid interactions, yet the plethora of lipids constituting
cells leaves us far away from understanding them all. Parallely, data on the bioactivities of small drug-like
molecules is accumulating at a tremendous speed, and high-throughput assay can now span molecular,
phenotypic and organismal readouts. Chemical’s therapeutics and o  targets are coming from in vitro
screens are complemented by high-throughput cell based assays and organismal responses to chemical
perturbations. The plurality of these assays paired with a generalized e ort to collect the produced data
in public databases, have created unprecedented opportunities to develop computational tools aiming at
integrating these heterogeneous data in order to make new inferences on the complex e ects chemicals
can have on biological systems.
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Development of an e cient and
scalable chemical analysis platform
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Summary
In this part, I present CART, a Chemical Analysis and Retrieval Toolkit. CART
represents a major contribution to the field of large-scale chemical biology in the sense
that it is the first scalable computational platform, which annotates chemicals and
computes enrichments on these annotations by integrating many chemical centric
databases. I am first author the CART publication (manuscript currently in
preparation), and have contributed to all aspects of the project. I am the main
contributor of source code, have co-designed the pipeline, performed the benchmarks and
analysis mentioned in this chapter, and I am co-writing the manuscript.
CART: an e cient and scalable Chemical Annotation Retrieval Toolkit
Deghou, S., Zeller, G.,Iskar, M., van Noort V., Bork P Bioinformatics, Manuscript
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Chapter 3
Introduction
3.1 Publicly available resources
T he number of small molecules to which humans are exposed has tremendously increased in the lastcentury [149]. These small molecules are found in our food, constitute the drugs we take and can
be found in very high concentration in the environment when produced in massive amounts by industries.
The various e ects of these small molecules on our physiology are far from being unravelled, and while
their mechanisms of action are being studied, small molecules can also be used to understand how
biological systems function. In chemical biology, the perturbation of a biological system upon chemical
treatment can lead to a better understanding of biology. There is a growing awareness of this reality
within the scientific and politic community, and this is translated by an increasing number of large-scale
studies with the aim to generate comparable and standardized assays as current knowledge is scattered
and heterogeneous [150] [151]. These large-scale studies are often made available to the public through
open access databases. The number of these databases as well as their content is constantly growing.
The program REACH (Registration Evaluation Authorisation and Restriction of Chemicals) constitutes
for instance a good illustration. REACH is a European Union regulation of 2006 [152]. REACH demands
that chemical companies provide information regarding the compounds they manufacture, import and use.
The program has been initially timed to last 12 years. By 2018, around 140 000 chemical substances will
be registered. The PubChem database is another prime example of growing chemical centric database.
PubChem bioassay contained 800 entries in 2008, almost 500,000 in 2011 and almost 1,200,000 in 2015.
PubChem substance has grown from 17 million to more than 100 million entries [153]. The Supplementary
Table V.1 lists some of the most cited chemical resources that link chemicals to biological activities and
span molecular and phenotypical readouts. The raise of high-throughput screenings has breached into
chmical biology, which can now profile tens of thousands of chemicals and provide them with rich and
heterogeneous readouts regarding their engendered gene expression profiles, metabolic changes, toxicity
profiles, modified cellular phenotypes or target profiles [154] [155] [156]. As a consequence of this, a
myriad of open access databases dedicated to chemicals and their associated biological entities emerged
in the last 10 years, and the number of these databases as well as their content flourishes dramatically.
63
Part III Chapter 3 – Introduction Chapter 3 – Introduction
3.2 Toward an integration of the publicly available
resources
T hese big e orts have created the opportunity to integrate these various heterogeneous data underthe same umbrella and therefore to open the door to new questions and inferences. Characterizing
relationships between chemicals and biological entities as well as similarities amongst chemicals helps in
drug repurposing, new drug development and elucidation of gene functions by linking drug induced gene
expression profiles to phenotypes [30]. Many studies have for instance shown that side e ects were
primarily caused by the interaction between a drug and a unique protein [36], and that the target profile
of drugs was often predictive of their side e ects [34]. Alternatively, if each compound of a chemical family
or library is annotated on one side in terms of side e ects it induces, and on the other side in terms of
toxicity it induces, then one can attempt to predict whether which toxicity readouts are most predictive
of some side e ects. Answering these questions requires an integration of the existing resources, and an
analogy with the genomic field helps to understand why this integration is very challenging in the field
of chemical biology.
3.3 The example of the genomic field
W ithin the genomics field it is already possible to gain a better understanding of links betweengenes and phenotypes. E orts toward creating a controlled vocabulary to describe the function
and localization of gene products as well as the use of common unique identifier to refer to genes helped
the process of data integration [157]. It facilitated the implementation of gene enrichment tools [158],
which enabled a better understanding of the relationships between the genome of an organism and its
phenotype. Although there is a growing demand for such tools in chemical biology, to our knowledge,
there exist no software that would enable finding which biological propertiesare shared and/or enriched
within a set of chemicals, or simply to have overview of all biological activities that are known of a
particular chemical. Many reasons might explain this absence.
3.4 The challenges
F irst, some chemical entities can have hundreds of synonyms and the absence of o cially recognizedunique identifiers makes the search of a compound across databases very di cult. The Interna-
tional Union of Pure and Applied Chemistry (IUPAC) 1 has set rules to generate systematic names for
chemical compounds. This nomenclature aims at leaving no ambiguity whatsoever when mentioning a
given chemical name (either written or spoken). Each chemical name should refer to a single chemical
structure. In reality, the interpretation of chemical names is obscured by a tremendous amount syn-
onyms and inaccurate names in usage. Di erent salts, mixtures and stereoisomers of the same chemical
compound often account for the increasing number of names under which chemical compounds (like for
instance drugs) can be refered to. Two chemical centric databases could for instance link certain biolog-
ical activities to two di erent chemical names (like phthalonitrile and o-dicyanobenzene) refering in fact
to the same chemical compound.
1http://www.iupac.org/
64
Chapter 3 – Introduction 3.4. The challenges
3.4.1 Chemical name search
Chemical names are often long and complicated, which can make the search for a given chemical whose
spelling is not clear very di cult. Searching for a chemical name in a database often needs to take
into account possible mistakes (for instance, a user might look for “acetamnophen” when he actually
is looking for “acetaminophen”). Not many software programs enables chemical name matching taking
into account spelling mistakes (so called “fuzzy search”), and the one providing this option (PubChem,
ChemDB [159]) usually limit the search input to one chemical name. Other available online tools like
STITCH [160] enable the search of multiple chemical names but prevent fuzzy searches. Additionally,
STITCH limits the search input to 200 chemical names. The actual status is that there is no available
free open source software that would allow a user to input hundreds, thousands or tens of thousands
of chemical names with or without spelling mistakes to get back any information from the database
against which the chemical names are matched. This complex problem lies in the fact that many of
the existing chemical centric databases rely on relational databases (mostly MySQL or PostgreSQL).
Relational databases can store and index vast amount of data and o er some semblance of text-based
search functionalities, but they are mostly tuned toward relational operations between tables including
joins, and more generally at storing and manipulating structured data. Database Models (DBMs) will
perform well when it comes to matching exact chemical names, but are not conceived for fuzzy matching.
A fuzzy search for a given chemical name in a big table can often take up to two minutes with a default
indexing scheme. Besides, fuzzy searches within a relational database are often tuned for English language
and not for chemical names.
Second, open access databases focusing on particular biological activities of chemical entities use
their own identifier and rarely cross-reference themselves. Third, chemical entries are not referred to a
unique chemical identifier that would help mapping a chemical name to several databases. Fourth, the
absence of controlled vocabulary in some databases makes it di cult to identify identical readouts shared
by di erent chemicals.
In the next chapter, I present a computational platform addressing the above-mentioned challenges.
It enables the integration of data on chemical bioactivities that are scattered across many di erent
databases.
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Results
We have developed CART, a computational platform that retrieves biological annotations of chemical
sets and computes which are enriched. In a nutshell, CART is a software available as a command line
tool and via a web interface (http://cart.embl.de) whose input consists in a list of chemical names and
the output is a table of enriched biological terms that are associated to these chemical names. CART
consists of three modules: Name Matching, Enrichment, Visualization. The Figure 1 represents the
CART’s workflow.
4.1 Features and functionality
Matching chemical names
C ART expects a tab-delimited file as an input for the name matching module. This is the namematching input file. The first column of the name matching input file has to contain chemical
names. Optionally, the user can add a second column containing scores proper to each chemical. These
are used for rank based statistics. Within that universe, each chemical name is associated to a single
Chemical ID (CID). The Name matching module will match each chemical present in the name matching
input file against the indexed chemical universe according to di erent matching algorithms. The CID
corresponding to the best match is return. The Name matching modules iterates through the entire list
of chemicals and produces the name matching output. This output is then fed to the enrichment module.
Retrieving biological annotations
T he enrichment module matches the fetched CIDs to those present in the database selected by theuser and get the annotation terms associated to those CIDs provided by the database. Each
CID present in the database will thus be assigned to one or several annotation term. Those results
are concatenated in a first table, which is the first output of the enrichment module: the annotation
table. The enrichment module will compute which of these terms are enriched within the list of chemicals
provided by the user (the foreground) by comparing their occurrence to those found either in the database
selected by the user, or in a second list of chemicals optionally provided by the user (the background,
which also has to be run through the name matching module and then fed to the enrichment module as
background). Enriched terms will be printed to a second output file: the enrichment table.
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Visualizing results
T he two enrichment output files will then be fed to the visualization module, which will generatestwo html files. One html file containing the enrichment table with links to external resources.
One html file rendering an interactive network of the foreground chemicals associated to their enriched
terms.
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Figure 1: CART’s workflow
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4.2 Data integration
C hemical annotation data from nine databases were collected and their chemical names werematched to flat Stitch IDs (CIDs) using Name Matching module described in the next section
4.2.1 Molecular targets
Stitch[160]
URL: http://stitch.embl.de
Stitch is the largest resource focused on chemical-protein interactions.It contains interactions for between
300,000 small molecules and 2.6 million proteins from spanning 1133 organisms.
TTD[161]
URL: http://bidd.nus.edu.sg/group/cjttd/
The Therapeutic Target Database (TTD) is a resource containing information relating to therapeutic
protein and nucleic acid targets. It also provides information on targeted disease. The database contains
information on 2025 targets and 17,816 drugs.
DrugBank[162]
URL: http://www.drugbank.ca/
DrugBank is a database providing chemical, pharmacological and pharmaceutical data. It contains 7759
drug entries and 4282 protein targets (annotated in three main categories : therapeutic targets , metabolic
enzyme, transporter).
4.2.2 Therapeutic classifications
Chembl ftc[163]
URL: https://www.ebi.ac.uk/chembl/ftc/
The Functional Therapeutic Classification system is a controlled vocabulary defining and structuring
more than 20,000 drugs mechanisms and modes of action.
ChEBI[164]
URL: http://www.ebi.ac.uk/chebi/
The CHemical Entities of Biological Interest (ChEBI) is a database containing a structured vocabulary
describing 43216 small molecules in terms of chemical structure and biological function.
4.2.3 Phenotypic readouts
Sider[165]
URL: http://sidee ects.embl.de/
The Side e ect resource database (SIDER) contains information on drugs and their side e ects. The
database contains 996 drugs, 4192 side e ects and 99,423 drug-side e ects pairs.
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DrugMatrix[166]
URL: https://ntp.niehs.nih.gov/drugmatrix/
DrugMatrix contains information on drugs and their induced toxicity in rat. It contains information on
638 drugs and gene expression data generated by extracting RNA from the toxicologically relevant organs
and tissues (10,000 gene array).
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Figure 2: Overview of the resources integrated in CART.
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4.3 Name matching
T he Name Matching aims at fetching CIDs so that the Enrichment module can use them in orderto retrieve annotation terms from any incorporated database.
Input The user input consists of a single file in which each line contains one or two columns. The
first column holds the chemical name, and the second column a potential score assigned to the chemical
(which might be used for ranked statistics).
Preparing the chemical universe The chemical universe encompasses both STITCH and
PubChem. From the STITCH database, we downloaded two source files. The ‘alias file‘ containing a
one to one mapping between the CIDs and the chemical names, and the ‘synonym file‘, containing a n
to one mapping between the CIDs and the chemical names. The union of these two files needed to be
performed for the simple reason that the ‘alias file‘ contained many CIDs which were not found within
the ‘synonym file‘. The ‘non flat stitch file‘ contained thus all CIDs and chemical names present in the
STITCH database. We subsequently added each CID as a synonym of itself to the chemical name column
both for the ‘non flat stitch universe‘ and ‘non flat PubChem universe‘. This aims at retrieving CIDs
in the event that the user would directly input CIDs instead of chemical names. Finally, the CIDs of
both universes were mapped against the flat CID mapping file in order to transform each CID to its
parent CID in order to avoid stereochemical and salt form confusion(Figure 3). The final files ‘flat stitch
universe‘ and ‘flat pubchem universe‘ were then indexed.
Indexing the chemical universe Chemical name matching is a complex problem for which
we have not found any suitable service capable of matching thousands of chemical names against a
database in order to retrieve their IDs in an acceptable time and with an acceptable accuracy. This task
is hampered by the fact that there exists no o cially accepted reference chemical universe that would
contain every single compound ever studied and to which the community could refer. Resources like
STITCH or PubChem are two initiatives beginning to address this issue. A second obstacle impeding
this function lies in the fact that chemicals rarely have a single universally accepted name, making
each compound having tens or sometimes hundreds of names, which engender a theoretical huge chemical
universe. More importantly, chemical names very often consist of chemical formulas which when inputted
by a user are prone to typos, as a results of which, searches for an exact chemical name within a database
can often yield no results. Finally, chemical related resources create their own chemical IDs, rarely
reference their IDs to other IDs and in the vast majority of cases do not include an exhaustive list of
chemical names per ID, making the search for a particular chemical even more di cult. Some of these
web services (STITCH) do not provide fuzzy matches, that is, recognizing an inputted chemical name
even if it contains some typos. Some of these web services limit the number of possible inputted chemical
names in order not to overload their server (STITCH limit the input to 200 chemical names) or disable
completely multiple inputs (PubChem). Other web services do not even support fuzzy matches, that
is, recognizing a chemical name even if it contains typos. The reason for these restrictions lies in the
storing and indexing systems used by these web services. Many of them make use of DBMs including
PostgreSQL 1, and even though DBMs can store and index vast amount of data and o er some semblance
of text-based search functionalities, they are mostly tuned toward relational operations between tables
including joins, and more generally at storing and manipulating structured data. DBMs will perform well
when it comes to matching exact chemical names, but are not conceived for fuzzy matching. Thus, we
decided to employ a full text search engine in order to store and index our chemical universe. Full text
1http://www.postgresql.org/
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search engine can o er sub-second search results indicating which indexed documents contain exactly
or partially the queried term out of millions or even billions of indexed documents, when DBMs can
sometime take over a minute (Figure 4). They o er rich and flexible parameters, algorithms and distance
metrics in order to rank the retrieved documents according to their similarity to the input query, which
is very di cult to achieve with DBMs. Full text search engines are very well suited for adding, deleting
or updating indexed document, which is advantageous to continuously integrate new chemicals that are
deposited to PubChem on a daily basis. We have chosen to use the full text search engine library Apache
Lucene 2. It is a scalable, high-performance library entirely written in Java capable of indexing more than
150GB/hour on modern hardware 3, and has very small RAM requirements (only 1MB heap). It uses
an incremental indexes as fast as batch indexing and the engendered index size is roughly 25% the size
of text indexed. In order to index the chemical universes, we used Solr 4. Solr is a web application built
around lucene which functions as REST-like API. It can be used as an interface between the developer
and lucene in order to index documents in lucene. Solr can be deployed in any servlet container and
easilly configured through two configuration files (schema.xml, solrconfig.xml).
Matching algorithms Inputted chemical names are matched against the selected universe(s) (in-
dexes) according to three matching algorithm. The exact matching looks for chemicals corresponding
exactly to the inputted name and return a NA if no matches has been found. The fuzzy matching tolerates
mistakes including missing misspelt chemicals. For instance, if the user inputs ‘acetominophen’ instead
of ‘acetaminophen’, the name matching will still return the correct CID. The heuristic matching removes
part(s) of the chemical names that are found in many chemicals and considered as non-informative. For
instance “hcl”, “dihydrochloride”, “hydrochloride”, “salt”, “potassium”, “dehydrate, “acid”, “oxide” and
“chloride”.
Output The output of the name matching is a tab-delimited file containing five columns. (‘name
matching [foreground/background] file‘). The first column contains the matched CIDs. The second
column contains the score provided by the user in the input file. If no score is found in the file, this
column contains NA values. The third column contains the chemical names inputted by the user. The
fourth column contains the chemical names found in the universe and corresponding to the CID printed
in the first column. The fifth column contains the name of the algorithm that identified the CIDs
corresponding to the user’s chemicals (EXACT MATCH, FUZZY MATCH or HEURISTIC MATCH)
(Figure 1).
4.4 Enrichment
Input A first input corresponding to the output of the name matching tool is provided. This is the
foreground. Optionally, a second input can be provided and will be considered as the background.
Module The fetched CIDs of the foreground are matched against the collected databases and corre-
sponding annotation terms are retrieved. If background is provided, the same operation is repeated. If
no background is provided, the default background is set to the CID found in the database(s) chosen for
the enrichment tool, and thus, all the enrichment terms contained in the databases are retrieved. A fisher
test is then computed on each annotation term retrieved and a correction method for multiple hypotheses
2http://lucene.apache.org/core/
3http://people.apache.org/ mikemccand/lucenebench/indexing.html
4http://lucene.apache.org/solr/
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Figure 3: Resources integration process. (Top left)s Two source files are downloaded from
the stitch web server. The ‘alias file‘ (named chemical.aliases.v.X.Y.tsv.gz) contains a one
to one mapping between the CIDs and the chemical names. The ‘synonym file‘ (named
chemicals.v.X.Y.tsv.gz) contains an n to one mapping between the CIDs and the chemical
names. The CID of these files are first converted to flat CID using the flat CIDs mapping
file (top right). The union of these two newly mapped flat CIDs mapped files is then
performed. This is the Stitch universe. We subsequently added each CID as a synonym
of itself to the chemical name column. (Top right) Resources were downloaded from URLs
mentioned in the paragraph "Data integration" (4.2). The CIDs of each database are first
converted to flat CIDs before being integrated to CART. Every CID of the databases has
to be included in the indexed chemical universe.
72
Chapter 4 – Results 4.5. Visualization
    


	


 	




 
!"#"$
##%"
 &#$
"""'
Figure 4: Overview of the lucene full text search engine chemical fuzzy name search
performance vs an InnoDB full text index (MySQL). Search time grows linearly for the
lucene full teaxt search engine whereas it grows exponentially for the InnoDB full text
index.
is applied. Annotation terms yielding a P value inferior to the type I error cut o  (by default 0.05) are
retained and displayed to the user.
Output Two outputs files are provided. The first output is a tab-delimited file, this is the ‘enrichment
output file‘. It contains the enriched terms the enriched terms along with database of origin, links to
external resources, p-values and odd-ratios. The second output is another tab-delimited file, this is the
‘annotation output file‘. It contains all the annotation terms that have been retrieved for the foreground
chemicals using the selected resources (Figure 1).
4.5 Visualization
Input Three input files are required: the two output files from the enrichment module as well as the
output of the name matching module corresponding to the foreground.
Output The visualization module generates two .html files. The first one represents a table of the
enriched biological annotation terms including URL links redirecting to the databases where the terms
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was extracted from. The second .html file represents a dynamic and interactive network representing the
links between the chemical from the foreground and their annotation terms. Five layouts are currently
included, which algorithmically position the chemicals and biological annotation terms in the graph
(Figure 1). The network generation was implemented using the cytoscape.js API [167] and thus benefits
of many of the cytoscape.js features.
4.6 Synonyms
Input The required input is the same as the one described in the name matching module
Output The synonym modules uses the same search algorithm described in the Name Matching
module and uses PubChem as a default chemical universe. It returns a two tab-delimited
4.7 Web interface
The web interface has been implemented with the galaxy framework. Galaxy is a flexible and modular
open source web based platform automatically managing user sessions and workspaces. It keeps track of
every file inputted and job ever run. The software is integrated into galaxy and each module can be run
independently from each other. The whole workflow can also be run at once. Inputted and outputted
files appear in the user’s history (or workspace) and can be downloaded and edited, and corresponding
jobs can be re-run with the exact same settings, which. Since the history keeps track of a user’s action,
galaxy is an excellent platform for user to perform reproducible data analysis. Galaxy uses by default a
NoSQL database, which is not suitable for a multi user application. Thus, we configured it to work with
a PostgreSQL database.
4.8 Standalone version
The software is available at: http://cart.embl.de/static/automatic-installer.sh.
A single shell script takes care of the entire installation process. It downloads the software, resources and
sets up the user environment.
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Figure 5: (Left) Overview of the name matching module sensitivity benchmarked against
four independent datasets. The name matching modules yields an average of 94% sen-
sitivity and the fuzzy and heuristic match always increase the sensitivity of the search.
(Right) Overview of the name matching module precision benchmarked against the same
four datasets. The name matching modules yields an average 93% precision.
4.9 Benchmarking
Accuracy The core of CART lies in the name matching module. Fetching the correct CID by match-
ing to the correct chemical is of upmost importance in order not to wrongly annotate a chemical set.
Thus, we measured the reliability of the name matching module by evaluating its accuracy. To do so,
we have selected four datasets whose chemicals had already been matched to either STITCH CIDs or
PubChem CIDs. We subsequently fed the name matching module with the chemical names present in
those four datasets and measured the accuracy of matching by comparing the CIDs fetched by the name
matching module to those manually matched by the original authors of the dataset (Figure 5). The
sensitivity was computed as being the ratio of fetched CIDs over the total number of inputted chemicals
and the precision as being the fraction of correctly matched CIDs. On average, the name matching mod-
ule yielded a 96% sensitivity and 94% precision. In all datasets benchmarked, the fuzzy matching and
heuristic matching increased the sensitivity (on average by 12%) and the specificity. In the future, we
plan to include an option through which the user will be able to adjust the heuristic matching by setting
himself words he wishes to remove from chemical names.
Speed As mentioned earlier, the main motivation for choosing a full text search engine as core of
the name matching tool over a DBM lied in the fact that fuzzy matching results can be return within a
second depending on the size of the query. We benchmarked the speed of the name matching module on
a Macintosh HD 2.8Ghz Intel Core i5 with 8GB of RAM. To this purpose, we generated several datasets
of di erent increasing size by randomly selecting the chemicals from the PubChem universe and run them
through the name matching module using the STITCH universe. In a first time, we measured the time
taken for it to return the results in order to see whether the trend was linear or exponential. In a second
time, we decomposed it per algorithm in order to analyze whether the fuzzy and heuristic matching took
significantly longer than the exact matching. Finally, we compared these results to those obtained with
a MySQL database having indexed the same universe using a B-tree index (Figure 6). The results of the
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Figure 6: (sLeft) Box plot illustrating the name matching module speed. The x axis rep-
resents the dataset size. For each size, 10 random chemical name datasets were generated
using the pubchem universe. The y axis represent the time (in seconds) required to match
all chemicals using the three chemical name searching algorithms (exact, fuzzy, heuristic).
(Right) Detailed overview of the time required by each chemical name searching algorithm
using one dataset per size.
benchmarking clearly indicated that the matching speed grew linearly with the size of the query and that
the fuzzy and heuristic matching were not significantly slower than the exact matching. When it came to
exact matching, DBMs performed slightly better but proved to be unusable when it came to fuzzy and
heuristic matches.
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Future directions
CART is a software providing an integrative, scalable, accurate and very fast chemical name matching
tool and annotation platform. It can be used in any small molecule high-throughput screening or in
any study attempting to make sense of chemical sets. It is available over the web with via an intuitive
graphical user interface managing user sessions and is also available as a command line tool for more
programmatic uses.
Improvement on the name matching So far, the heuristic matching works with a set of
commonly encountered terms that can be removed from the chemical name to increase the likelihood of
finding a match. The next version could take into account user specific terms, which should be avoided
during the heuristic match of the name matching step. On a technical note, the parallelization of the
index building and the name search will also greatly improve the search time performance. Preliminary
tests have shown that the search time performance could be increased by a factor 8 (with 10 CPU used as
opposed to one in the current release of CART). The parallelization of the name matching step is currently
in beta testing. The nature of the name matching could also be extended. CART expects chemical names
as an input so that the name matching can match them against the chemical universe chose, which solely
consists of chemical names. The scalability and flexibility of the search engine integrated could make
possible the integration of chemical structures or experimental outputs. This would be particularly useful
for scientists working with high-throughput technologies. Most of the time, high-throughput technologies
output particular chemical fingerprints (for instance the NMR or MS profile of a chemical). These could
be used as an alternative of chemical names for the ID retrieving step. The advantage of such a matching
algorithm would be that it does not assume that the user (typically an experimentalist) knows anything
about its chemicals.
More Integration CART includes seven databases from which it extracts biological annotation
terms to extend the covered molecular and phenotypic read-outs. One of the first resources to be inte-
grated will be LINCS [168]. Integrating LINCS would enable users having a better understanding of the
gene expression profiles and phenotypic readouts induced by more than 10,000 chemicals.
Prediction module The goal of the prediction module is to predict a phenotypic read-out based
on another readout. For instance, given a set of toxicological endpoints, can we predict a drug side
e ect(s)? Can new drug-target connections be inferred from toxicological similarity? Can we use a
drug’s cytochrome P 450 profile to infer side e ect or toxicological endpoints? These predictions would
imply measuring the pairwise similarity of inputted chemicals with regards to two di erent read-outs (for
instance, cytochrome P450 and side e ects) and to perform a ROC analysis to get the prediction power
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of one read-out with regard to a second read-out. This module is still in beta test and will be part of the
next CART release.
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Conclusion
I n this dissertation, state-of-the-art computational methods are presented to take the maximum ad-vantage of large scale small molecule data that is increasingly becoming available. I contributed
to the field of large scale chemical biology by developing computational methods analyzing and making
sense of protein-lipid interactions using readouts produced by LiMA, cutting edge technology with a focus
on PH-domains. The results of this analysis pipeline are illustrated in two publications [28] [38]. The
analysis pipeline itself is presented in a third publication, whose manuscript is currently in preparation
[37], so that it can be reused in any other screen utilizing the technology LiMA with any kind of lipid
or protein. Given that a eukaryotic cell usually produces more than 1,000 di erent lipid species that
possess a wide range of structural, physical and biochemical properties, the rules governing protein-lipid
interactions are far from being solved, and this work is a first step toward a systematic understanding of
these regulatory elements.
The computational tools developed in this context have for instance demonstrated that the membrane
recruitment of PH domains necessitates the presence of secondary lipids, which can either increase or
decrease the binding a nity of PH domains to the biological membranes. The undertook computational
analyses have shown that most PH domains were capable of cooperative recruitment and that it generally
translated into similar biological functions (Figure 24). Additionally, the clustering analyses has shown
how PH-domain liposome binding data reflected the actual biological repartition of lipids within plasmic
and organellar membranes. It led to the identification of a motif conferring PH domains the ability to
bind one or both of these membranes and thereby helped to interpret why and how some PH domains
were more involved in cellular transport activation than others. The developed methods also helped
enabling the interpretation of disease-associated mutations, for the discovered motif was also found to
contain amino-acids that are often found naturally mutated in some human cancer biopsies (Figure 22
and Figure 23). We also generalized the concept of cooperative binding to the majority of PH domains,
which has important consequences in terms of biological processes (Figure 25).
However, future screens might contain many sources of batch e ects 1. Therefore, some steps would
probably need to be generalized in order to apply the computational analysis pipeline to such screens.
For instance, the current implementation has been adapted to the screen presented in this study [38],
and does not normalize the NBI for protein concentration since no batch e ect has been observed on
that front. However, other screens whose protein concentrations are not found to be at saturating con-
ditions could realistically generate NBI that are heavily influenced by the protein concentration. These
NBIs would need to be normalized in order not to misinterpret some binding events that could lead
to false biological conclusions. The consideration of possible spatial bias as a possible source of batch
e ects would also need to be integrated into future implementations of this computational pipeline. For
that purpose, we could envisage applying iterative rank-order normalization methods or neighborhood
expectation maximization algorithms to correct for spatial bias, as it has been already applied for gene
1Non biological sources of variation
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expression microarray data [94] [169].By doing so, LiMA could be employed to study any protein-lipid
interaction screen containing sources of batch e ects.
Such target-based screens could also be used in combination with chemical libraries to try perturbing
protein-lipid interactions that are found exacerbated in some diseases including diabetes and cancer. In
that respect, LiMA could represent a new door to identify new classes of drugs specifically perturbing
some protein-lipid interactions. Understanding what these perturbing agents have in common and making
inferences on their modes of action and their complex e ects on biological systems would require e orts on
the data integration front, and CART represents a milestone in that respect. CART provides the frame-
work required to find common biological themes amongst chemicals and a suited platform for the scalable
integration of chemical centric databases. CART currently works with chemical names, which restricts
its use-cases by implicitly expecting a user to know the names of his chemical of interests. Ideally, CART
should also be able to recognize structures from SMILES 2, sketches or more interestingly from Mass
Spectrometry or Nuclear Magnetic Resonnace signatures. Comparing the bioactivity properties of known
or unknown chemicals across all the available databases would enable relevant predictions of chemicals
impact on biological processes, and thereby unleash the true potential of computational chemical biology.
I hope my contributions to the field of chemical biology have brought us closer to understand how a
tiny fraction of the estimated 1018 to 10200 3 small molecules on earth impact biological systems.
2A SMILE is a one line representation of a chemical’s formula
3The author who came up with this number could not be identified: http://www.wisegeek.com/how-
many-chemicals-are-there.htm
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Table V.1: Summary of the most popular chemical centric databases. The first column
indicate the name of the database, the second column the readout associated to each
chemical of the database, and the third column the URL under which the database is
accessible.
Database Description Reference
PubChem Chemical/bioactivity https://pubchem.ncbi.nlm.nih.gov/
ChEMBL Chemical/Bioactivity https://www.ebi.ac.uk/chembl/
ChEBI Chemical/Bioactivity https://www.ebi.ac.uk/chebi
ChemBank Chemical/bioactivity http://chembank.broadinstitute.org/
DrugBank Targets www.drugbank.ca/
BIDD Targets http://bidd.nus.edu.sg/
STITCH Targets http://stitch.embl.de/
BIND Targets www.bindingdb.org/
ToxScan Toxicological readout http://ntp.niehs.nih.gov/results/dbsearch/index.html
SIDER Side effects http://sider.embl.de/
KiBank Structural information http://www.ncbi.nlm.nih.gov/pubmed/15556481
ZINC Structural information http://zinc.docking.org/
GPCRDB G protein-coupled receptors www.gpcr.org/7tm/
NucleaRDB Nuclear Hormone Receptor www.receptors.org/nucleardb/
NURSA Nuclear Receptor Signalling www.nursa.org/
IUPHAR Pharmacological targets www.iuphar-db.org/
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Table V.2: Table summarizing the 30 di erent lipids used in this study (28 lipids of inter-
ests, 1 PEGylated lipid and 1 biotinylated lipid). The first column indicates the family of
the lipid, the second column the name of the lipid, the third column the abbreviation of
the lipid used in this study, the fourth column the possible synonyms and the fifth column
the CAS number of the lipid.
Family Name Abreviation Synonyms CAS No
 Glycerolipids 1,2-di-(9Z-octadecenoyl)-sn-glycerol DAG 1,2-dioleoyl-sn-glycerol 24529-88-2
Glycerophospholipids 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine PC POPC 26853-31-6
Glycerophospholipids 1,1',2,2'-tetra-(9Z-octadecenoyl) cardiolipin Cardiolipin tetraoleoyl cardiolipin
115404-77-
8
 Glycerophospholipids 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoserine PS DOPS 90693-88-2
 Glycerophospholipids 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-rac-glycerol) PG DOPG 67254-28-8
 Glycerophospholipids 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine PE POPE 26662-94-2
 Glycerophospholipids 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate PA DOPA
108392-02-
5
 Glycerophospholipids 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoinositol PI DOPI 799268-53-4
Glycerophosphoinositol phosphates 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-myo-inositol-3'-phosphate) PI(3)P DOPI(3)P
1246303-09-
2
Glycerophosphoinositol phosphates 1,2-di-(palmitoyl)-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) PI(4)P DPPI(4)P n/a
Glycerophosphoinositol phosphates
1-heptadecanoyl-2-(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-glycero-3-
phospho-(1'-myo-inositol-4'-phosphate)
PI(4)P* n/a 475995-51-8
Glycerophosphoinositol phosphates 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-myo-inositol-5'-phosphate) PI(5)P DOPI(5)P
1246303-10-
5
Glycerophosphoinositol phosphates 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-myo-inositol-3',4'-bisphosphate) PI(3,4)P2 DOPI(3,4)P2
799268-54-
5
Glycerophosphoinositol phosphates 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-myo-inositol-3',5'-bisphosphate) PI(3,5)P2 DOPI(3,5)P2
799268-55-
6
Glycerophosphoinositol phosphates 1,2-di-(palmitoyl)-sn-glycero-3-phospho-(1'-myo-inositol-3',5'-bisphosphate) PI(3,5)P2# DPPI(3,5)P2 n/a
Glycerophosphoinositol phosphates 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate) PI(4,5)P2 DOPI(4,5)P2
799268-56-
7
Glycerophosphoinositol phosphates 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-[phosphoinositol-3,4,5-trisphosphate] PI(3,4,5)P3 DOPI(3,4,5)P3
799268-57-
8
 Sphingolipids N-(octadecanoyl)-4R-hydroxysphinganine Phytocer 34354-88-6
 Sphingolipids N-(octadecanoyl)-sphinganine Dihydrocer N-(stearoyl)-dihydroceramide 2304-80-5
 Sphingolipids  N-(hexadecanoyl)-sphing-4-enine Cer
N-palmitoyl-D-
erythro-
sphingosine
24696-26-2
 Sphingolipids N-(hexadecanoyl)-sphing-4-enine-1-phosphate Cer1P
N-palmitoyl-
ceramide-1-
phosphate
1246303-22-
9
 Sphingolipids Sphing-4-enine Sphingosine D-erythro-sphingosine 123-78-4
 Sphingolipids 4R-hydroxysphinganine PHS 388566-94-7
 Sphingolipids Sphinganine DHS Dihydrosphingosine 764-22-7
 Sphingolipids  (2S,3S,4R)-2-amino-3,4-dihydroxyoctadecyl dihydrogen phosphate PHS1P
383908-62-
1
 Sphingolipids Sphinganine-1-phosphate DHS1P 19794-97-9
 Sphingolipids Sphing-4-enine-1-phosphate S1P 26993-30-6
Pegylated lipid
1,2-di-(9Z-octadecenoyl)-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-350]
PE-PEG350 474922-90-2
Fluorescent lipid PE-Atto647 n/a
Biotinylated lipid PE-Biotin n/a 384835-54-5
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Table V.3: Table summarizing the lipid mixtures used in the liposomes of this study. Each
mixture listed in the table is complemented with PC (carrier lipid) as well as PEGylated
lipid and a fluorescent lipid as liposome marker. The concentrations indicated in the
sixth, seventh, eight and ninth column are in mol %.
Primary lipid Secondary lipid 1 Secondary lipid 2 Secondary lipid 3 Primary lipid Secondary lipid 1 Secondary lipid 2Secondary lipid 3
Lipid_ID_1 PI(3)P 10,0
Lipid_ID_2 PI(4)P 10,0
Lipid_ID_3 PI(5)P 10,0
Lipid_ID_4 PI(3,4)P2 10,0
Lipid_ID_5 PI(3,5)P2 10,0
Lipid_ID_6 PI(3,5)P2# 10,0
Lipid_ID_7 PI(4,5)P2 7,0
Lipid_ID_8 PI(4,5)P2 10,0
Lipid_ID_9 PI(3,4,5)P3 10,0
Lipid_ID_10 Sphingosine 10,0
Lipid_ID_11 PHS 10,0
Lipid_ID_12 DHS 10,0
Lipid_ID_13 S1P 10,0
Lipid_ID_14 PHS1P 10,0
Lipid_ID_15 DHS1P 7,0
Lipid_ID_16 DHS1P 10,0
Lipid_ID_17 Cer 10,0
Lipid_ID_18 Cer1P 10,0
Lipid_ID_19 Phytocer 10,0
Lipid_ID_20 Dihydrocer 10,0
Lipid_ID_21 PC 99,4
Lipid_ID_22 PS 10,0
Lipid_ID_23 PI 10,0
Lipid_ID_24 Cardiolipin 10,0
Lipid_ID_25 PG 10,0
Lipid_ID_26 PE 10,0
Lipid_ID_27 PA 10,0
Lipid_ID_28 DAG 5,0
Lipid_ID_29 PI(3)P Sphingosine 10,0 10,0
Lipid_ID_30 PI(3)P PHS 10,0 10,0
Lipid_ID_31 PI(3)P DHS 10,0 10,0
Lipid_ID_32 PI(3)P S1P 10,0 10,0
Lipid_ID_33 PI(3)P PHS1P 10,0 10,0
Lipid_ID_34 PI(3)P DHS1P 10,0 10,0
Lipid_ID_35 PI(3)P Cer 10,0 10,0
Lipid_ID_36 PI(3)P Cer1P 10,0 10,0
Lipid_ID_37 PI(3)P Phytocer 10,0 10,0
Lipid_ID_38 PI(3)P Dihydrocer 10,0 10,0
Lipid_ID_39 PI(4)P Sphingosine 10,0 10,0
Lipid_ID_40 PI(4)P PHS 10,0 10,0
Lipid_ID_41 PI(4)P DHS 10,0 10,0
Lipid_ID_42 PI(4)P S1P 10,0 10,0
Lipid_ID_43 PI(4)P PHS1P 10,0 10,0
Lipid_ID_44 PI(4)P DHS1P 10,0 10,0
Lipid_ID_45 PI(4)P Cer 10,0 10,0
Lipid_ID_46 PI(4)P Cer1P 10,0 10,0
Lipid_ID_47 PI(4)P Phytocer 10,0 10,0
Lipid_ID_48 PI(4)P Dihydrocer 10,0 10,0
Lipid_ID_49 PI(5)P Sphingosine 10,0 10,0
Lipid_ID_50 PI(5)P PHS 10,0 10,0
Lipid_ID_51 PI(5)P DHS 10,0 10,0
Lipid_ID_52 PI(5)P S1P 10,0 10,0
Lipid_ID_53 PI(5)P PHS1P 10,0 10,0
Lipid_ID_54 PI(5)P DHS1P 10,0 10,0
Lipid_ID_55 PI(5)P Cer 10,0 10,0
Lipid_ID_56 PI(5)P Cer1P 10,0 10,0
Lipid_ID_57 PI(5)P Phytocer 10,0 10,0
Lipid_ID_58 PI(5)P Dihydrocer 10,0 10,0
Lipid_ID_59 PI(3,4)P2 Sphingosine 10,0 10,0
Lipid_ID_60 PI(3,4)P2 PHS 10,0 10,0
Lipid_ID_61 PI(3,4)P2 DHS 10,0 10,0
Lipid_ID_62 PI(3,4)P2 S1P 10,0 10,0
Lipid_ID_63 PI(3,4)P2 PHS1P 10,0 10,0
Lipid_ID_64 PI(3,4)P2 DHS1P 10,0 10,0
Lipid_ID_65 PI(3,4)P2 Cer 10,0 10,0
Lipid_ID_66 PI(3,4)P2 Cer1P 10,0 10,0
Lipid_ID_67 PI(3,4)P2 Phytocer 10,0 10,0
Lipid_ID_68 PI(3,4)P2 Dihydrocer 10,0 10,0
Lipid_ID_69 PI(3,5)P2 Sphingosine 10,0 10,0
Lipid_ID_70 PI(3,5)P2 PHS 10,0 10,0
Lipid_ID_71 PI(3,5)P2 DHS 10,0 10,0
Lipid_ID_72 PI(3,5)P2 S1P 10,0 10,0
Lipid_ID_73 PI(3,5)P2 PHS1P 10,0 10,0
Lipid_ID_74 PI(3,5)P2 DHS1P 10,0 10,0
Lipid_ID_75 PI(3,5)P2 Cer 10,0 10,0
Lipid_ID_76 PI(3,5)P2 Cer1P 10,0 10,0
Lipid_ID_77 PI(3,5)P2 Phytocer 10,0 10,0
Lipid_ID_78 PI(3,5)P2 Dihydrocer 10,0 10,0
Liposome ID Lipid composition Lipid concentration
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Lipid_ID_79 PI(3,5)P2# Sphingosine 10,0 10,0
Lipid_ID_80 PI(3,5)P2# PHS 10,0 10,0
Lipid_ID_81 PI(3,5)P2# DHS 10,0 10,0
Lipid_ID_82 PI(3,5)P2# S1P 10,0 10,0
Lipid_ID_83 PI(3,5)P2# PHS1P 10,0 10,0
Lipid_ID_84 PI(3,5)P2# DHS1P 10,0 10,0
Lipid_ID_85 PI(3,5)P2# Cer 10,0 10,0
Lipid_ID_86 PI(3,5)P2# Cer1P 10,0 10,0
Lipid_ID_87 PI(3,5)P2# Phytocer 10,0 10,0
Lipid_ID_88 PI(3,5)P2# Dihydrocer 10,0 10,0
Lipid_ID_89 PI(4,5)P2 Sphingosine 10,0 10,0
Lipid_ID_90 PI(4,5)P2 PHS 10,0 10,0
Lipid_ID_91 PI(4,5)P2 DHS 10,0 10,0
Lipid_ID_92 PI(4,5)P2 S1P 10,0 10,0
Lipid_ID_93 PI(4,5)P2 PHS1P 10,0 10,0
Lipid_ID_94 PI(4,5)P2 DHS1P 7,0 7,0
Lipid_ID_95 PI(4,5)P2 DHS1P 10,0 10,0
Lipid_ID_96 PI(4,5)P2 Cer 10,0 10,0
Lipid_ID_97 PI(4,5)P2 Cer1P 10,0 10,0
Lipid_ID_98 PI(4,5)P2 Phytocer 10,0 10,0
Lipid_ID_99 PI(4,5)P2 Dihydrocer 10,0 10,0
Lipid_ID_100 PI(3,4,5)P3 Sphingosine 10,0 10,0
Lipid_ID_101 PI(3,4,5)P3 PHS 10,0 10,0
Lipid_ID_102 PI(3,4,5)P3 DHS 10,0 10,0
Lipid_ID_103 PI(3,4,5)P3 S1P 10,0 10,0
Lipid_ID_104 PI(3,4,5)P3 PHS1P 10,0 10,0
Lipid_ID_105 PI(3,4,5)P3 DHS1P 10,0 10,0
Lipid_ID_106 PI(3,4,5)P3 Cer 10,0 10,0
Lipid_ID_107 PI(3,4,5)P3 Cer1P 10,0 10,0
Lipid_ID_108 PI(3,4,5)P3 Phytocer 10,0 10,0
Lipid_ID_109 PI(3,4,5)P3 Dihydrocer 10,0 10,0
Lipid_ID_110 PI(3)P PS 10,0 10,0
Lipid_ID_111 PI(4)P PS 10,0 10,0
Lipid_ID_112 PI(5)P PS 10,0 10,0
Lipid_ID_113 PI(3,4)P2 PS 10,0 10,0
Lipid_ID_114 PI(3,5)P2# PS 10,0 10,0
Lipid_ID_115 PI(3,5)P2 PS 10,0 10,0
Lipid_ID_116 PI(4,5)P2 PS 7,0 7,0
Lipid_ID_117 PI(4,5)P2 PS 10,0 10,0
Lipid_ID_118 PI(3,4,5)P3 PS 10,0 10,0
Lipid_ID_119 DAG PS 5,0 5,0
Lipid_ID_120 PE PA 10,0 10,0
Lipid_ID_121 PE PA PS 10,0 10,0 10,0
Lipid_ID_122 PE PA PS PI 10,0 10,0 10,0 10,0
Lipid_ID_123 PE-Biotin 4,0
Lipid_ID_124 PE-Biotin 7,0
Lipid_ID_125 PE-Biotin 10,0
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Table V.4: Table summarizing the 95 LBDs used in this assay, amongst which 91 are
PH domains. The first column indicates the name of the LBD (_1 and _2 are di erent
variants of the same LBD, _A and _B are orthologous of the same protein in S. cerevisiae
and C. thermophilum). The second column is the standard name of the protein, the third
column indicate the PH domain prediction score (e value) using the SMART database,
the fourth column the PMID of the publication in which the domain was discovered.
The fifth column includes in the sequence of the domain used in this assay and the
sixth column show the median protein concentration used across all replicates (µM). The
seventh column indicates the mean TI of the LBD across all its interactions and the eighth
column the cooperativity class to which the PH domain belong to. The ninth and tenth
columns show cellular localization of the PH domain.
Ask10 Ask10p 7,83E-07 15023338 RKVSDVIYPHMKSPLAKCIKAGYFLKKSELLPTYH
QGYFVLTSNYIHEFQSSDFYNLSSSTPNSTKSSA
YSSSVSIADTYANANNAKANNHHRQASDVHNSS
TTTGGTAGANGIRGIRKKSYLAPIMSIPLNDCTLK
DASSTKFVLVGKPTLNENADVRKSSSSTYLSGSS
QASLPKYGHETAKIFSKAPFHKFLKGSKPKNKNT
KSSELDQFYAAAQKESNNYVTWTFKIVSPEPSEE
ELKHFKRWVQDLKNLTSFNDTK
2.99‡ Yes 2a Cytoplasm Nucleus#
Atg26 Atg26p 2,03E-14 15023338 KNPRSVKMSGNLNIRTKLIRSTRYWCVLKNHLFS
MYTSSTELYFPVLTIDLREVQKIETQKHTLNGSAT
KTFKLYTDESTFKFNADSEFSAKSWVNALKKEQF
AAQNSENN
12.84‡ Yes 1 Cytoplasm Other
Atg26Ct - 1,05E-16 - NEVVKSGYLSKCGKRNPKYNRYWFRLKGVVLSY
YRDPQDLYFPSGHIDLRYGISASITDKDKEGINFTI
ETHNRTYYFRADSAQSAKEWVKCIQRVIFRSHN
20.37‡ Yes - n/a -
Avo1 Avo1p 42.5
(BLAST: 5E-54)
22505404 DNFQDLFTGAYHKYKVWRRQQMSFINKHERTLA
IDGDYIYIVPPEGRIHWHDNVKTKSLHISQVVLVK
KSKRVPEHFKIFVRREGQDDIKRYYFEAVSGQEC
8.68‡ Yes 1 n/a Other
Bem2_1 4.21
(BLAST: 3E-59)
15023338 NTGQTPSLGSVMESNNSARNRRDSRASFSTNR
SSVVSNSSHNGVSKKIGGFFRRPFSIGGFNTSSS
NYSLNSILSQEVSSNKSILPSILPEVDSMQLHDLK
3,18 No - Bud neck, cytoplams -
Bem2_2 22
(NCBI CDS: 5.51E-05)
- KKIGGFFRRPFSIGGFNTSSSNYSLN ILSQEVSS
NKSILPSILPEVDSMQLHDLKPSYSLKTFEIKSIME
IINHRNIPAYYYAFKIVMQNGHEYLIQTASSSDLTE
WIKMIKASKRFSFHSKKYK
8,27 Yes 2a Bud neck, 
cytoplasm
Cdc42 network
Bem3 Bem3p 4,85E-12 15023338 MDDNVKDGSLLLRRPKTLTGNSTWRVRYGILRD
DVLQLFDKNQLTETIKLRQSSIELIPNLPEDRFGT
RNGFLITEHKKSGLSTSTKYYICTETSKERELWLS
AFSDYIDPSQS
4.54‡ Yes 2a Bud neck, 
cytoplasm
Cdc42 network
Bem3Ct - 1,66E-19 - GGRPYRSGYLTKRGKNFGGWKARYFVLDGPQL
KYYETPGGAHLGTIKLRGAQIGKQTNHSNDGSQ
GSNEDGDNQYRHAFLILEPKKKDPNSMTKHVLC
AESDKERDQWVDALIRWVDYKDP
16.44‡ Yes 2b n/a -
Boi1 Boi1p 9,11E-17 15023338 SMQTADCSGWMSKKGTGAMGTWKQRFFTLHG
TRLSYFTNTNDEKERGLIDITAHRVLPASDDDRLI
SLYAASLGKGKYCFKLVPPQPGSKKGLTFTEPRV
HYFAVENKSEMKAWLSAIIKATIDIDTSVPVISS
7,05 No - Bud, bud neck, cell 
periphery, cytoplasm
Cdc42 network
Boi2 Boi2p 1,48E-16 15023338 SISVKEAMKDADFSGWMSKKGSGAMSTWKTRF
FTLHGTRLSYFSSTTDTRERGLIDITAHRVVPAKE
DDKLVSLYAASTGKGRYCFKLLPPQPGSKKGLTF
TQPRTHYFAVDNKEEMRGWMAALIKTTIDIDTSV
P
34.08‡ Yes 2b Bud, bud neck, 
punctuate 
composite, 
cytoplasm
Cdc42 network
Bud4 Bud4p 4,10E-10 15023338 QNIYKEGYLLQDGGDLKGKIENRFFKLHGSQLSG
YHEISRKAKIDINLLKVTKVLRNEDIQADNGGQRN
FTDWVLFNECFQLVFDDGERITFNAECSNEEKS
DWYNKLQEVVELNVFHQ
3.83‡ Yes 2a Bud neck Cdc42 network
Bud4Ct - 3,62E-11 - ARTWEGHLSQQGGDCPYWRRRYFKLVGTKLTA
YHEATRQPRATINLANAKRLIDDRRTLLEKGTIDK
NGKRRRSAFAEDEEGYMFVEEGFRIRFNNGEVI
DFYADSTKEKEEWMRVLGEVIGRDSLL
11.41‡ Yes 2b n/a -
Caf120N Caf120p 3,65E-07 15023338 SPVSPELVPILTLLNAHTHRRYHEGVFLILQDLNN
NGTHAARKWKDVYGVLLGTQLALWDAKELAEFT
DPSCPVSEKKLKEVASKPTYINLTDATLRTLDNSD
NIVMECGKNLTNALVVSTTLKNRYFLQFGNKESF
NAWNSAIRLCLYECSSLQEAYTGAFISSRGAKLG
5,35 Yes 2b Bud, bud neck, 
cytoplasm
Other
Caf120NCt - 3,23E-08 - LQPIFSLLNGHANKLYQEGYFLKLDDQDIRGNLN
PDRTWTECFAQLVGTVLSLWDAAELDAAGEDGE
VLPKFINLTDASIKMIESLPTKSNDEQPLQNILSIST
AGRNRYLLHFNSHHSLIQWTSGIRLAMYEHATLQ
EAYTGSLVAG
9,96 n/a - n/a -
Caf120C Caf120p not detected
(BLAST: 5E-63)
- YDYKDWVSVRFGAGMPWKRCYAVISQSSSKKK
GHFGEINLYENDKKVKKNHAMATIVEAKALYAVYP
SSPKLIDSSTIIKVVGSVKFEKKESAQEKDVFIMP
EKHQAVPSYDTIIRFLIPAMDTFKLYGRPEKLLSSK
N
2,09 No - Bud, bud neck, 
cytoplasm
-
Caf120CCt - not detected
(BLAST: 9E-28)
- PISEWVRVRFGAGVPWKRCYCVIEPPSEKEYQK
AQKEWKKKNPYDRSHGPILKGQIKFFESKKDAE
KKKKHQRPIASITDAYSAYAIYPQAKALIDGSTLLKI
EGDITIHSEPPSTTEGFVFIMPETHPAVPGFEMLL
RFLFPTWDTFGLY
4,93 Yes 2a n/a -
Caf120_tandem Caf120p 3,65E-07 - SPVSPELVPILTLLNAHTHRRYHEGVFLILQDLNN
NGTHAARKWKDVYGVLLGTQLALWDAKELAEFT
DPSCPVSEKKLKEVASKPTYINLTDATLRTLDNSD
NIVMECGKNLTNALVVSTTLKNRYFLQFGNKESF
NAWNSAIRLCLYECSSLQEAYTGAFISSRGAKLG
DIRILLTNRKYDYKDWVSVRFGAGMPWKRCYAVI
SQSSSKKKGHFGEINLYENDKKVKKNHAMATIVE
AKALYAVYPSSPKLIDSSTIIKVVGSVKFEKKESAQ
EKDVFIMPEKHQAVPSYDTIIRFLIPAMDTFKLYGR
PEKLLSSKN
0,93 No - Bud, bud neck, 
cytoplasm
-
Caf120Ct_tandem - 3,23E-08 - LQPIFSLLNGHANKLYQEGYFLKLDDQDIRGNLN
PDRTWTECFAQLVGTVLSLWDAAELDAAGEDGE
VLPKFINLTDASIKMIESLPTKSNDEQPLQNILSIST
AGRNRYLLHFNSHHSLIQWTSGIRLAMYEHATLQ
EAYTGSLVAGKGKTLNSINIIMERARQPISEWVRV
RFGAGVPWKRCYCVIEPPSEKEYQKAQKEWKK
1,37 Yes 2a n/a -
Cdc24 Cdc24p 3,49E-04 15023338 ISKFGELLYFDKVFISTTNSSSEPEREFEVYLFEKII
ILFSEVVTKKSASSLILKKKSSTSASISASNITDNN
GSPHHSYHKRHSNSSSSNNIHLSSSSAAAIIHSS
TNSSDNNSNNSSSSSLFKLSANEPKLDLRGRIMI
MNLNQIIPQNNRSLNITWESIKEQGNFLLKFKNEE
TRDNWSSCLQQLIHDLKNEQFKARHHSST
1.82‡ Yes 2b Nucleus, cytoplasm Cdc42 network
Cdc24Ct - 7,48E-04 - QFGKLLLHGVYTVITGKGDQEKDYEIYLFECILLC
CKEVVPGKTKDKRDKARPAQPKVRNKNAKLQLK
GRIFMTNVTDVVAMSKPGSYMVQIWWKGDPGV
ENFMIKFQNEETMKKWAAGLEQQRKLNAPQP
7,70 No - n/a -
Cla4 Cla4p 5,75E-14 15023338 TSTSKKKSGWVSYKDDGILSFIWQKRYLMLHDS
YVALYKNDKQNDDAILKIPLTSIISVSRTQLKQYCF
ELVRCSDRNSVSSGSSSSLNVSSDSNSKKSIYIA
TKTESDLHSWLDAIFAKCPLLSGVSSPTNFTHK
11.16‡ Yes 2b Bud, cytoplasm Cdc42 network
Cla4Ct - 2,48E-09 - GGLAIIKQGYVGLPSKNPFQTWKSRFMILRKDVL
DFHKNENGKHLYKILLADVVSVDRVPDPNGDPVF
EIRRHSTNQYEAPPGEDQGNGVKATKICVKTDD
ELYEWIDCIYARCPGGVSNPVNFSHPV
16,80 Yes 1 n/a -
Dcp1 Dcp1p not detected 21119626 SNDSLTYNCGKTLSGKDIYNYGLIILNRINPDNFS
MGIVPNSVVNKRKVFNAEEDTLNPLECMGVEVK
DELVIIKNLKHEVYGIWIHTVSDRQNIYELIKYLLEN
EPKDSFA
1,87 No - Punctuate 
composite
-
Exo84 Exo84p 947
(NCBI CDS:
9.62E-08)
21119626 STKGRHILMNSANWMELNTTTGKPLQMVQIFILN
DLVLIADKSRDKQNDFIVSQCYPLKDVTVTQEEF
STKRLLFKFSNSNSSLYECRDADECSRLLDVIRK
AKDDLCDIFHVEEENSKRIRESF
4.74‡ Yes 2a Bud, bud neck, cell 
periphery
Other
Exo84Ct - 1380
(NCBI CDS: 1.98E-06)
- NSPGRHVVQNAGLWVELDNATYRSRRAMQIFLL
NDHILIASRKKRKVDAPNDSRAPMTKLVADRCWH
LLDVEIVDMAGPSDSSSGRNKLADAIMIRGGGNE
SFIYRTEKPGDPEKASLLLNIRKQVEELRRTLQSE
REATNKAKETINYFASR
2.12‡ Yes 2a n/a -
Ira1 not detected 16397625 LEVLKDVRVTLHDITLYDKEKKKFCPVSLKIGNKY
FQVLHEIPQLYKVTVSNRTFSIKFNNVYKISNLISV
DVSNTTGVSSEFTLSLDNEEKLVFCSPKYLEIVK
1,83 No - Cytoplasm Other
Cooperativity 
class
Reference 
(PMID)
Ira1p
Median protein 
concentration
[µM]
LBD name Standard name
Bem2p
Annotations used 
in Fig. 4
Interaction with 
liposomes
(0 <TI <2)
Annotations of in 
vivo localization 
(Huh et al., 2003)
SMART
e-value score 
(BLAST/NCBI CDS e-
value) 
Domain sequence (AA)
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Ira1_CRAL-TRIO-PH not detected 16397625 PFVVENREKYPSLYEFMSRYAFKKVDMKEEEED
NAPFVHEAMTLDGIQIIVVTFTNCEYNNFVMDSLV
YKVLQIYARMWCSKHYVVIDCTTFYGGKANFQKL
TTLFFSLIPEQASSNCMGCYYFNVNKSFMDQWA
SSYTVENPYLVTTIPRCFINSNTDQSLIKSLGLSG
RSLEVLKDVRVTLHDITLYDKEKKKFCPVSLKIGN
2,07 Yes 2a Cytoplasm -
Ira2_1 not detected 16397625 KVLQDIRVSLHDITLYDEKRNRFTPVSLKIGDIYFQ
VLHETPRQYKIRDMGTLFDVKFNDVYEISRIFEVH
VSSITGVAAEFTVTFQDERRLIFSSPKYLEIVKMF
1,43 No - Cytoplasm -
Ira2_2 not detected 21119626 VRRNVLNEAKHDDGDIDGDDFYKTTFLLIDDVLG
QLGQPKMEFSNEIPIYIREHMDDYPELYEFMNRH
AFRNIETSTAYSPSVHESTSSEGIPIITLTMSNFSD
RHVDI
8,87 Yes 2a Cytoplasm Other
Ira2Ct - not detected - VVTDTRYVFQPVTRLSRTRGKIEVVIKVGSQYVQ
VTTCKKQEVPGFHLSTTINDIFRLGEIEEAPTMIQ
TEDDSAFCLRADNGKIVMYFTSPKKADVLQAIRL
AKAKYSKDMR
1,72 No - n/a -
Ira2_CRAL-TRIO-PH Ira2p not detected 16397625 IYIREHMDDYPELYEFMNRHAFRNIETSTAYSPSV
HESTSSEGIPIITLTMSNFSDRHVDIDTVAYKFLQI
YARIWTTKHCLIIDCTEFDEGGLDMRKFISLVMGL
LPEVAPKNCIGCYYFNVNETFMDNYGKCLDKDN
VYVSSKIPHYFINSNSDEGLMKSVGITGQGLKVL
QDIRVSLHDITLYDEKRNRFTPVSLKIGDIYFQVLH
2,66 No - Cytoplasm -
Ira2Ct_CRAL-TRIO-PH - not detected - HISANTPPAYSRFQDFMIRNAFRNTESYLTARAIY
DGGESKDGLSIICIILRHIDAESIDYDTLIFCYLKIAS
RLWHRPFGLLIDVTGYNGQAEPKDELFQKLEMLT
PTELARQLSRIYIYNMNSVSKKCLRRLLRASTRN
EASVFSPTNVDYHLIGSLQDLQTHFHLSQLHLPK
ETISVVTDTRYVFQPVTRLSRTRGKIEVVIKVGSQ
1,81 No - n/a -
Las17 Las17p not detected 21119626 PKASNKIIDVTVARLYIAYPDKNEWQYTGLSGALA
LVDDLVGNTFFLKLVDINGHRGVIWDQELYVNFE
YYQDRTFFHTFEMEECFAGLLFVDINEASHFLKR
1,51 No - Punctuate 
composite
-
Mdr1 Mdr1p not detected 21119626 RKTAYVYSGRLFLTPHFLVFRDAFDHSSCVLILNI
STIKRVERSPSESYEFALLVTLYTGAKVLIQFIGIR
YRSEQFCDKLKLNLKENIPNA
0,60 No - Cytoplasm -
Mdr1Ct - not detected - NRGFQYAGRLHLSESYLCFSTTPSSFLQSASSSS
SLLFTGQTHGAGPSGNGFTFPLCAIRRVERLHS
QNFQFALAITTWNGISQDAAKDKDRKDLREQRITI
QLAGSRQACERFCDGLKKGLRANVVHV
0,33 No - n/a -
Num1 Num1p 2,15E-04 15023338 NEPSIIPALTQTVIGEYLFKYYPRLGPFGFESRHE
RFFWVHPYTLTLYWSASNPILENPANTKTKGVAIL
GVESVTDPNPYPTGLYHKSIVVTTETRTIKFTCPT
RQRHNIWYNSLRYLLQRNMQGISLE
2.19‡ Yes - Punctuate 
composite
Other
Num1Ct - 2,69E-05 - GSGTDPRMIQAITQTMIGEYLWKYTRKKTGRGE
MSENRHRRYFWVHPYTRTLYWSTRDPSTAGRS
ELRAKSVQIEAVRVVNDDNPFPPGLHQKSLIIVSP
GRSIKFTCTTGQRHETWFNALSYLLLRTANEG
4.30‡ Yes 1 n/a -
Nup2 Nup2p not detected 21119626 EEDEVALFSQKAKLMTFNAETKSYDSRGVGEMK
LLKKKDDPSKVRLLCRSDGMGNVLLNATVVDSF
KYEPLAPGNDNLIKAPTVAADGKLVTYIVKFKQKE
2.67‡* Yes 2b Nuclear periphery Nucleus
Nvj2 Nvj2p 1,63E-04 15023338 NKDSDTALQEQILQRTDLKKKQRFFAVLRHGNLF
LYKDDSQNANLVHAISLQNRFITIWPRFDELGKEE
LPDASLFTKRTCIAIFKNDLVSIDSKNHNVILPHFD
PLTSAESNNGDISTNDTTHEYQSQFHSSNQFFLY
FDNNMDKEDWYYQLINASKNSNSLST
1,36 Yes 2a ER Other
Opy1N 6,08E-04 15023338 MIAGATAPSSQHEILIASNLIKKPSTSQNKTPTAQS
SSGNNGAADGAPQGYHHHHHHHRHLWWPRTT
DHQYWCVLRKNQFAYYKTRDEREAISVIPRFDIL
NFKISELDGILTVYTPSKDLIFKFPRGQNEKVGME
LMHNWKIALEKFLSSPSGN
12,23 Yes 2b Cytoplasm Other
Opy1C 6,21E-10 15023338, 
22562153
DPRNAEHQVCSGILYTKVKKKKLFNRAKWQKFN
VELTNTSFNLYSFKTGKLKKSIKLDKIIDCIELDNN
SKMKNDDTNFALITFDERLSFKAANDQDMVDWII
11.55‡ Yes 1 Cytoplasm Other
Osh2 Osh2p 3,25E-13 15023338 ASS PPTYKGFLKKWTNFAHGYKLRWFILSGDG
NLSYYKDQSHVDRPRGTLKVSTCRLHIDSSEKLN
FELLGGITGTTRWRLKGNHPIETTRWVNAIQSAIR
5.14‡ Yes 1 Punctuate 
composite
Cdc42 network
Osh3 Osh3p 1,21E-12 15023338 QDMLFRVGQGRYLQGYLLKKRRKRLQGFKKRF
FTLDFRYGTLSYYLNDHNQTCRGEIVISLSSVSA
NKKDKIIIIDSGMEVWVLKATTKENWQSWVDALQ
TCFDDQFEDK
7,25 Yes 2b n/a Cdc42 network
Osh3Ct - 2,16E-09 - NSTTGIVPTTYHVGVLLKRRRKKGQGYARRFFSL
DYITCTLSYYHSRNSSALRGAIPLSLAAIAADERR
REFTIDSGAEVWHLKASNAKEFSDWARALERAS
17.35‡* Yes 1 n/a -
Pkh2 Pkh2p 8,30E+02 21119626 SVFSGKIKKLFHPTSAAETLSSSDEKTKYYKRTIV
MTSFGRFLVFAKRRQPNPVTNLKYELEYDINLRQ
QGTKIKELIIPLEMGTNHIVVIQTPYKSFLLSTDKK
6.42‡ Yes 2a Cytoplasm Other
Plc1 Plc1p not detected
(NCBI CDS: 4.69E-33)
- RRRRKFYEFKLINNNGQIIWKDGSKYLELDSVKDI
RIGDTASTYQEEVDPKRLRSDSKLWIAIIYKVSNK
LKALHVVALNELDFNTFLSCICGLVKLRRELMESI
LLPDNSQFA
0,94 Yes 2b n/a Other
Plc1Ct - 2.67
(NCBI CDS: 1.56E-45)
- VLRQGMPMEKLRIKRGNLKPITLYIDPDAAKIWW
DRPHRSPRFIYIDDIAEIRIAEDTRQYRLDANLPDS
YESRWFTLKLRLPDKQGDKFVHLIAPTEAACEQ
WVQALETISKHRQDFA
5.04‡ Yes 2b n/a -
Psy2 Psy2p not detected 21119626 VNTEPKRVKVYILENNEWKDTGTGFCIGEVDEG
KFAYLVVSDEDSPTETLLKSKLEGNIEYQRQEETL
IVWKDLGGKDIALSFEESMGCDTLCEFIVHVQRNI
E
5.86‡ Yes 2a Nucleus Nucleus
Rgc1 Rgc1p 6,02E-08 15023338 RRLSDIVYPNMKSPLAKCIRVGYLLKKTESSKSFT
KGYFVLTTNYLHEFKSSDFFLDSKSPRSKNKPVV
EQSDISRVNKDGTNAGSHPSSKGTQDPKLTKRR
KGLSSSNLYPISSLSLNDCSLKDSTDSTFVLQGY
ASYHSPEDTCTKESSTTSDLACPTKTLASNKGKH
QRTPSALSMVSVPKFLKSSSVPKEQKKAKEEANI
NKKSICEKRVEWTFKIFSASLEPTPEESKNFKKW
VQDIKALTSFNSTQER
8,05 No - Cytoplasm Other
Rom1 Rom1p 66.1
(BLAST: 7E-9)
- NNEKRKIKHEGLLSRKDVNKTDASFSGDIQFYLL
DNMLLFLKSKAVNKWHQHTVFQRPIPLPLLFICPA
EDMPPIKRYVTENPNCSAGVLLPQYQTSNPKNAI
VFAYYGTKQQYQVTLYAPQPAGLQTLIEKVKQEQ
KRLLDETKHITFKQMVGQFF
1,27 No - n/a -
Rom1Ct_A - 4.12
(BLAST: 1E-95)
- TRLARYPLLLENVLKYTEPDNPDKEDIPKVLQMIR
DLLSRVNAESGKAENRFNLRRLHEQLRFRSPAE
RVDLKLTEEGRELVFKTQFKKSPTENPDITAFLFD
HAVLLVRIKQVGKTEEYKAYRRPIPLELLSIKEMEE
IFPQNGAVKRSSSSLLPALRNTSTEAKKGEGWPI
TFRHLGKNGYELTLYATNQSGRQKWLEHIDQAQ
QRLRARADFLNRTVISH
4,33 Yes 2b n/a -
Rom1Ct_B - 2,48E-09 - LDHLGRELLKQGELQRQGSKGVRWVDTHALLFD
HYFILAKAFMAKDGSGKKYDVSKEPIPMPLLFLE
STNDEPVAKQKSLTAPLTRTAVTGAGSQLMSKSA
TMSEKPGADDDGKIIYPFRIKHLGHEIYTLYASSA
QERTAWCNAIIEAKTRHARALHAQNAEPF
8,70 No - n/a -
Rom2 Rom2p not detected
(NCBI CDS: 6.55E-48)
12015967 GTVVGDIQFYLLDNMLLFLKAKAVNKWHQHKVF
QRPIPLPLLFACPGEDMPALRKYIGDHPDCSGTVI
QPEYNTSNPKNAITFLYYGAKQRYQVTLYAAQYA
GLQTLLEKIKQGQAAIISKTEMFNV
2,04 No - Bud, bud neck, 
cytoplasm
-
Rtt106 Rtt106p not detected
(NCBI CDS:
PH1 5.06E-80;
PH2 3.48E-43)
22307274 SETNTIFKLEGVSVLSPLRKKLDLVFYLSNVDGSP
VITLLKGNDRELSIYQLNKNIKMASFLPVPEKPNLI
YLFMTYTSCEDNKFSEPVVMTLNKENTLNQFKN
LGLLDSNVTDFEKCVEYIRKQAILTGFKISNPFVN
STLVDTDAEKINSFHLQCHRGTKEGTLYFLPDHII
3.89‡ Yes 2b Nucleus Nucleus
Rtt106Ct - not detected
(NCBI CDS:
PH2 7.45E-31)
- VSEPVLLEIKDISVVVPQRKKYDICFTQSCLFAKA
QGATGPAPGLVYPWIEIEHAFFLPVPDKSQTQYN
YILLPRDSYLPTSKASGVSSDRQASLEPLVFTVPA
AAPKAGSIKGTAAKTAEAFAESYSCLFHWALTTSL
RAAGNESFQLISSDPRVFHSLVKQPHRPNEKAVH
VKAFRGSKEGFLFFLPTGILWGFKKPLVFLPLDKI
AAVSYTNVLRTTFNLVIELDSDVTAGGNATDKEIE
FGMIDQEDYQVINENYVQRHGLAD
2.64‡ Yes 2a n/a -
Sec3 Sec3p 194
(NCBI CDS: 8.31E-83)
20062059 HKRNVSRASNSSQTSNFLAEQYERDRKAIINCCF
SRPDHKTGEPPNNYITHVRIIEDSKFPSSRPPPD
SKLENKKKRLLILSAKPNNAKLIQIHKARENSDGS
FQIGRTWQLTELVRVEKDLEISEGFILTMSKKYYW
3.29‡ Yes 1 Bud, bud neck, cell 
periphery
Cdc42 network
Opy1p
Ira2p
Ira1p
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Sec3Ct - 610
(NCBI CDS: 2.65E-67)
- DGSVPETYITHIRITEWQNYPSSPPPPSARAPQY
EKPRVIIVAVRKSGRLRVHKSKENANGTFSIGKT
WWLDDLQSIESFTSPSANPNLREWARDVGFIVTL
GKPYYWEAHSDKEKKFFIASLIKIFNRYTGGRTP
0,56 No - n/a -
Sip3 Sip3p 1,94E-11 15023338 KSPEKSGWLYMKTQVGKPTREIWVRRWCFLKN
AVFGMFLLSPSKTYVEETDKFGVFLTNVRYDPEE
DRKFCFEVKIFGNKVTEAHDNMSKDITLVFQTSN
YLDLKSWLIAFEATKKYVMSIQHDSLE
2,14 Yes 2a n/a Nucleus#
Skg3N 6,17E-05 15023338 GDISPELVPIVTLLSAQAHRRYHYGIFLILHDLKTD
GTPAARQWEECYGVLLGTQLALWDAKELSDSKN
NKNTSTMKKAASRPSFINFTDASVRSLDANDQVII
ASENEKTKKDLDNVLVVSTTLKNRYFLKFKNSKS
7.36‡ Yes 1 Bud, bud neck, cell 
periphery
Other
Skg3C 29.3
(BLAST: 1E-99)
15023338 GDIKVVMADTKFTYEDWVSVRFGTGMPWKRCY
AVISPQSGKKKKNSKGSICFYENNKKTKKSNIMT
TVVDARALYAVYPSSPILIDTSTIIKLEGFVSFDKSE
EPQETNLFIMPEKHQGVPGYDTIIRFLIPAMNAFY
LYGRPKGLIANRTDPDSLLFALPTLPHIYYLQVDD
VLSLTKDKNYIHWSAADWRNNIVQVLQKKLSKGY
KG
0,97 No - Bud, bud neck, cell 
periphery
-
Skm1 Skm1p 9,33E-14 15023338 MKGVKKEGWISYKVDGLFSFLWQKRYLVLNDSY
LAFYKSDKCNEEPVLSVPLTSITNVSRIQLKQNCF
EILRATDQKENISPINSYFYESNSKRSIFISTRTER
DLHGWLDAIFAKCPLLSGVSSPTN
2,86 Yes 2b n/a Cdc42 network
Slm1 Slm1p 1,23E-13 15023338, 
21119626
EIKSGFLERRSKFLKSYSKGYYVLTPNFLHEFKTA
DRKKDLVPVMSLALSECTVTEHSRKNSTSSPNS
TGSDAKFVLHAKQNGIIRRGHNWVFKADSYESM
12,15 No - Punctuate 
composite
Other
Slm1Ct - 3,91E-07 - HYACQEIRAGLLERKSKYLKSYTPGWYVLSPTHL
HEFKSADKTQAPVMSLYLPEQKLGSHSEEGSSS
NKFILKGRQTGHMHRGHTWVFRAESHDTMMAW
YEDIKALTERTPEER
16.42‡ Yes 2b n/a -
Slm2 Slm2p 8,71E-14 15023338 NQNDPFTFEVKSGFLEKRSKFLKSYSRGFYVLTP
SFLHEFKTPDKHKFSTPLMSIPLVECTVTEHSKKT
KSNSEQGKNKFILRTNSNGLIHRGHNWVFKVDS
YDDMIEWFGNIKALSSLPNYDDK
5.82‡ Yes 2a n/a Other
Spo14 Spo14p 1,97E-03 15023338 GFQGKQGYLVIRSTAKAQGWRVSHFGKHAFKD
MIDRHTTKWFLVRNSYLTYVSDLSSTTPLDVFLID
WKFKVRFSGNKNNILDNENEINWIIHDPNLEINDE
LEEFGIENDANNILDKNGKSKTHQKKSNISSKLLL
1,11 No - Cytoplasm -
Spo14Ct - 13.2
(BLAST: 6E-32)
- SYHGK CYLHIQSS GLDFRRVLTPGKVIARHTR
KWFLVRQSYIVCVESPENMNIYDVYLVDSKFQIV
SKKSKKQAAEQDDDDDDGDDNIENLDLSTRPQQ
KHQKHHTLKLITSERKVKLFSPNQHLIAQFEESIR
EMLKNTPW
0,40 No - n/a -
Spo71N 402
(BLAST: 9E-17)
- KKRTGQILKKEKMLVMVKEAIQNKVPLPNFSENE
CFDTRVSERWKEYIVIARSTGRFDPPILLQFYRH
RHIPEIEDISSIATKYHRNPLDFFLSRNCIVKFYSS
LDKTISIQKPDKRLGGFIDESIEKKDELKHYSPIKIF
ILRCSSIRSSGRWYKFLLESLDRQ
3,53 Yes 2a n/a Other
Spo71M 4.92
(BLAST: 1E-115)
15023338 PIANRLRETKSLEGKCLKEPTPIEGFLIRLTDKYG
SARTNFGKYSISTAYFFTCENLLFSMKAYRANPPL
PIDSMIDDTSTEIEKEEIWKQWKKIPEVYEQQPYP
LDTNDHIEWMNCQTTQSEYDSRDFYAFHCFHRR
IDQILKTDNVIDLTEVKDIYQGTRTDYEADKIKYGV
5,67 Yes - n/a Other
Spo71C 1,36E-06 15023338 NGISLSRPLIQKGPLYQKPHKHSVFSKYYVVLISG
FIVLFHCFHRSTTGFAKEVLEYAHYVTIPIDDCYLY
SGTTTELDLLQRDRTFDEINYGSHALPRVYGDG
WRSVEDESSRCFTLWFGTRRALSSNRLQKKGN
EKQYTQDYGRQDNNIDPPSAPEADLNNSNVPSN
TDKIHFTKKLGVSGKSMVFMARSRQERDLWVMS
IYYELERLRRTASTSNSR
0,89 No - n/a -
Ste5 Ste5p 1,47E+03 16847350 ETKTTLPLLRSYFIQILLNNFQEELQDWRIDGDYG
LLRLVDKLMISKDGQRYIQCWCFLFEDAFVIAEVD
NDVDVLEIRLKNLEVFTPIANLRMTTLEASVLKCT
LNKQHCADLSDLYIVQNINSDESTTVQKWISGILN
QDFVFNED
1,56 Yes - Nucleus, cytoplasm -
Swh1 Swh1p 4,29E-13 15023338 LHEAPTYKGYLKKWTNFAQGYKLRWFILSSDGK
LSYYIDQADTKNACRGSLNMSSCSLHLDSSEKLK
FEIIGGNNGVIRWHLKGNHPIETNRWVWAIQGAI
RYAKDREILL
1.62‡ Yes 1 n/a Cdc42 network
Swh1Ct - 5,66E-13 - GREAREMRGYLKKWTNYRKGYQLRWFVLEDGV
LSYYKHQDDAGSACRGAINMRIAKLHMSPDEKT
KFEIIGKSSVKYTLKANHEVEAKRWFWALNNSIQ
WCKDQAREEERQRQRNAELLRQAKAEAQALSE
AA
16.61‡* Yes 1 n/a -
Syt1 Syt1p 1,72E-03 15023338 NSDYKYCKILQMGAIMNLGMPSRKFSIVNSAKIH
WKKEFAILTSLGLLICDKMDWINPQMMKDPKSGT
TNYIIDFKSGFSFVPGSTIDVYNGLFADRERDSLG
KSHFASLVLAYTEHHSTGSHTSNTTAASSSAKHN
EGVFEPSSDEEDSITNSTDGTSSVSNGESDNDS
1,85 No - n/a -
Syt1Ct_A - 1,87E-04 - AAHPGIVDIKITKVGLLWRKDTKKKKTRSPWQEW
GAILTGAQLYFFRNTAWVKHLMHQQKDHIKKGH
DGDPCIFKPPLDQFKPDALMSTDGAVALMDSSYT
KHKHAFLYVRHGGLEEVLLAEDEDDMNDWLAKL
NYAAAFRTSGVRM
2.31‡ Yes - n/a -
Syt1Ct_B - 170
(BLAST: 3E-70)
- KDRNWTEVFAVIQKGQLSLFSFSPNKSLRNKGR
RGPGHNNSLPKGAVVGGGNWQDNATNLGTFSL
RQTLASALPPPGYSRTRPYVWALSLPTGAVHLF
QVGTPEICKEFVNTVNYWSARLSTHP
1,33 Yes - n/a -
Tfb1 Tfb1p not detected
(NCBI CDS: 1.08E-14)
15909982 MSHSGAAIFEKVSGIIAINEDVSPAELTWRSTDGD
KVHTVVLSTIDKLQATPASSEKMMLRLIGKVDESK
KRKDNEGNEVVPKPQRHMFSFNNRTVMDNIKM
2,34 No - Nucleus -
Tfb1Ct - not detected
(NCBI CDS: 5.94E-22)
- MSIPRSQTTYKKKEGILTLTEDRKFLIWTPLPATG
PPTVSLALDNITNLQQTPPGSAKVILKFTERPRPN
AEPGAPPPQYMFQFTHPTDARAEANAIRDLLSQ
1,96 Yes 2a n/a -
Tus1 Tus1p 2,32E-09 15023338 LTYPERKLVLSGTVYKKRDLWLDPTPVYIALLDNC
LLITEEISKGETQKYKLIERPIPIDYLSLEKRKIPGT
SKQPLRNYSQKEHKSPMHNFSTPINSMRPLLKS
SGNHMSTAYGDRKTSNTEISNANPNTDEFSFKIR
NTATGESFKFFTESAEVLNQWIDAIMESFKRNAE
NHDLN
4,33 No - n/a -
Yel1 Yel1p 35.7
(BLAST: 1E-78)
15023338 LNKDSEWERVKIQVKEGRIFIFKIKPDVKDIIQSSE
TDSATIDYFKDISSSYFAYSLLEAEAHVVQDNIIIGS
GAMKSNVCNKNTKRKSGNFTVSFPENINGPKLV
LEFQTRSVEEAHKFMDCINFWAGRISPVPLTQ
0,95 No - Bud neck, 
cytoplasm
-
Yhr131c Yhr131cp 43.5
(BLAST: 2E-62)
15023338 NRSWRNFIIEINSTQLNFYHIDESLTKHIRNYSSG
ETKSEKEDRIHSDLVHRSDQSQHLHHRLFTLPTR
SASEFKKADQERISYRVKRDRSRYLTDEALYKSF
TLQNARFGIPTDYTKKSFVLRMSCESEQFLLRFS
HIDDMIDWSMYLSIGISV
0,14 No - Cytoplasm -
Ynl144c Ynl144cp not detected
(BLAST: 3E-24)
15023338 SSRLWNNFILQINSTQINFYSIDDSLTRHIKNYRG
GDMFDHSHHSKTASDRHHSARSLLNAFTTKSTY
QFDKYDKERICGEIARDEHKFLSDERLFKSYSLQ
CAKVGLPIDYSSRDFVLRMRCEGQQFLVQFSHV
DELIYWAMYLNMGISLSLDLELR
0,31 No - n/a -
Ynl144cCt - 7,15E-01 - STDIQLEGVFMRKMEIEETTKRAEYRDWRMVYV
ELRGTMLNVYSVKKERGWWASKHDGPDISPDN
PPWVKKGSLERAYSLLYADAGIAADYRKRRYVIR
MRLETDQFLLSCVELSTFVKWLDGIFAAINISAPID
ERD
1.59‡ Yes 2a n/a -
Yrb2 Yrb2p not detected 21119626 GEESEECIYQVNAKLYQLSNIKEGWKERGVGIIKI
NKSKDDVEKTRIVMRSRGILKVILNIQLVKGFTVQ
KGFTGSLQSEKFIRLLAVDDNGDPAQYAIKTGKK
2.27‡ Yes 2a Nucleus Nucleus
Ysp1 Ysp1p 9,05E-12 15023338 NSEEKGLSGWLYMKTTVGHDPKRVVWVRRWCF
LQNNVFGVFSLSPSKTYVEETDKFGILWITVEYLP
KEPRNFCFKLRIQNPNCKTEEENTYIDIILQAESID
13.64‡ Yes 2b Mitochondrion Other
Ysp1Ct - 7,53E-09 - GAAILEKQGWLFLRVMAGKPVRTTWIRRWYYCR
DGVFGWLAQGPNGVLMGDEIGVLLCSARPAVQE
ERRFCFEIKTKTQTILLQAETQAQLVEWLEVFETA
KNRYIEASMKRHQKSVTLPVG
17,92 Yes 1 n/a -
AKT1 AKT1 8,50E-17 12176338 MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDG
TFIGYKERPQDVDQREAPLNNFSVAQCQLMKTE
RPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTT
5.05‡ Yes 1 n/a -
Spo71p
Skg3p
10
Chapter 6 – Relative to Part II
Dynamin1 Dynamin-1 2,70E-10 7954789 KTSGNQDEILVIRKGWLTINNIGIMKGGSKEYWFV
LTAENLSWYKDDEEKEKKYMLSVDNLKLRDVEK
GFMSSKHIFALFNTEQRNVYKDYRQLELACETQE
EVDSWKASFLRAGVYPERVGDK
13.07‡ Yes 2b n/a -
PDK1 PDK1 9.52
(NCBI CDS: 5.99E-67)
15457207 GSNIEQYIHDLDSNSFELDLQFSEDEKRLLLEKQ
AGGNPWHQFVENNLILKMGPVDKRKGLFARRR
QLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEA
KNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQE
VWRQRYQSHPDAAVQ
9.11‡ Yes 1 n/a -
Plcδ1 Plcδ1 8,32E-11 8521504 HGLQDDPDLQALLKGSQLLKVKSSSWRRERFYK
LQEDCKTIWQESRKVMRSPESQLFSIEDIQEVRM
GHRTEGLEKFARDIPEDRCFSIVFKDQRNTLDLIA
PSPADAQHWVQGLRKIIHHSGSMDQRQK
16.40‡ Yes 1 n/a -
Pleckstrin Pleckstrin 4,28E-22 15698571 DVILKEEFRGVIIKQGCLLKQGHRRKNWKVRKFIL
REDPAYLHYYDPAGAEDPLGAIHLRGCVVTSVES
NSNGRKSEEENLFEIITADEVHYFLQAATPKERTE
31.32‡ Yes 2b n/a -
SOS1 SOS1 5,24E-17 9374522 QQMKG QLAIKKMNEIQKNIDGWEGKDIGQCCN
EFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHG
QPRLPGASNAEYRLKEKFFMRKVQINDKDDTNE
YKHAFEIILKDENSVIFSAKSAEEKNNWMAALISL
QYRSTLE
8.55‡* Yes 1 n/a -
EEA1 EAA1 - 9702203 NQDERRALLERCLKGEGEIEKLQTKVLELQRKLD
NTTAAVQELGRENQSLQIKHTQALNRKWAEDNE
VQNCMACGKGFSVTVRRHHCRQCGNIFCAECS
AKNALTPSSKKPVRVCDACFNDLQG
15.07‡ Yes ND n/a -
p40phox p40phox - 11684018 AVAQQLRAESDFEQLPDDVAISANIADIEEKRGFT
SHFVFVIEVKTKGGSKYLIYRRYRQFHALQSKLE
ERFGPDSKSSALACTLPTLPAKVYVGVKQEIAEM
RIPALNAYMKSLLSLPVWVLMDEDVRIFFYQSPY
DSEQVPQALRR
11,19 Yes ND n/a -
Lactadherin Lactadherin - 18160406 CTEPLGLKDNTIPNKQITASSYYKTWGLSAFSWF
PYYARLDNQGKFNAWTAQTNSASEWLQIDLGSQ
KRVTGIITQGARDFGHIQYVAAYRVAYGDDGVTW
TEYKDPGASESKIFPGNMDNNSHKKNIFETPFQA
RFVRIQPVAWHNRITLRVELLGC
1.84‡* Yes ND n/a -
Hsv2 Hsv2p - 22704557 - 1,52 Yes ND n/a -
11
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Table V.5: Table summarizing the TIs computed for each interaction of the screen. The
columns represents the liposomes of the assays and the rows the proteins used in the
assay. A green cell indicates a 0 < TI < 2 (confident binder). An orange cell indicates a
TI > 2 (non confident binder). A blue cell indicate a -2 < TI < 0 ( confident non binder).
A violet cell indicates a -2 < TI (non confident non binder). A white cell represents an
interaction for which not enough replicates were available to compute a TI
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Ask10 -0,216 -0,075 -0,3 -0,332 -0,195 -0,378 -0,5 n/a -0,505 -0,308 -0,169 -0,247 -0,418 -0,473 -0,186 -0,331 -0,181 -0,241 -0,262 -0,276 -0,087 n/a -0,526 -0,328 -0,9 -0,666 n/a -0,265 -0,097 -0,2 -0,112 -0,183 -0,325 -0,149 -0,215 -0,312 -0,242 -0,269 -0,319 -0,166 -0,45 -0,343 -0,227 -0,126 -0,999 -0,075 -0,779 -0,193 -0,217 -0,336 -0,293 -0,21 -0,209 -0,33 -0,169 -0,311 -0,452 -0,689 -0,188 -0,193 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,916 n/a -1,068 -0,447 -0,439 -0,356 -1,127
Atg26 -0,187 n/a -0,338 -0,185 n/a -0,525 1,798 -0,374 n/a n/a -0,072 n/a n/a -0,682 n/a -0,56 -0,512 n/a -0,068 n/a -0,234 -0,285 n/a 0,749 1,207 0,497 0,188 n/a 1,058 2,794 1,063 1,139 n/a -1,597 1,037 -0,701 2,194 2,171 1,824 -0,932 -0,251 -0,482 n/a -0,198 -0,534 n/a -0,884 -0,913 -0,178 -0,826 -0,992 1,203 -0,722 1,562 1,035 0,938 0,987 -0,37 -2,592 -3,284 1,734 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,692 0,671 0,552 1,084 0,531 0,636 n/a
Atg26Ct -0,14 -0,164 -0,166 -0,182 -0,211 -0,336 -0,464 -0,212 -0,824 -0,153 n/a -0,133 -0,057 -0,212 -0,471 -0,295 -0,145 -0,042 -0,211 -0,205 -0,26 -0,177 n/a 1,295 -1,959 0,978 n/a -0,174 -0,528 n/a n/a -0,125 n/a -0,119 -1,008 -0,169 -0,866 -0,273 -0,237 -0,187 -0,143 n/a -0,07 -0,138 -0,213 -0,26 -0,196 -0,661 -0,323 -0,162 -0,401 -0,105 -0,006 -0,205 -0,272 -0,323 3,663 -0,322 -0,063 -0,12 -0,373 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,322 1,829 0,967 1,267 0,936 0,938 1,096
Avo1 1,036 1,537 -0,335 -0,279 1,325 -0,254 -0,532 0,804 -0,28 0,931 -0,748 -0,725 -0,784 -1,549 1,192 0,739 -0,35 -1,127 -0,469 0,687 -1,58 0,738 n/a 0,469 0,698 0,595 n/a -0,326 0,829 -0,655 1,064 -1,64 0,677 0,929 0,94 0,564 1,114 0,81 0,677 1,25 -0,532 -0,604 1,067 -0,33 -0,501 -2,314 -0,239 -2,879 0,91 0,719 0,504 -1,304 0,849 1,053 -0,599 2,404 0,545 0,661 1,018 0,711 0,758 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,597 0,639 0,912 0,69 0,728 0,597 n/a
Bem2_1 -0,712 -0,013 -0,193 -0,114 -0,172 -0,104 -0,638 -0,245 -0,273 -0,166 -0,169 -0,198 -0,319 -0,157 -0,173 -0,436 -0,194 -0,463 -0,833 -0,284 -0,125 -0,276 n/a -0,27 -0,324 -0,767 -0,37 -0,104 -0,392 -0,091 -0,183 -0,159 n/a -0,201 -0,318 -0,133 -0,24 -0,324 -0,164 -0,273 -0,753 -0,189 -0,31 -0,182 -0,073 -0,169 -0,125 -0,106 -0,753 -0,57 -0,39 -0,185 -0,46 -0,18 -0,238 -0,281 -0,488 n/a -0,206 -0,225 -0,18 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,222 -0,553 -0,896 -0,413 -0,631 -0,43 -0,639
Bem2_2 -0,478 -0,036 -0,149 -0,135 -0,17 -0,359 -0,261 -0,301 -0,133 -0,264 -0,128 -0,111 -0,497 -0,25 -0,19 -0,334 -0,238 -0,225 -0,132 -0,218 -0,053 -0,233 n/a -0,111 -0,151 -0,606 -0,959 -0,062 1,499 -0,153 -0,362 n/a -0,381 -0,026 -0,421 -0,297 -0,218 -0,313 -0,255 -0,228 -0,086 -0,711 n/a -0,122 -0,267 -0,328 -0,359 -0,25 -0,111 -0,425 -0,279 -0,202 -0,211 -0,113 -0,357 -0,374 -0,358 -0,173 n/a -0,048 -0,413 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,341 -0,175 -0,178 -0,205 -0,136 -0,22 -0,219
Bem3 -0,189 -0,159 -0,136 -0,3 n/a -0,181 -0,382 -0,259 -0,113 -0,167 -0,072 -0,202 -0,731 -0,156 -0,57 -0,5 -0,122 -0,178 n/a -0,083 -0,088 -0,282 n/a -1,249 -0,194 -1,206 n/a n/a -0,094 -0,151 n/a -0,87 n/a n/a n/a -0,11 -0,616 -0,175 -0,281 -0,151 -0,746 -0,442 -0,092 -0,379 n/a -0,489 -0,263 -0,484 -0,144 -0,163 -0,178 -0,148 -0,177 -0,118 -0,239 -0,157 -0,155 n/a -0,284 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -2,533 -0,424 -1,528 -0,994 8,919 0,812 n/a
Bem3Ct -0,152 -0,489 n/a -0,058 -0,348 -0,108 -1,345 -0,077 1,654 n/a -0,165 -0,238 n/a -0,13 -1,003 -0,051 -0,401 -0,421 -0,076 n/a -0,484 -1,313 n/a 0,514 -2,998 n/a 0,287 n/a -0,79 -0,371 n/a -0,033 n/a -0,919 -0,749 -0,286 -0,628 -0,717 -0,218 -0,43 -0,15 -0,226 -0,062 -0,509 -0,224 -0,395 n/a -0,442 n/a -0,085 n/a -0,386 -0,044 -0,454 -1,145 -2,569 0,63 -0,167 -0,454 -0,339 -0,904 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,896 n/a 0,933 0,27 0,902 0,814 n/a
Boi1 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Boi2 n/a -1,605 -0,248 n/a n/a -0,172 n/a -0,052 -0,653 n/a -0,414 -0,554 -0,581 -0,247 n/a n/a n/a n/a n/a -2,585 -0,532 n/a n/a 0,99 -0,031 n/a n/a n/a -0,954 n/a n/a n/a n/a -0,188 -0,188 n/a -2,268 n/a -0,311 -0,279 -0,34 -0,216 -0,269 -0,311 -0,157 -0,189 -0,098 0,521 n/a n/a n/a n/a n/a n/a n/a -1,278 1,468 -0,618 -0,364 -0,43 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,57 0,737 0,792 n/a
Bud4 -0,288 -0,341 -0,438 -0,457 -0,098 -0,455 -0,182 -0,23 1,291 -0,405 -0,229 -0,416 n/a n/a 1,19 -0,218 -0,351 -0,305 -0,301 -0,089 -0,55 -0,285 n/a 1,309 -0,264 -0,948 1,39 n/a -1,754 -0,363 n/a -0,254 n/a -0,737 n/a -0,309 -0,825 -0,424 2,587 -0,282 -0,26 1,531 -0,319 -0,158 -0,24 -0,569 -0,286 6,442 -0,202 -0,299 -0,243 1,354 -0,189 -0,177 n/a -0,262 -0,577 -0,342 1,649 -0,355 -0,313 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 3,165 -2,466 2,383 -2,798 0,975 n/a n/a
Bud4Ct -0,194 -0,054 n/a -0,095 -0,138 -0,189 -0,239 -0,18 -0,19 -0,397 -0,178 -0,061 -0,134 -0,094 -0,321 -0,299 -0,164 -0,183 -0,202 -0,15 -0,241 -0,279 n/a 2,715 1,968 1,252 0,976 n/a -0,725 -0,283 -0,333 -0,176 -0,487 -0,259 -0,574 -0,207 -0,476 -0,364 -0,231 -0,332 -0,268 -0,273 -0,355 -0,083 -0,157 -0,212 n/a 1,123 -0,262 -0,433 -0,275 -0,294 -0,47 -0,265 -2,755 -0,742 -0,659 -0,175 -0,654 -0,32 -0,629 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,978 -0,509 1,559 -1,964 1,083 1,166 1,032
Caf120N n/a -0,281 -0,15 -0,042 n/a n/a n/a -0,276 n/a -0,207 -0,275 n/a n/a -0,521 -0,699 -0,112 n/a -0,088 -0,281 -0,159 -0,176 -0,179 n/a -0,645 -0,382 0,188 1,478 n/a -0,269 -1,207 -0,132 -0,265 -0,329 -0,56 -0,586 -0,193 -0,396 -0,474 -0,219 -0,22 -11,366 -0,06 -0,308 -0,105 -0,297 n/a -0,241 1,16 -2,274 -0,307 -0,181 n/a -0,198 -0,437 -0,152 -0,703 -0,398 -0,581 -0,519 -0,142 -0,515 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,685 1,183 -0,123 -0,956 0,535 0,618 0,452
Caf120NCt n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Caf120C -0,183 -0,143 -0,217 -0,147 -0,215 -0,08 -0,136 -0,144 -0,293 -0,192 -0,226 -0,186 -0,728 n/a -0,125 -0,341 -0,233 -0,204 -0,123 -0,074 -0,121 -0,126 n/a -0,436 -0,231 -0,343 -0,526 -0,194 -0,128 -0,183 -0,203 -0,203 -0,411 -0,273 -0,228 -0,111 -0,392 -0,414 -0,084 -0,227 -0,229 -0,471 -0,555 -0,225 -0,222 -0,224 -0,129 -0,08 -0,327 -0,181 -0,188 -0,162 -0,178 -0,321 -0,198 -0,155 -0,172 -0,294 -0,341 -0,304 -0,16 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,191 -0,172 -0,374 -0,23 -0,223 -0,215 -0,226
Caf120CCt n/a n/a 2,704 -0,338 -0,278 -0,053 -0,171 -0,223 -0,167 -2,66 n/a -0,382 n/a -2,44 -0,332 n/a -0,168 n/a n/a n/a -0,041 n/a n/a -1,326 -0,964 n/a n/a -0,287 n/a -0,139 n/a -0,153 -0,025 -1,179 -0,092 -0,161 n/a n/a -0,213 -0,259 n/a -1,535 -2,619 -0,188 -0,142 -0,177 -0,958 -0,292 -0,371 n/a n/a -0,19 -0,096 -0,07 1,199 -0,464 n/a n/a -0,156 -0,923 -0,479 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -1,022 -0,317 -0,49 -0,288 n/a 0,964 0,869
Caf120_tandem -0,195 -0,149 -0,318 -0,204 -0,217 -0,173 -0,123 -0,098 -0,186 -0,351 -0,246 -0,095 n/a n/a n/a -0,259 -0,236 -0,181 -0,069 -0,116 -0,138 -0,461 n/a -0,062 -0,37 -0,245 -0,184 n/a -0,198 -0,467 -0,272 n/a n/a -0,242 n/a -0,106 -0,226 -0,087 -0,033 -0,098 -0,183 -0,365 -0,288 -0,149 -0,28 -0,312 -0,337 n/a -0,175 -0,111 -0,135 -0,065 -0,116 -0,218 -0,127 -0,283 -0,27 -0,085 -0,323 -0,08 -0,996 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,303 -0,079 -0,089 -0,074 -0,074 -0,296 -0,169
Caf120Ct_tandem -0,22 n/a -0,225 -1,071 -0,264 -0,077 n/a -0,255 n/a -0,27 -0,474 -0,242 n/a -4,667 -0,139 -0,456 -0,333 -0,157 -0,065 n/a -4,988 -0,253 n/a n/a n/a n/a n/a n/a -0,393 -0,374 1,485 n/a n/a -0,529 -0,21 -0,295 -0,465 n/a -0,578 -0,298 n/a -0,315 n/a -0,389 -0,592 -1,271 n/a n/a n/a n/a -0,883 n/a -0,147 -0,354 n/a -0,158 -0,144 -0,249 -0,073 n/a -0,204 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,11 n/a n/a -0,141 n/a -1,046 -1,242
Cdc24 -0,413 -0,073 -0,352 -0,413 -0,099 -0,443 -0,509 -1,149 -0,247 -0,24 1,737 -0,169 n/a -0,409 -0,204 -0,187 -0,115 -0,518 -0,073 -0,255 -0,459 -0,376 n/a 2,322 1,078 1,086 0,994 -0,198 -0,851 -0,184 -0,269 -0,446 -0,249 -0,177 -0,209 -0,366 -0,116 -2,128 -0,538 -0,798 -0,36 -0,285 -0,414 2,3 -0,296 -0,501 -0,895 -1,242 -0,398 -0,158 -0,39 -0,292 -0,512 -0,336 -1,512 1,448 -0,277 -0,967 -0,396 -0,463 2,239 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,99 -3,736 -0,7 -0,547 -1,155 1,196 -3,433
Cdc24Ct n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cla4 -0,348 -0,225 -0,172 -0,306 -0,214 -0,07 -0,285 -0,941 -0,2 -0,912 -0,181 -0,212 -0,042 -0,319 1,236 -0,297 -0,095 -0,157 -0,244 -0,373 -0,19 -0,45 n/a 0,847 1,384 0,809 0,753 n/a -1,151 -0,644 -0,484 -0,372 -0,427 -0,607 2,547 -0,376 -2,544 -0,348 -0,209 -0,443 -0,23 -0,112 -0,206 -0,388 -0,154 -0,27 -0,045 -1,189 -0,221 -0,532 -5,184 -0,139 -0,199 -0,286 -0,131 -0,839 1,205 -0,514 -1,131 -0,118 -0,337 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,071 0,7 0,421 0,889 0,628 0,305 0,535
Cla4Ct 1,757 -1,179 n/a n/a -1,612 -1,046 1,398 -0,935 -0,447 n/a -1,015 1,818 n/a -1,193 0,949 1,887 -0,649 n/a 1,957 -1,014 -0,846 2,474 n/a 1,056 -1,344 0,634 0,313 n/a 0,504 -0,694 -2,101 1,584 -1,349 n/a -4,557 -1,153 -1,403 1,502 -8,457 -1,895 n/a -1,121 n/a n/a -1,583 -1,576 -1,406 0,693 -2,291 n/a -0,185 1,376 -0,486 -1,213 -1,081 1,359 1,844 -1,899 -0,642 1,916 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,009 1,033 1,058 0,783 0,894 0,756
Dcp1 -0,347 -0,278 -0,42 -0,259 -0,357 -0,506 -0,167 -0,188 -0,279 -0,282 -0,307 -0,224 n/a -0,257 n/a -0,362 -0,195 -0,273 n/a -0,231 -0,262 -0,397 -0,353 -0,264 -0,371 -0,954 n/a n/a -0,124 -0,318 -0,074 -0,649 -0,362 -0,391 n/a -0,332 -0,502 -0,532 -0,229 -0,228 -0,296 -0,381 -0,398 -0,319 -0,106 -0,284 -0,156 -0,604 -0,312 -0,216 -0,179 n/a -0,439 -0,448 -0,527 -0,408 -0,365 -0,413 -0,397 -0,116 -0,373 -0,256 -0,319 -0,551 -0,312 -0,308 n/a -0,465 -0,769 -1,01 -0,24 -0,138 -0,301 n/a -0,163 n/a n/a -0,281 n/a
Exo84 -0,423 -0,209 n/a -0,16 -0,139 -0,262 n/a -0,329 -1,045 -0,696 -0,267 -0,239 -1,206 -0,279 -0,032 n/a -0,247 n/a n/a n/a -0,321 -0,426 n/a -0,288 -0,187 -0,412 n/a -0,24 -0,204 -0,297 -0,258 -0,146 -0,195 -0,236 -0,091 -0,271 -0,495 -0,308 -0,228 -0,737 -0,285 -0,105 -0,384 -0,455 -0,179 -0,235 -0,262 -0,134 -0,312 -0,244 -0,181 -0,11 -0,197 -0,117 -0,265 -0,21 -0,308 n/a -0,301 -0,275 -0,59 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,185 -0,406 -1,239 -0,165 -0,116 -0,243 -0,47
Exo84Ct -0,207 -0,23 -0,168 -0,157 -0,148 -0,234 -0,087 -0,089 -0,093 -0,82 -0,137 -0,307 -0,434 -0,161 -0,611 -0,218 -0,134 -0,096 -0,178 -0,035 -0,088 -0,174 -0,253 -0,247 -0,142 -0,403 n/a n/a -0,114 -0,283 -0,171 -0,114 -0,221 -0,263 -0,151 -0,258 -1,045 -0,157 -0,355 -0,185 -0,101 -0,158 -0,183 -0,717 -0,615 1,101 -0,212 0,987 -0,091 -0,393 -0,298 -0,278 -0,28 -0,381 -0,125 -0,398 -1,133 -0,552 -0,486 -0,304 -0,246 -0,214 -0,208 -0,279 -1,032 -0,362 -3,929 0,958 -0,33 1,06 -0,311 2,435 -0,318 -0,534 0,93 -0,708 0,63 0,513 0,722
Ira1 -0,171 -0,299 -0,265 -0,232 -0,232 -0,257 -0,098 -0,105 -0,131 -0,253 -0,153 -0,148 -0,513 -0,673 -0,074 n/a -0,149 -0,166 -0,187 -0,14 -0,172 -0,139 -0,128 -0,131 -0,158 -0,059 n/a n/a -0,112 -0,204 -0,157 -0,344 -0,144 -0,214 -0,141 -0,203 -0,489 -0,196 -0,165 -0,117 -0,158 -0,185 -0,197 -0,428 -0,392 -0,07 -0,226 -0,996 -0,136 -0,142 -0,253 -0,264 -0,133 -0,356 -0,31 -0,244 -0,348 -0,191 -0,338 -0,255 -0,216 -0,337 -0,316 -0,307 -0,578 -0,11 -0,322 -0,821 -0,36 -0,392 -0,296 -0,4 -0,056 -0,366 -0,241 n/a -1,253 -0,813 n/a
Ira1_CRAL-TRIO-PH -0,354 -0,316 -0,245 -0,059 -0,413 -0,242 -0,187 -0,244 -0,329 -0,076 -0,154 -0,2 -0,436 -0,307 -0,263 n/a -0,245 -0,108 -0,167 -0,227 -0,19 -0,446 -0,174 -0,182 -0,279 -0,142 n/a n/a -0,184 -0,334 -0,327 -0,167 -0,24 -0,195 -0,169 -0,267 -0,267 -0,268 -0,173 -0,143 -0,29 -0,22 -0,26 -0,162 -0,234 -0,21 -0,213 -0,261 -0,222 -0,242 -0,198 -0,227 -0,26 -0,332 -0,835 -0,366 -0,33 -0,296 -0,419 -0,315 -0,214 -0,129 -0,235 -0,211 -0,256 -0,464 -0,391 -0,771 -0,259 -0,497 -0,217 -0,496 -0,211 -0,284 -0,234 -0,319 3,058 1,595 1,302
Ira2_1 -0,262 -0,297 -0,259 -0,395 -0,261 -0,217 -0,274 -0,357 -0,273 -0,262 -0,267 -0,27 -0,646 -0,219 -0,061 -0,542 -0,324 -0,165 -0,237 -0,276 -0,206 -0,291 -0,116 -0,034 -0,146 -0,194 n/a n/a -0,313 -0,233 -0,261 -0,363 -0,3 -0,288 -0,339 -0,239 -0,221 -0,332 -0,313 -0,249 -0,181 -0,364 -0,226 -0,216 -0,378 -0,237 -0,267 -0,257 -0,242 -0,289 -0,24 -0,408 -0,186 -0,409 -0,316 -0,39 -0,175 -0,479 -0,291 -0,356 -0,31 -0,105 -0,186 -0,25 -0,308 -0,228 -0,2 -0,246 -0,222 -0,407 -0,247 -0,246 -0,132 -0,118 -0,213 -0,348 -0,312 -0,193 -0,299
Ira2_2 -0,437 n/a -0,461 -0,132 -0,396 -0,327 -0,094 -0,223 -0,252 -1,98 n/a -0,219 5,485 n/a -0,89 n/a -0,367 -0,338 -0,454 -0,162 -0,041 -0,093 n/a -0,797 -0,235 -1,397 n/a -0,356 -0,33 -0,041 -0,179 -0,325 -0,378 -0,271 -0,336 -0,512 -0,654 -0,481 -0,482 -0,267 -0,308 -0,295 -0,239 -0,339 -0,115 1,651 n/a n/a -0,276 n/a -0,313 -0,41 -0,147 -0,17 -0,304 -0,29 -0,235 -0,15 -0,944 -0,332 -0,163 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,108 -0,876 -0,311 -0,936 -0,871 1,654 1,044
Ira2Ct -0,154 n/a -0,136 -0,188 -0,221 -0,111 -0,103 -0,082 -0,068 -0,239 -0,131 -0,248 n/a -0,122 -0,095 -0,165 -0,121 -0,149 -0,083 -0,092 -0,025 -0,147 -0,216 -0,106 -0,134 -0,132 n/a n/a -0,096 -0,246 -0,062 -0,102 -0,062 -0,075 -0,077 -0,316 -0,23 -0,13 -0,081 -0,121 -0,096 -0,097 -0,044 -0,213 -0,203 -0,16 -0,129 -0,277 -0,133 -0,164 -0,107 -0,123 -0,138 -0,112 -0,187 -0,096 -0,114 -0,127 -0,1 -0,222 -0,146 -0,207 -0,085 -0,077 -0,615 -0,156 -0,141 -0,228 -0,102 -0,151 -0,148 -0,443 -0,178 -0,109 -0,062 -0,078 -0,183 -0,271 n/a
Ira2_CRAL-TRIO-PH -0,183 -0,204 -0,2 -0,146 -0,205 -0,222 -0,092 -0,049 -0,083 -0,244 -0,174 -0,114 -0,372 -0,214 -0,334 -0,689 -0,136 -0,158 -0,056 -0,091 -0,13 -0,127 -0,163 -0,177 -0,142 -0,145 n/a n/a -0,075 -0,206 -0,118 -0,236 -0,049 -0,066 -0,067 -0,105 -0,185 -0,191 -0,158 -0,138 -0,157 -0,123 -0,057 -0,072 -0,188 -0,161 -0,136 -0,142 -0,15 -0,159 -0,082 -0,127 -0,134 -0,189 -0,162 -0,085 -0,157 -0,188 -0,174 -0,23 -0,173 -0,081 -0,117 -0,092 -0,171 -0,149 -0,092 -0,095 -0,164 -0,14 -0,163 -0,221 -0,195 -0,338 -0,146 -0,048 -0,101 -0,141 -0,158
Ira2Ct_CRAL-TRIO-PH -0,173 -0,136 -0,108 -0,088 -0,153 -0,067 -0,049 -0,062 -0,09 -0,319 -0,143 -0,145 -0,198 -0,075 -0,197 -0,206 -0,197 -0,129 -0,182 -0,126 -0,176 -0,16 -0,142 -0,339 -0,091 -0,127 n/a n/a -0,089 -0,139 -0,104 -0,19 -0,139 -0,235 -0,129 -0,106 -0,393 -0,135 -0,237 -0,095 -0,122 -0,187 -0,103 -0,262 -0,206 -0,324 -0,121 -0,366 -0,082 -0,138 -0,241 -0,165 -0,097 -0,135 -0,216 -0,162 -0,089 -0,115 -0,595 -0,094 -0,196 -0,154 -0,066 -0,116 -0,113 -0,184 -0,117 -0,109 -0,163 -0,227 -0,105 -0,163 -0,066 -0,168 -0,151 n/a -0,788 -0,548 n/a
Las17 -0,215 -0,289 -0,221 -0,301 -0,32 -0,341 -0,279 -0,191 -0,24 -0,339 -0,26 -0,232 -0,22 -0,284 -0,044 -0,086 -0,214 -0,241 -0,114 -0,229 -0,214 -0,246 -0,196 -0,181 -0,212 n/a n/a n/a -0,158 -0,291 -0,223 -0,238 -0,249 -0,181 -0,219 -0,47 -0,361 -0,235 -0,229 -0,222 -0,25 -0,261 -0,249 -0,339 -0,323 -0,237 -0,337 -0,241 -0,246 -0,32 -0,212 -0,233 -0,065 -0,258 -0,267 -0,36 -0,31 -0,328 -0,227 -0,617 -0,226 -0,126 -0,201 -0,234 -0,068 -0,397 -0,223 -0,275 -0,408 -0,472 -0,263 -0,242 -0,11 -0,421 -0,422 -0,31 -0,067 -0,444 -0,5
Mdr1 -0,191 -0,111 -0,041 -0,126 -0,085 -0,116 -0,108 -0,114 -0,124 -0,097 -0,137 -0,154 -0,112 -0,112 n/a n/a -0,149 -0,116 -0,143 -0,089 -0,103 -0,156 -0,116 -0,103 -0,093 -0,072 n/a n/a -0,194 -0,135 -0,15 -0,17 -0,117 -0,14 -0,162 -0,155 -0,115 -0,199 -0,117 -0,062 -0,118 -0,12 -0,116 -0,113 -0,126 -0,125 -0,136 -0,115 -0,099 -0,113 -0,137 -0,303 -0,235 -0,298 -0,166 -0,252 -0,383 n/a -0,123 -0,204 -0,161 -0,131 -0,043 -0,113 -0,186 -0,118 -0,211 -0,12 -0,148 -0,22 -0,091 -0,282 -0,12 -0,189 -0,172 -0,16 n/a -0,14 -0,144
Mdr1Ct -0,181 -0,2 -0,142 -0,134 -0,176 -0,157 -0,139 -0,072 -0,1 -0,102 -0,186 -0,115 -0,132 -0,17 -0,719 -0,223 -0,122 -0,14 -0,131 -0,112 -0,136 -0,13 -0,108 -0,133 -0,146 -0,15 n/a n/a -0,086 -0,189 -0,12 -0,158 -0,122 -0,095 -0,128 -0,199 -0,162 -0,158 -0,163 -0,143 -0,172 -0,192 -0,13 -0,154 -0,151 -0,167 -0,133 -0,136 -0,168 -0,184 -0,153 -0,15 -0,102 -0,135 -0,129 -0,124 -0,159 -0,114 -0,141 -0,185 -0,165 -0,152 -0,085 -0,14 -0,142 -0,181 -0,159 -0,137 -0,164 -0,157 -0,158 -0,209 -0,162 -0,193 -0,167 -0,138 -0,142 -0,169 -0,106
Num1 -0,525 n/a -2,102 2,168 -0,732 -0,499 -0,777 1,182 -0,249 -0,556 -0,455 1,382 -0,178 -1,637 -0,215 -0,328 1,247 2,198 -0,153 -0,392 -0,209 -5,723 n/a 1,137 0,972 0,926 n/a 1,793 -0,318 -0,228 n/a -0,592 n/a -0,435 -0,285 n/a -0,194 -0,873 -0,593 -0,579 -0,709 -0,209 -0,655 -0,397 -0,732 -0,596 -0,335 -0,522 -0,364 -0,693 1,658 -0,501 -0,211 -0,169 2,079 -1,219 1,347 -5,519 7,186 -0,425 9,364 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,429 1,474 -2,605 -0,651 1,015 1,879 -1,471
Num1Ct -1,517 -0,375 n/a -0,304 -0,339 -0,209 n/a -0,477 -0,067 -0,39 -0,42 -0,089 n/a -0,529 -0,185 -0,147 n/a -0,306 -0,234 1,146 -0,26 -0,978 n/a 1,008 0,939 0,863 n/a -0,735 6,212 1,31 -0,468 -2,394 1,035 -0,352 -0,492 -1,292 -0,471 n/a -0,619 -0,089 -0,314 -0,294 -0,476 -0,247 -0,297 -0,416 -0,277 -0,985 -1,477 1,398 -1,451 -0,709 -0,373 -0,914 -0,336 -0,3 1,09 -0,635 -0,524 1,077 1,517 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,374 -0,165 1,001 -1,719 1,093 1,065 0,769
Nup2 -0,107 -0,157 -0,141 -0,343 -0,263 -0,228 -0,118 -0,221 -0,209 -0,565 -0,226 -0,172 -0,172 -0,373 n/a -0,382 -0,144 -0,185 -0,192 -0,21 -0,211 -0,171 -0,23 1,312 -0,144 3,146 n/a n/a -0,212 -0,226 -0,214 -0,717 -0,264 -0,191 -0,338 -0,223 -1,098 -0,249 -0,163 -0,123 -0,421 -0,318 -0,223 -1,428 -1,208 1,448 -0,244 1,48 -0,169 -0,367 -0,238 -0,414 -0,606 -0,537 -0,423 -0,322 -0,452 -0,096 -0,409 -0,356 -0,669 -0,512 -0,21 -0,35 -0,364 1,777 -1,038 -0,634 -0,414 2,224 -0,435 -0,214 -0,239 1,221 0,958 1,088 0,875 0,758 0,736
Nvj2 -0,2 -0,096 -0,169 -0,069 -0,061 -0,124 -0,267 n/a -0,044 -0,265 -0,334 -0,293 n/a n/a n/a -0,26 -0,449 -0,136 -0,125 -0,112 -0,314 -0,077 n/a -0,048 n/a -0,864 -0,473 n/a n/a n/a -0,299 n/a -0,083 -0,179 -0,112 -0,304 -0,183 -0,308 -0,171 -0,116 -0,301 -0,168 -0,154 -0,299 -0,198 -0,281 -0,252 -0,23 -0,386 -0,437 -0,317 -0,394 -0,169 -0,531 n/a -0,358 -0,183 -0,464 -0,236 -0,46 -0,289 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,553 -0,216 -0,171 -1,658 -0,083 -0,927
Opy1N n/a -0,235 n/a -0,225 -0,301 -0,172 -0,283 -0,079 -0,13 -0,085 n/a n/a -0,189 -0,207 -0,776 -0,199 n/a n/a -0,26 -0,379 -0,405 n/a n/a 0,854 0,765 0,671 0,71 n/a -0,129 n/a n/a -0,283 -1,167 n/a n/a -0,156 -0,438 -0,263 n/a -0,988 -0,359 n/a -0,31 -0,178 -0,344 n/a n/a -1,103 -0,116 -0,154 0,934 n/a n/a n/a -1,519 n/a -0,626 -1,636 -2,359 -1,643 -0,843 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,999 1,199 0,379 0,819 n/a n/a
Opy1C n/a n/a n/a -0,098 -0,257 -0,247 -0,492 -0,17 n/a n/a -0,381 n/a n/a -0,392 n/a -0,403 -0,183 n/a n/a 0,403 -0,476 1,08 n/a 0,513 0,672 0,402 0,544 n/a 0,457 n/a n/a n/a n/a -1,18 -0,612 n/a 1,124 n/a n/a 1,219 -0,124 n/a n/a -0,186 -0,647 -0,236 -0,074 1,124 n/a n/a 0,68 n/a 2,355 0,911 -0,364 0,869 1,056 0,796 0,482 n/a 0,386 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,844 0,602 0,712 n/a 0,156 0,675 n/a
Osh2 -0,467 -0,444 -0,185 -0,579 -0,338 -0,24 -0,177 -0,266 -0,32 -0,3 -0,182 -0,397 -0,98 -0,247 -1,113 -0,249 -0,077 -0,019 n/a 1,005 n/a 1,973 n/a 0,797 1,214 0,688 n/a n/a 0,688 -1,399 -0,581 -0,403 n/a -0,54 1,065 -0,787 1,042 1,046 1,052 -0,278 -0,356 -0,408 -0,187 -0,402 -0,724 -0,394 -0,847 -0,322 -0,362 -0,467 1,121 -0,318 -0,436 -0,843 -0,358 -1,005 0,937 -0,794 -0,191 0,971 0,989 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,819 1,348 0,779 0,736 0,544 0,517 0,028
Osh3 -0,337 -0,267 -0,054 n/a -0,281 -0,285 -0,333 n/a n/a -0,084 -0,14 -0,135 n/a -0,134 -0,399 -0,84 -0,305 -0,311 -0,372 2,239 -1,526 -1,517 n/a 1,154 -0,387 1,463 -0,035 n/a 1,103 n/a n/a -0,414 n/a 1,122 2,192 -0,71 1,335 -0,322 -0,768 -0,405 -0,279 -0,321 -0,406 -0,376 -0,371 n/a -0,303 2,512 n/a -0,464 2,264 4,501 -0,571 2,05 -0,328 -0,63 -2,126 -0,236 -0,482 -0,768 2,599 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,098 n/a n/a 2,3 n/a 1,261 0,915
Osh3Ct -0,219 -0,77 -0,154 1,988 -0,071 -0,366 -1 -0,135 -0,424 -0,401 -0,348 -0,337 n/a -1,023 1,198 -0,406 -0,249 -0,255 -0,171 13,676 -0,28 -3,541 n/a 0,881 0,875 0,647 1,131 n/a 0,76 -0,659 -0,357 -0,326 -1,521 1,048 1,502 1,575 0,837 0,843 n/a 0,841 -0,325 -0,247 -0,084 -0,823 2,564 -3,093 -0,389 -1,68 n/a 1,16 0,603 -0,49 25,193 1,832 1,053 0,783 0,443 -0,979 -0,558 -0,941 1,048 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,722 0,351 0,636 0,67 0,586 0,654 0,553
Pkh2 -0,938 -0,286 -0,532 -0,137 -0,279 -0,482 -0,432 -0,608 -0,113 n/a -0,512 -0,427 -0,552 -0,216 -0,198 -1,311 -0,573 -0,613 -0,397 n/a -0,479 -0,355 n/a -0,773 -0,196 -0,464 n/a -0,206 -0,32 -0,535 -0,333 -0,839 -0,279 -0,615 -0,21 -0,499 -0,424 -0,726 -0,25 -0,57 -0,483 -0,143 -1,466 -0,486 -0,412 -0,207 -0,571 -0,268 -0,344 -0,513 -0,343 -0,184 -0,557 -0,236 -0,233 -0,442 -0,508 -0,906 -0,297 -0,582 2,385 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -1,356 -0,542 n/a -0,542 -0,502 -0,379 n/a
Plc1 1,83 -0,095 -0,356 -0,357 -0,548 -0,149 -0,354 1,135 -0,588 2,29 -0,316 -0,656 -0,049 -0,389 1,106 1,15 -0,27 -0,124 -0,242 1,541 -0,296 1,13 n/a 1,039 1,029 1,035 n/a -0,354 -0,827 1,798 -0,58 -0,054 1,09 1,687 -0,461 1,319 -0,4 -0,382 -0,996 -0,118 -0,157 -0,131 -0,334 -0,469 1,091 1,523 -0,234 -4,165 1,109 -0,597 1,061 1,542 n/a n/a n/a 1,168 1,076 1,419 1,276 1,186 1,118 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,081 1,148 1,094 1,072 1,05 1,098 1,086
Plc1Ct -0,23 -0,164 n/a -0,216 -0,138 -0,114 -0,543 -0,178 -0,842 -0,207 -0,137 -0,205 -0,349 -0,569 -0,311 -0,081 -0,191 -0,203 -0,105 -0,135 -0,24 -0,184 n/a -0,792 -0,745 0,723 0,728 -0,14 -0,122 -0,246 -0,15 -0,332 -0,13 -0,227 -0,286 -0,005 -0,394 -0,321 -0,136 -0,137 -0,236 -0,239 -0,165 -0,203 -0,216 -0,212 -0,18 -0,732 -0,548 -0,345 -0,608 -0,212 -0,132 -0,214 -0,72 -0,052 -0,252 -0,25 -2,285 -0,178 -0,314 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,753 -0,92 -0,925 -6,866 0,285 1,057 0,862
Psy2 2,72 -0,391 -0,448 -0,514 -0,416 -0,445 -0,061 -0,421 -0,245 n/a -0,496 -0,744 -1,596 -0,794 -1,206 n/a -0,538 -0,511 -0,379 n/a n/a -0,228 n/a -0,62 -0,32 -0,534 n/a -0,327 -0,346 -0,561 -0,425 -0,238 -0,158 -0,58 -0,328 -0,705 -0,657 n/a -0,448 -0,279 n/a -0,372 -1,107 -0,308 -0,326 -0,393 -0,459 -0,6 -0,483 -0,406 -0,639 n/a -0,681 -0,324 -0,292 -0,425 -0,482 n/a -0,277 -0,512 -2,19 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -1,223 -0,648 n/a -0,441 -1,993 -0,522 4,39
Rgc1 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Rom1 -0,276 -0,14 -0,443 -0,128 -0,151 -0,091 -0,131 -0,343 n/a -0,012 n/a -0,114 -2,364 -0,257 -0,229 -0,248 -0,073 -0,151 n/a -0,172 -0,148 -0,213 n/a -0,188 -0,148 -0,154 n/a -0,176 -0,031 -0,168 -0,19 n/a -0,076 -0,143 -0,059 -0,408 -0,164 -0,338 -0,071 -0,041 -0,134 -0,031 -0,168 -0,317 n/a -0,293 -0,414 -0,038 n/a n/a -0,201 -0,304 n/a -0,162 -0,183 -0,043 -0,078 -0,371 -0,049 n/a -0,358 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,222 -0,367 -0,109 -0,233 -0,353 -0,141 -0,117
Rom1Ct_A -0,182 -0,116 -0,293 -0,083 -0,242 -0,055 -0,12 -0,116 -0,091 n/a -0,178 -0,101 n/a -0,236 -0,268 -0,286 -0,03 -0,095 n/a -0,222 -0,114 -0,152 n/a -1,224 -0,218 3,033 -4,737 -0,309 -0,098 -0,035 -0,109 -0,172 -0,13 -0,293 -0,172 -0,24 -0,249 -0,225 n/a -0,101 -0,249 -0,205 -0,235 -0,131 -0,266 -0,1 -0,206 -0,232 -0,348 -0,177 -0,168 -0,143 -0,047 -0,054 -0,128 -0,155 -0,338 -0,183 -0,205 -0,296 -0,299 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 5,896 -0,362 -0,493 -0,73 -0,594 -0,268 -2,032
Rom1Ct_B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Rom2 -0,177 -0,298 -0,033 -0,293 -0,159 -0,11 -0,115 -0,191 -0,478 -0,221 -0,16 -0,043 -0,456 -0,25 -0,371 -0,413 -0,292 -0,13 -0,117 -0,14 -0,142 -0,257 n/a -0,129 -0,256 -0,129 -0,107 -0,377 -0,221 -0,12 -0,173 -0,104 -0,189 -0,251 -0,228 -0,123 -0,206 -0,13 -0,139 -0,164 -0,157 -0,537 -0,117 -0,137 -0,143 -0,345 -0,133 -0,176 -0,106 -0,186 -0,244 -0,28 -0,169 -0,229 -0,118 -0,159 -0,106 -0,125 -0,313 -0,138 -0,123 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,109 -0,127 -0,158 -0,268 -0,234 -0,189 -0,246
Rtt106 -0,19 -0,389 -0,923 -0,218 -0,186 -0,067 -0,12 -0,308 -0,451 -0,265 -0,35 -0,098 -0,715 -0,244 -0,229 -0,604 -0,078 -0,115 -0,146 -0,226 -0,154 -0,167 n/a 4,307 -0,279 1,131 n/a -0,277 -0,368 -0,251 -0,207 -0,226 -0,255 -0,314 -0,268 -0,114 -2,149 -0,51 -0,25 -0,183 -0,14 -0,377 -0,248 -0,228 -0,311 -0,551 -0,329 -0,256 -0,462 -0,246 -0,241 -0,19 -0,278 -0,42 -0,135 -0,618 -0,564 -0,409 -0,312 -0,168 -0,286 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,786 -0,613 -2,361 1,601 1,267 -0,619 1,053
Rtt106Ct -0,13 -0,12 -0,085 -0,172 -0,136 -0,184 -0,14 -0,087 -0,183 -0,171 -0,195 -0,143 -0,387 n/a -0,331 -0,138 -0,126 -0,094 -0,097 -0,069 -0,088 -0,113 n/a -0,539 -0,137 -0,863 -0,228 -0,203 -0,192 -0,122 -0,128 -0,179 -0,186 -0,142 n/a -0,13 -0,295 -0,306 -0,112 -0,17 -0,138 -0,266 -0,077 -0,143 -0,214 -0,264 -0,252 -0,59 -0,163 -0,058 -0,125 -0,127 -0,174 -0,116 -0,251 -0,182 -0,148 -0,36 -0,563 -0,053 -0,249 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,894 -0,318 -0,23 -0,255 -1,918 -0,508 0,729
Sec3 n/a -0,097 -0,49 -0,221 -0,125 -0,181 -0,288 -0,206 -0,152 -0,355 n/a -0,177 214,388 -0,351 -0,364 -0,234 -0,2 -0,121 -0,262 -0,135 -0,147 -0,326 n/a 1,039 -0,594 1,051 0,793 -0,19 -0,217 -0,3 -0,071 -0,407 -0,232 1,666 -0,057 -0,15 -0,267 n/a -0,243 -0,427 -0,319 -0,538 -0,433 -0,132 -0,389 -0,207 -0,501 n/a -0,384 n/a -0,33 -0,268 -0,225 -0,228 -0,303 -0,504 -0,661 -0,124 -0,295 -0,309 -0,79 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,872 n/a -0,841 1,459 1,092 -0,938 0,919
Sec3Ct -0,244 n/a -0,128 -0,136 -0,077 -0,124 -0,118 -0,216 -0,135 -0,161 -0,118 -0,194 -0,793 -0,192 -0,124 -0,368 -0,145 -0,226 -0,277 -0,135 -0,152 -0,12 n/a n/a -0,136 -0,188 n/a n/a -0,168 -0,091 -0,149 -0,204 -0,111 -0,219 -0,093 -0,162 -0,309 -0,199 -0,303 -0,195 -0,281 -0,098 -0,113 -0,256 -0,175 -0,045 -0,128 -0,171 -0,089 -0,282 -0,397 -0,15 -0,07 -0,187 -0,231 -0,22 -0,088 -0,272 -0,097 -0,13 -0,174 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,239 -0,063 -0,222 -0,183 -0,047 -0,282 -0,405
Sip3 -0,099 n/a -0,125 n/a n/a -0,136 -0,241 -0,245 -0,401 -0,735 -0,115 -0,476 n/a -0,236 -5,472 -0,452 -0,299 -0,183 n/a -0,168 -0,499 n/a n/a -1,001 -1,256 n/a -0,862 -0,255 -0,675 -0,235 n/a -0,059 n/a -0,717 -0,284 -0,569 n/a -1,023 2,527 n/a -0,497 -1,658 -0,379 -0,163 -0,514 -1,849 -0,203 -1,238 -0,253 -0,401 n/a 1,396 -0,464 1,368 -0,291 -0,82 2,32 -0,338 -4,519 -0,161 -0,2 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,507 -1,446 1,202 -0,045 1,462 1,143 0,756
Skg3N -0,277 -0,201 -0,238 -0,068 -0,221 -0,216 -0,11 -0,756 -0,206 -0,139 -0,044 -0,251 -0,475 -0,171 -0,373 -0,261 -0,176 -0,12 -0,221 -0,967 -0,251 -0,721 n/a 0,851 -2,31 1,001 n/a n/a 2,696 0,759 n/a -0,61 -9,627 -0,41 -0,657 -0,341 -2,51 -0,396 -0,43 -0,294 -0,291 -0,212 n/a -0,283 -1,085 -0,794 -0,265 -0,416 -0,481 -1,056 n/a -0,711 -0,067 -0,327 -0,417 -0,934 -1,328 -0,684 -0,475 -0,746 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -3,259 0,722 0,84 1,161 0,66 1,028 0,66
Skg3C -0,131 n/a n/a -0,574 -0,085 n/a n/a -0,025 -0,043 -0,103 n/a n/a -0,4 n/a -0,038 -0,256 -0,509 -0,182 n/a n/a n/a -0,113 n/a n/a n/a n/a n/a n/a -0,208 -0,147 n/a -0,116 -0,104 -0,208 n/a n/a -0,167 n/a n/a -0,122 n/a n/a -0,276 n/a n/a -0,302 -0,245 n/a n/a -0,123 -0,155 n/a n/a n/a -0,153 -0,12 -0,106 -0,456 -0,255 n/a -0,299 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,399 n/a -0,133 -0,074 n/a n/a n/a
Skm1 n/a n/a n/a -0,449 -0,583 n/a -0,531 n/a -0,065 -0,274 -0,309 -0,432 n/a n/a n/a n/a n/a -0,336 n/a n/a -0,535 -0,274 n/a -2,576 -0,337 1,17 1,588 n/a -0,569 -0,062 -0,166 n/a n/a -0,166 n/a n/a -0,328 n/a -0,296 -0,476 n/a n/a -0,135 n/a -0,275 -0,314 -0,302 n/a -0,563 -0,103 -0,732 n/a -0,124 -0,151 -0,365 -0,357 -0,583 -0,524 -0,465 -0,432 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,185 1,339 1,228 3,188 1,218 1,939 1,253
Slm1 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Slm1Ct n/a n/a -0,364 n/a -0,465 -0,257 -0,14 -0,245 -0,064 -0,168 -0,43 n/a -0,411 -0,06 -0,382 -0,337 -0,681 n/a -0,214 -0,362 -0,416 -0,547 n/a n/a -0,78 n/a n/a n/a -2,334 n/a -0,239 -0,316 n/a n/a n/a 1,44 -1,248 -0,483 -0,185 -0,646 n/a n/a -0,181 n/a -0,614 n/a 2,895 -1,022 -0,517 -0,3 -0,658 -0,212 -0,045 -1,159 -0,493 -0,767 1,143 -0,767 -0,777 -1,024 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,742 0,692 0,557 1,136 0,658 0,736 n/a
Slm2 -0,557 -0,957 -0,644 -0,29 -0,211 -0,556 -0,388 -0,135 -0,204 -0,145 -0,179 -0,483 n/a -0,155 -0,277 -0,132 -0,252 -0,226 -0,477 -0,557 -0,574 -0,227 n/a -0,444 -0,339 -0,246 -1,303 n/a -1,314 -0,328 -0,764 -0,694 -0,16 -0,175 -0,614 -0,218 -0,099 -0,418 -0,573 -0,305 -0,401 -0,512 -0,306 -0,244 -0,116 -0,294 -0,474 -0,188 -0,268 -0,341 -0,113 -0,271 -0,484 -0,26 -0,759 -0,695 -0,686 -0,292 -0,291 -0,265 -0,446 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,746 -1,339 1,083 -0,825 -0,866 0,646 0,666
Spo14 -0,223 -0,033 -0,234 -0,06 -0,09 -0,098 -0,27 -0,138 -0,138 -0,168 -0,086 -0,099 -0,065 -0,215 -0,219 -0,131 -0,205 -0,195 -0,112 -0,078 -0,04 -0,149 n/a -0,136 -0,09 -0,135 -0,233 -0,083 -0,127 -0,223 -0,125 -0,241 -0,107 -0,115 -0,082 -0,17 -0,118 -0,193 -0,138 -0,331 -0,066 -0,236 -0,115 -0,08 -0,066 -0,186 -0,147 -0,193 -0,109 -0,208 -0,073 -0,281 -0,134 -0,043 -0,145 -0,119 -0,083 -0,104 -0,076 -0,09 -0,184 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,293 -0,179 -0,21 -0,111 -0,175 -0,336 -0,178
Spo14Ct -0,172 -0,008 -0,118 -0,095 -0,102 -0,109 -0,228 -0,128 -0,221 -0,063 -0,014 -0,101 n/a n/a -0,288 -0,11 -0,094 -0,097 -0,089 n/a -0,006 -0,11 n/a -0,08 -0,142 -0,061 -0,184 n/a -0,114 -0,153 -0,163 -0,157 -0,086 -0,134 -0,041 -0,117 -0,098 -0,237 -0,206 -0,026 -0,167 -0,191 -0,313 -0,158 -0,124 -0,127 -0,143 -0,115 -0,063 -0,11 -0,089 -0,126 -0,091 -0,101 -0,079 -0,079 -0,059 -0,07 -0,04 -0,119 -0,22 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,195 -0,397 -0,138 -0,049 -0,212 -0,121 -0,162
Spo71N -0,082 -0,069 -0,218 -0,058 -0,045 n/a -0,045 -0,107 n/a -0,152 -0,04 -0,057 n/a n/a -0,264 -0,533 -0,136 n/a -0,229 -0,222 -0,085 -0,36 n/a -0,49 -0,593 -0,997 -0,387 -0,069 -0,327 -0,148 -0,111 -0,047 -0,474 -0,159 -0,282 -0,137 -0,259 -0,17 -0,208 -0,104 -0,084 n/a n/a -0,147 -0,266 -0,266 -0,145 -0,604 -0,106 -0,238 -0,324 -0,149 -0,098 -0,292 -0,349 -0,217 -0,434 -0,226 -0,181 n/a -0,179 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,486 n/a -0,826 -0,339 -0,701 -43,177 1,132
Spo71M -0,299 -0,197 -0,202 -0,298 -0,226 -0,108 -0,173 -0,196 -0,243 -1,014 n/a -0,225 -0,21 -0,359 -0,511 -0,237 -0,222 -0,319 -0,131 -0,174 -0,118 -0,538 n/a -0,176 n/a n/a n/a n/a -0,146 -0,325 -0,081 -0,312 -12,538 -0,526 -0,744 -0,226 -0,279 -0,021 -0,41 -0,276 -0,195 -0,331 -0,302 -0,03 -0,44 -0,821 -0,291 -0,828 -0,18 -0,24 1,201 -1,789 -0,229 2,357 -0,293 -0,337 -0,211 -0,295 n/a -0,411 -0,267 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,312 -0,291 -0,114 -0,198 -0,268 1,756 -0,649
Spo71C n/a -0,311 -0,171 -0,469 -0,194 -0,211 -0,179 -0,227 -0,399 -0,169 -0,119 -0,238 n/a -0,207 -0,181 -0,322 -0,274 -0,231 n/a -0,237 -0,198 -0,269 n/a -0,21 -0,33 -0,456 n/a n/a -0,329 -0,096 -0,393 -0,186 -0,485 -0,271 -0,222 -0,175 -0,402 -0,267 -0,258 -0,148 -0,439 -0,23 -0,25 -0,274 -0,202 -0,246 -0,206 -0,405 n/a -0,339 -0,178 -0,459 -0,135 -0,232 -0,094 -0,259 -0,378 -0,29 -0,234 -0,308 -0,169 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,175 -0,05 n/a -0,348 -0,317 -0,306 -0,343
Ste5 -0,143 -0,416 -0,608 -0,07 -0,541 -0,236 -0,166 -0,228 -0,42 -0,306 -0,218 -0,257 -0,198 -0,427 -0,487 n/a -0,209 -0,155 n/a -0,217 -0,187 -0,176 n/a -0,183 -0,11 -0,14 n/a -0,26 -0,534 -0,31 -0,438 -0,2 -0,182 -0,184 -0,218 -0,088 -0,404 -0,467 -0,201 -0,239 -0,185 -0,389 -0,307 -0,145 -0,196 -0,187 -0,229 -0,146 -0,211 -0,078 -0,139 -0,192 -0,138 -0,288 -0,308 -0,163 -0,199 -0,375 -0,294 -0,371 -0,24 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,134 -0,232 -0,254 -0,18 -0,242 -0,163 -0,171
Swh1 -0,164 -0,113 -0,045 -0,063 -0,309 -0,153 -0,914 -0,131 -0,492 -0,337 -0,313 -0,122 -0,282 -0,226 -0,692 -0,238 -0,341 n/a n/a 0,986 0,982 n/a n/a 0,605 0,941 0,628 0,691 n/a 0,775 0,939 1,096 -1,18 1,176 0,675 0,59 0,699 1,021 0,498 0,581 0,761 -0,214 -0,308 -0,319 -4,165 1,058 0,973 1,068 0,902 1,066 -3,427 0,938 -1,029 4,867 -1,401 0,718 0,509 0,734 0,688 0,771 0,489 0,576 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,271 0,425 0,709 0,468 0,353 0,45 0,593
Swh1Ct 1,273 1,066 n/a n/a 1,287 n/a n/a -0,408 2,61 1,047 -0,476 -0,201 n/a n/a 0,734 1,057 1,139 -0,552 2,467 0,722 0,713 0,565 n/a 0,12 0,556 0,207 0,779 n/a 0,447 0,244 0,67 n/a n/a 0,698 0,413 0,681 0,658 0,61 n/a 0,771 1,033 0,768 0,956 0,895 0,968 0,876 0,558 0,179 0,41 0,742 0,291 0,647 0,802 0,05 0,33 0,834 0,411 0,676 0,268 0,617 0,585 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,405 0,359 0,217 0,362 n/a 0,355 n/a
Syt1 -0,396 -0,225 n/a n/a -0,098 -0,119 n/a -0,223 -0,343 -0,059 -0,128 -0,322 n/a n/a -0,095 -0,116 -0,129 -0,083 -0,261 -0,217 -0,19 -0,082 n/a -0,127 -0,46 -0,348 -0,173 n/a -0,044 -0,165 -0,541 -0,176 -0,221 -0,07 n/a -0,113 -0,158 -0,529 -0,67 -1,505 -0,354 -0,201 -0,336 -0,247 -0,172 -0,201 -0,195 -0,173 n/a -0,33 -0,216 -0,297 -0,266 -0,691 -0,207 -0,235 -0,288 n/a -0,458 -0,239 -0,129 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,035 -0,184 -0,272 -0,229 -0,232 n/a -0,313
Syt1Ct_A n/a -0,296 -0,531 -0,423 -0,212 -0,148 -0,343 -0,16 -0,206 -0,147 -0,226 -0,307 n/a -0,25 -0,278 -0,07 -0,348 -0,31 -0,311 -0,125 -0,08 -0,219 n/a -0,486 -1,331 -5,77 -7,196 n/a -0,162 n/a -0,135 n/a -0,288 -0,072 -0,113 -0,219 -0,287 n/a -0,204 -0,316 -0,257 -0,12 -0,163 n/a -0,165 -0,294 -0,156 -0,749 -0,494 -0,266 -0,239 -0,175 -0,221 -0,181 -0,324 -0,332 -0,243 -0,302 -0,458 -0,258 -0,06 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 4,432 -0,917 -0,123 -0,252 -0,623 -1,354 -0,091
Syt1Ct_B -0,123 -0,11 n/a -0,162 -0,114 -0,226 n/a n/a -0,162 -0,138 -0,086 -0,163 n/a n/a n/a n/a -0,288 -0,192 -0,082 n/a -0,414 -0,381 n/a -0,187 -0,379 -0,575 n/a n/a -0,301 -0,293 -0,472 n/a -0,061 -0,196 n/a -0,168 -0,293 -0,138 -0,093 -0,307 -0,216 -0,289 -0,178 -0,169 -0,092 -0,203 -0,165 -0,53 -0,281 -0,126 -0,049 n/a -0,303 -0,209 -0,137 -0,179 -0,336 -0,155 -0,095 n/a -0,101 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,419 n/a -0,471 -0,421 n/a n/a -0,462
Tfb1 -0,348 -0,314 -0,364 -0,257 -0,254 -0,4 -0,183 -0,39 -0,254 -0,397 -0,248 -0,186 -0,13 -0,359 -0,256 -0,934 -0,216 -0,359 -0,218 -0,453 -0,236 -0,328 -0,248 -0,128 -0,194 -0,268 n/a n/a -0,225 -0,31 -0,398 -0,345 -0,419 -0,262 -0,48 -0,372 -0,545 -0,353 -0,208 -0,208 -0,207 -0,334 -0,299 -0,235 -0,316 -0,191 -0,252 -1,097 -0,205 -0,297 -0,258 -0,456 -0,774 -0,771 -0,302 -0,542 -0,604 -0,443 -1,033 -0,669 -0,41 -0,156 -0,386 -0,248 -0,209 -0,616 -0,339 -0,713 -0,313 -0,332 -0,356 -0,292 -0,196 -0,577 -0,387 -0,404 -0,042 -0,477 -0,464
Tfb1Ct -0,249 -0,475 -0,164 -0,169 -0,251 -0,268 -0,176 -0,558 -0,146 -0,092 -0,238 -0,114 -1,039 -0,344 -0,373 -0,481 -0,189 -0,168 -0,11 -0,15 -0,217 -0,264 -0,212 -0,255 -0,178 -0,287 n/a n/a -0,152 -0,347 -0,219 -0,291 -0,203 -0,178 -0,17 -0,411 -0,295 -0,227 -0,293 -0,248 -0,47 -0,272 -0,207 -0,144 -0,426 -0,208 -0,314 -0,49 -0,3 -0,312 -0,181 -0,063 -0,217 -0,409 -0,231 -0,201 -0,291 -0,438 -0,381 -0,376 -0,259 -0,258 -0,289 -0,308 -1,176 -0,549 -0,267 -0,252 -0,342 -0,245 -0,385 -0,397 -0,203 -0,489 -0,268 -0,422 -0,678 -0,66 1,942
Tus1 -0,228 -0,046 -0,15 -0,09 -0,07 -0,234 -0,126 -0,146 -0,141 -0,127 -0,297 n/a -0,101 n/a -0,239 -0,234 -0,074 -0,214 -0,086 -0,153 -0,069 -0,08 n/a -0,439 -0,295 -0,23 -0,361 -0,042 -0,079 -0,314 -0,046 -0,227 -0,057 -0,126 -0,183 -0,56 -0,176 -0,268 -0,177 -0,146 -0,113 -0,199 -0,235 -0,444 -0,122 -0,202 -0,084 -0,309 -0,14 -0,122 -0,057 -0,282 -0,145 -0,06 -0,104 -0,048 -0,089 -0,09 -0,098 -0,087 -0,175 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -1,224 -0,107 -0,13 -0,113 -0,206 -0,135 -0,1
Yel1 -0,357 -0,103 -0,191 -0,181 -0,127 -0,107 -0,141 -0,405 -0,106 -0,256 -0,063 -0,176 -0,457 n/a -0,253 -0,157 -0,184 -0,168 -0,09 -0,088 -0,134 -0,16 n/a -0,184 -0,329 -0,223 -0,173 -0,381 -0,132 -1,188 -0,106 -0,223 -0,263 -0,237 -0,173 -0,199 -0,172 -0,102 -0,175 -0,146 -0,122 -0,264 -0,322 -0,215 -0,549 -0,225 -0,294 -0,167 -0,228 -0,326 -0,263 -0,294 -0,329 -0,066 -0,154 -0,229 -0,25 -0,118 -0,12 -0,125 -0,205 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,262 -0,107 -0,099 -0,275 -0,234 -0,281 -0,283
Yhr131c -0,149 -0,557 -0,345 -0,099 -0,155 -0,126 -0,113 -0,407 -0,268 -0,182 n/a -0,184 -0,368 -0,073 -0,252 -0,143 -0,125 -0,214 -0,262 -0,229 -0,114 -0,231 n/a -0,335 -0,362 -0,172 -0,146 -0,875 -0,235 -0,108 -0,091 -0,099 -0,463 -0,152 -0,03 -0,206 -0,203 -0,366 -0,178 -0,179 -0,138 -0,472 -0,212 -0,194 -0,152 -0,085 -0,187 -0,083 -0,15 -0,147 -0,166 -0,164 -0,111 -0,049 -0,15 -0,16 -0,172 -0,291 -0,119 -0,257 -0,158 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,157 -0,278 -0,152 -0,14 -0,084 -0,058 -0,128
Ynl144c n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Ynl144cCt -0,266 -0,134 -0,222 -0,317 -0,198 -0,121 -0,274 -0,207 -0,108 -0,211 -0,12 -0,143 -0,547 -0,147 -0,123 -0,413 -0,097 -0,363 -0,424 -0,441 -0,269 -0,531 n/a -0,224 -0,563 -1,142 -1,281 -0,188 -0,357 -0,148 -0,304 -0,23 -0,146 -0,145 -0,458 -0,154 -0,277 -0,186 -0,207 -0,199 -0,371 -0,124 -0,14 -0,192 -0,208 -0,483 -0,151 -0,303 -0,243 -0,34 -0,156 -0,295 -0,186 -0,064 -0,275 -0,371 -0,309 -0,356 -0,349 -0,205 -0,13 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,556 -0,392 -0,611 -0,827 -0,773 -0,624 0,729
Yrb2 -0,168 -0,243 -0,058 -0,089 -0,245 -0,274 -0,323 -0,195 -0,124 -0,666 -0,24 -0,388 -0,668 -0,431 n/a -1,292 -0,47 -0,182 -0,168 -0,204 -0,261 -0,182 -0,146 -0,127 -0,244 -0,632 n/a n/a -0,196 -0,331 -0,191 -0,468 -0,156 -0,169 -0,182 -0,307 -0,955 -0,18 -0,362 -0,29 -0,243 -0,336 -0,168 -1,1 -0,71 1,596 -0,364 1,366 -0,137 -0,359 -0,265 -0,195 -0,353 -0,502 -0,3 -0,379 -0,378 -0,414 -0,863 -0,248 -0,433 -0,188 -0,123 -0,176 -0,607 1,35 4,806 1,29 -0,254 -0,727 -0,226 -0,631 -0,534 -1,641 0,834 1,563 0,642 0,663 0,622
Ysp1 -0,371 -0,241 -0,11 4,14 -0,323 -0,049 -1,232 -0,428 -0,734 -0,509 -0,311 -0,391 -0,121 -0,176 1,123 -0,368 -0,042 -0,128 -0,359 n/a -0,314 6,499 n/a 1,027 -8,51 0,775 0,539 n/a 1,589 -0,119 -2,119 -0,493 -0,551 -0,521 -2,997 -0,254 1,097 2,709 -0,337 -0,037 -0,922 -0,186 2,157 -0,896 -0,272 3,845 -0,561 1,337 -0,796 -1,992 -3,32 -0,376 -0,924 -0,2 -1,275 -1,915 0,482 3,256 -2,093 -1,031 1,44 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,918 0,848 0,865 0,411 0,766 0,351
Ysp1Ct -1,847 -0,374 n/a -0,222 -0,761 -0,412 1,194 n/a -0,428 -1,203 n/a -0,822 0,939 -0,72 -4,92 -0,878 -0,905 -0,442 n/a -0,492 -0,217 -0,556 n/a 1,132 -0,959 0,822 1,086 n/a 1,718 n/a n/a -1,212 1,135 n/a 0,913 n/a n/a n/a -0,925 -0,546 1,945 2,648 1,754 1,765 -0,28 -1,39 -0,585 0,991 1,108 1,087 1,125 1,728 1,329 -0,753 -1,383 1,417 0,877 1,155 -7,742 -6,435 1,237 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,045 0,634 0,764 0,746 0,559 0,981 1,116
AKT1 2,531 n/a n/a -0,212 -0,037 n/a n/a 0,451 n/a n/a n/a -0,678 -0,142 -0,08 -0,176 n/a 1,094 -0,729 -0,938 1,084 n/a 0,866 n/a 0,389 0,538 0,495 n/a -0,106 -0,864 n/a -0,408 -0,095 0,871 n/a 0,838 -0,081 n/a 1,394 -0,528 0,805 n/a -0,088 -0,612 -0,147 7,953 0,775 n/a 0,69 0,218 0,676 0,884 -0,165 n/a n/a -0,284 -0,299 0,572 0,184 n/a 0,672 1,534 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,244 n/a 0,706 0,544 0,425 0,81 0,711
Dynamin1 -0,78 -0,579 -0,395 -0,907 -0,406 -0,338 -0,376 -0,802 -0,486 2,018 -0,381 -1,025 5,678 -0,187 0,341 -0,724 -0,288 -0,702 -0,286 n/a -0,269 -0,751 n/a 0,184 -0,902 0,443 n/a -0,343 -0,568 -0,198 -0,211 -0,487 -0,437 -0,644 -0,161 -0,368 -0,683 -0,293 -0,377 -0,54 n/a -0,605 -1,67 -0,222 -0,278 -0,134 -0,314 -1,114 n/a -0,612 -0,515 -0,385 -0,503 -0,231 -0,532 -0,258 -0,475 n/a -2,256 1,091 -0,886 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,033 0,904 1,087 0,695 1,389 0,979 0,545
PDK1 0,824 0,835 -0,237 0,648 0,854 0,811 0,747 0,677 0,754 0,835 1,605 0,83 0,91 -0,813 0,718 0,589 -1,221 n/a -3,098 0,371 0,868 0,414 n/a 0,345 0,567 0,363 0,226 0,899 0,413 0,578 0,679 0,662 0,539 0,638 0,399 0,541 0,542 0,422 0,336 0,544 1,141 1,15 0,825 0,665 0,596 0,545 0,968 0,634 0,687 0,772 0,565 0,659 0,486 0,463 0,768 0,735 0,406 0,42 0,411 0,441 0,311 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,41 0,355 0,482 0,4 0,503 0,423 0,494
Plcδ1 1,266 -0,923 1,116 -0,647 -0,376 -1,141 1,188 1,242 -0,269 -0,764 -2,598 -0,77 1,039 0,89 2,102 0,841 -0,294 -0,138 1,739 0,998 -0,714 0,725 n/a 0,579 0,241 0,388 0,784 -1,041 0,912 1,459 -0,442 -0,436 1,154 -0,692 -0,429 0,872 1,308 1,246 1,086 1,068 -1,312 1,098 -0,233 1,042 2,404 0,87 -0,552 -0,894 1,064 1,01 0,777 1,018 1,181 -0,459 0,791 0,533 0,347 0,797 0,799 0,77 0,528 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,453 0,221 0,267 0,296 0,264 0,386 0,454
Pleckstrin -0,345 -0,183 -0,322 -0,121 -0,179 -0,115 -0,547 -1,354 -0,073 -0,207 -0,061 -0,281 -0,831 -0,47 -1,084 -0,382 -0,356 -0,106 -0,245 -0,184 -0,203 -0,385 n/a 0,584 1,353 1,039 0,037 -0,742 -0,489 -0,109 1,425 -0,287 -0,062 -0,471 -0,598 -0,277 -0,188 -0,476 -0,324 -0,244 -0,242 -0,116 -0,249 -0,315 -0,249 -0,58 -0,277 -1,301 -0,138 n/a -0,377 -0,508 -0,173 -0,284 -1,466 2,432 2,803 2,627 -0,151 -0,248 1,272 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,32 0,823 0,456 0,511 0,392 0,434 0,647
SOS1 -0,369 -0,362 -0,196 -0,196 -0,272 -0,237 -1,696 -0,94 -0,343 5,135 -0,192 -0,383 -0,723 -0,245 3,281 n/a -0,294 -0,267 -0,376 -0,212 -0,254 -0,546 n/a 0,86 0,702 0,508 0,658 -0,531 -0,742 -0,272 -0,024 -0,178 -0,724 1,607 -0,239 -0,281 1,784 -0,315 -0,197 -0,304 -0,417 -0,254 -0,457 -0,237 -0,249 -0,831 -0,205 1,046 -0,364 -0,589 -0,414 -0,225 -0,263 -0,171 -0,503 -1,089 -1,164 -0,933 -0,216 -0,17 -0,576 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,761 0,781 0,939 -1,399 0,792 0,669 0,71
EEA1 n/a -0,23 n/a -0,538 n/a -0,19 -0,428 -0,876 -0,116 n/a n/a -0,989 n/a n/a 1,33 -0,791 n/a -0,517 -0,091 0,775 n/a -2,17 n/a n/a 1,459 n/a n/a n/a 0,416 0,961 0,552 0,831 0,504 0,235 0,316 0,261 n/a 0,357 0,362 -1,279 n/a -0,227 n/a n/a n/a n/a n/a n/a n/a -0,843 -1,085 -0,084 -0,578 -0,11 n/a -1,094 n/a n/a -2,556 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,124 n/a -4,306 n/a n/a 1,097 1,042
p40phox -0,363 -0,089 n/a -0,034 -0,036 n/a -0,345 -0,365 -0,519 n/a n/a -0,048 n/a n/a n/a n/a -0,243 -0,156 -0,21 0,902 -0,483 1,348 n/a 1,192 -0,421 1,012 n/a n/a 0,724 0,574 0,314 0,754 0,381 0,221 0,208 n/a 0,265 n/a n/a -0,472 -0,497 -0,24 -0,378 -0,355 -0,163 -0,665 -0,25 n/a n/a n/a -0,43 -0,182 n/a n/a -0,175 -0,123 n/a -0,426 2,49 -0,208 -0,535 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,126 1,045 n/a n/a n/a n/a n/a
Lactadherin 0,699 n/a -0,36 -0,211 -0,272 -0,309 -0,282 -0,184 -0,118 n/a -0,269 -0,144 n/a -0,399 n/a -0,463 -0,243 -0,318 -0,121 -0,623 -0,423 n/a n/a -0,378 -0,317 n/a n/a n/a 0,619 -0,496 -0,376 -0,548 -0,221 -0,282 -0,268 -0,596 -0,346 -0,491 -0,513 0,631 -0,261 -0,34 -0,17 -0,212 -0,404 -0,385 -0,351 -0,284 n/a -0,507 0,878 -0,575 -0,359 -0,617 -0,322 -0,517 -0,509 -0,539 -0,3 -0,449 -0,263 0,546 -0,272 -0,321 -0,28 -0,394 -0,356 -0,21 -0,24 -0,183 -0,221 -0,386 0,514 n/a -0,204 -0,55 n/a -0,276 -0,228
Hsv2 -0,297 -0,093 -0,105 -0,158 -0,133 -0,148 -0,162 -0,201 -0,143 -0,271 -0,141 -0,104 -0,146 -0,186 -0,345 -0,242 -0,141 -0,361 -0,127 0,67 -0,169 -0,293 0,879 -0,193 -0,269 -0,483 n/a n/a 0,559 0,547 0,517 0,516 0,666 0,761 0,574 0,452 0,526 0,541 0,612 -0,239 -0,167 -0,205 -0,128 -0,17 -0,151 -0,168 -0,208 -0,579 -0,186 -0,129 -0,855 -0,388 -0,337 -0,301 -0,26 -0,292 -0,529 -0,415 -0,675 -0,691 -0,835 0,646 0,857 0,777 0,726 0,706 0,817 0,848 0,705 0,756 0,675 0,651 -0,194 -0,314 -0,533 -1,214 0,973 0,938 0,692
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-0,434 -0,307 n/a -0,831 -0,422 -0,758 -0,404 0,651 -0,67 -0,505 -0,63 0,787 3,961 -1,625 -0,918 0,727 1,744 -0,447 n/a -0,937 -0,98 -0,363 -0,297 n/a -0,801 -0,538 -0,59 -0,607 -0,34 -0,552 -0,481 -0,247 -0,302 -0,294 -0,195 -0,414 -0,484 n/a -0,268 -0,358 -0,312 -0,658 0,234
0,711 0,325 n/a 0,124 n/a 0,438 0,239 n/a 0,421 0,562 0,771 0,211 0,368 1,123 0,711 0,374 0,712 0,281 n/a n/a n/a 0,863 n/a 0,31 n/a 0,495 n/a 0,433 -0,389 n/a n/a n/a n/a -2,197 -0,613 -0,445 -0,068 -0,423 -0,326 -0,798 1,11 0,927 0,344
1,665 -0,549 1,073 0,757 0,876 0,283 0,802 1,086 1,569 1,46 n/a 0,396 0,691 -0,906 1,416 0,801 0,924 0,249 0,802 n/a n/a 0,699 0,494 0,754 n/a 0,496 n/a 0,743 -0,242 -0,014 n/a -0,016 -0,121 -0,029 -0,122 -0,106 -0,581 -0,238 -0,08 -0,177 n/a 1,168 2,644
0,527 0,695 0,665 n/a 0,597 0,576 0,602 0,898 0,637 0,631 0,578 0,738 0,567 0,764 0,727 0,894 n/a 0,625 0,66 0,423 0,284 0,621 0,62 n/a n/a 0,769 0,566 0,789 -3,649 0,781 1,482 -0,35 1,12 1,089 -0,381 -2,498 -0,403 1,416 1,045 -0,347 0,93 0,817 0,383
-0,408 -0,38 -0,45 -1,02 -0,328 -0,433 -0,576 -1,226 -0,3 -0,161 -1,38 -0,714 -0,4 -0,454 -1,681 -0,561 3,21 3,133 -0,28 -0,599 -0,412 -0,222 -0,804 -0,4 -0,888 -0,587 -0,645 -0,359 -0,613 -0,648 -0,998 -0,246 -0,265 -0,217 n/a -0,378 -0,155 -0,574 -0,563 -0,088 -0,246 -0,287 n/a
-0,541 -0,369 -0,469 -0,38 -0,79 -0,6 -0,417 -0,689 -0,201 -0,26 -0,747 1,895 -0,272 -0,129 -7,61 -0,446 -0,656 -0,217 -0,303 -0,298 -0,571 -1,026 -0,44 -0,37 -0,411 -1,89 -0,231 -0,298 -0,328 n/a -0,445 -0,109 -0,233 -0,343 -0,024 -0,462 -0,528 -0,226 -0,291 -0,311 -10,348 2,578 0,741
1,847 -1,016 -0,825 1,488 -0,304 0,246 0,856 n/a -1,569 -1,995 -2,447 0,804 0,859 -0,48 1,494 1,643 1,042 n/a 1,39 -1,057 n/a -1,052 1,015 0,842 -1,073 2,728 -0,792 1,411 -0,2 -0,06 -0,149 -0,193 n/a -0,062 n/a -0,173 n/a -0,732 -0,027 -0,136 -0,107 -0,541 -0,697
0,436 0,575 n/a 0,51 n/a n/a 0,273 n/a 0,866 0,841 0,852 0,618 n/a 1,018 0,761 0,567 n/a n/a n/a n/a n/a n/a n/a 0,718 n/a 0,78 n/a 0,421 -0,289 n/a n/a -0,332 -0,425 -0,433 -0,141 -0,107 -0,934 -0,024 -0,132 -0,783 1,545 0,748 0,459
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
0,803 1,027 0,766 n/a n/a n/a n/a n/a 1,035 n/a 0,597 n/a n/a 0,794 1,091 0,733 0,633 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,134 n/a n/a 1,006
-1,863 1,673 -0,082 2,375 1,268 1,023 2,215 n/a 1,461 1,792 1,944 0,149 -0,639 3,541 2,863 1,318 2,192 1,769 3,626 1,303 n/a -1,317 -0,833 2,599 n/a n/a 1,309 -1,034 -0,366 -0,938 n/a n/a n/a n/a n/a -0,398 -0,632 -0,183 -0,215 -0,487 1,117 -1,638 0,641
1,673 1,012 1,882 5,161 1,286 0,944 1,152 1,078 -0,458 0,848 1,175 5,667 2,325 -0,493 -3,306 -0,462 0,983 1,041 1,117 0,892 -0,962 1,12 1,012 -1,45 -0,93 0,951 -1,943 1,251 -0,093 -0,228 n/a n/a -0,134 -0,177 n/a -0,22 -0,548 -0,204 -0,125 -0,41 -0,479 1,367 1,105
-1,216 n/a 1,173 n/a n/a 1,121 0,59 n/a 1,049 0,163 1,63 0,811 n/a 1,073 0,866 0,82 n/a 1,118 1,991 n/a -5,647 -0,286 1,254 1,302 n/a 3,22 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,753 0,492 0,56
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
-0,149 -0,287 -0,218 -0,452 -0,657 -1,097 -0,35 -0,109 -0,284 -0,247 -0,155 -0,688 -0,303 -0,302 -0,142 -0,296 -0,232 -0,31 n/a -0,707 -0,021 -1,427 -0,34 -0,113 -0,113 -0,116 -0,147 -0,091 -0,152 -0,461 -0,315 -0,024 -0,105 -0,05 -0,449 -0,381 -0,095 -0,154 -0,105 -0,429 -0,126 -0,238 -0,083
1,183 -0,883 n/a 1,758 n/a n/a 0,986 -0,461 1,759 -0,954 -1,713 0,697 n/a 3,294 n/a 1,249 n/a n/a 0,369 1,037 -4,461 1,64 1,357 n/a n/a n/a n/a 2,195 n/a -0,173 -0,842 -0,14 -0,396 -0,285 n/a n/a -0,442 -0,36 n/a -0,503 n/a -0,441 n/a
-0,654 -0,312 -0,098 -0,295 -0,21 n/a -0,186 -0,182 -0,093 -0,194 -0,299 -0,148 -0,148 -0,086 -0,062 -0,193 n/a -0,255 -0,381 -0,416 -0,113 n/a -0,313 -0,193 n/a -0,101 -0,196 -0,305 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,405 -0,024 -0,24 n/a
-0,833 -0,221 n/a n/a n/a -0,254 -0,659 1,864 -0,416 -0,541 -1,791 2,675 -0,247 n/a n/a -0,393 1,185 -0,93 n/a -0,598 n/a -0,624 -1,049 n/a n/a n/a -0,419 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,368 -0,194 -1,987
1,366 -0,738 1,109 1,543 1,123 1,021 1,05 0,955 1,096 1,193 1,022 0,885 1,044 1,146 1,023 0,955 -1,16 n/a 1,056 1,04 n/a 1,053 1,183 1,081 n/a 1,065 1,09 1,08 -0,174 -0,116 -0,312 -0,267 -0,369 -0,151 -4,898 -0,159 -0,267 n/a -0,236 -0,931 -0,434 -0,41 0,876
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
0,441 0,733 0,644 0,513 1,209 0,468 0,559 0,934 0,81 0,818 0,432 0,334 0,374 0,777 0,797 0,588 0,634 n/a n/a 0,303 0,106 0,664 0,499 0,63 n/a 0,618 n/a 0,751 n/a n/a -0,121 -0,097 -0,143 -0,141 n/a -0,212 -1,546 -0,139 n/a -0,233 1,227 0,704 0,605
0,668 n/a n/a 0,214 0,677 0,576 0,604 0,56 0,224 0,588 0,119 n/a 0,52 0,904 0,342 0,98 0,204 n/a n/a n/a 0,694 n/a n/a n/a 1,008 0,851 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,881 0,595 0,633
-0,15 -0,239 -0,112 -0,267 -0,574 -0,913 -0,262 -0,342 -0,237 -0,457 -1,762 -1,142 -0,68 -0,352 -0,457 -0,325 -0,254 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,296 -0,269 -0,455 -0,626
-0,192 -0,465 -0,287 2,02 -0,315 -0,442 -0,07 n/a 1,07 -0,362 -0,662 0,49 1,336 -0,452 -0,266 0,315 n/a 1,162 0,745 1,004 0,353 1,184 1,046 n/a n/a 1,54 -0,871 2,468 -0,29 -0,732 -0,341 -0,208 n/a -0,41 -0,04 -1,549 -0,234 -0,277 -0,201 n/a -0,43 -0,289 -0,472
-0,431 0,694 -0,758 -0,772 -0,47 -5,241 -0,304 -4,441 0,923 -0,449 0,683 0,506 0,887 -0,877 0,66 -0,402 -0,099 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,131 -0,26 -0,157 -0,373
-0,228 -0,439 n/a -0,296 -0,093 -0,375 -0,161 -0,842 -0,321 -0,614 -0,731 -1,63 -0,735 -0,168 -0,224 -0,845 -0,44 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,219 -0,204 -0,161 -0,162
-0,248 -0,419 -0,217 -0,334 -0,326 -0,167 -0,342 1,416 -0,224 -0,331 -17,209 2,267 1,487 -0,404 -4,14 2,124 -3,174 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,3 -0,299 -0,673 -1,088
-0,25 -0,162 -0,15 -0,226 -0,14 -0,225 -0,205 -0,139 -0,227 -0,191 -0,185 -0,213 -0,331 -0,206 -0,249 -0,2 -0,264 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,281 -0,148 -0,095 -0,094
-0,31 -1,15 n/a -1,083 -0,527 -1,398 -1,018 1,506 -0,581 -0,113 -0,215 0,888 1,649 -1,317 1,209 0,652 -0,214 -0,485 n/a n/a -0,353 -0,567 4,784 1,246 2,125 1,177 n/a -0,052 n/a -0,383 -0,472 -0,095 -0,56 -0,281 -0,245 -0,265 -1,279 -0,45 -0,287 -0,473 n/a 1,949 -0,189
-0,213 -0,183 -0,206 -0,301 -0,645 -0,587 -0,107 -0,037 -0,075 -0,437 -0,203 -0,215 -0,167 -0,32 -0,283 -0,2 -0,155 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,275 -0,125 -0,136 -0,148
-0,223 -0,18 -0,215 -0,257 -0,116 -0,145 -0,089 -0,268 -0,109 -0,144 -0,118 -0,143 -0,076 -0,218 -0,247 -0,153 -0,065 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,312 -0,171 -0,25 -0,091
-0,21 -0,123 -0,044 -0,16 -0,096 -0,069 -0,111 -0,13 -0,07 -0,124 -0,141 -0,281 -1,459 -0,148 -0,686 -0,169 -0,28 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,224 -0,111 n/a -0,259
-0,33 -0,149 -0,195 -0,201 -0,157 -0,183 -0,307 -0,318 -0,303 -0,179 -0,223 -0,252 -0,228 -0,232 -0,299 -0,317 -0,375 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,232 -0,207 -0,167 -0,373
-0,209 -0,129 n/a -0,167 -0,067 -0,135 -0,128 -0,127 -0,123 -0,087 -0,066 -0,083 -0,079 -0,132 -0,17 -0,096 -0,053 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,164 -0,114 -0,093 -0,148
-0,251 -0,132 -0,16 -0,199 -0,112 -0,114 -0,188 -0,12 -0,14 -0,132 -0,126 -0,116 -0,2 -0,2 -0,14 -0,158 -0,111 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,215 -0,17 -0,166 -0,178
0,684 1,094 0,959 0,766 0,675 1,087 0,962 0,789 0,877 0,791 0,751 0,896 0,91 0,827 0,759 n/a 0,922 0,816 n/a 0,289 n/a 1,049 -0,43 1,073 n/a 0,9 n/a 1,073 -1,069 n/a -1,074 n/a -0,842 n/a n/a 1,066 -0,572 -0,425 -0,394 -0,286 1,519 10,873 -4,678
0,981 1,129 1,203 0,956 0,756 0,926 0,817 0,928 0,811 0,925 0,813 0,836 0,889 0,791 1,013 0,921 0,864 1,594 n/a 1,23 n/a 0,763 0,898 0,637 n/a n/a 1,089 1,752 n/a -0,444 -2,662 -0,223 -0,717 -0,796 -0,443 -0,065 n/a n/a n/a -0,291 -2,123 -0,759 1,178
-0,917 -0,497 1,567 1,129 -0,542 0,904 -1,634 0,984 1,065 1,04 0,94 0,723 0,842 1,047 1,06 -0,095 -0,734 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,166 -0,162 n/a -0,164
-0,582 -0,365 n/a -0,409 -0,388 -0,324 -2,274 -0,428 -1,123 -1,279 -1,122 0,832 -0,837 -0,448 -0,036 -3,152 -0,501 -0,305 n/a n/a n/a n/a 1,12 n/a n/a n/a n/a -0,38 -0,071 n/a n/a -0,068 -0,075 -0,03 -0,352 n/a n/a n/a -0,079 -0,213 -0,243 -0,427 -0,501
n/a 0,151 0,2 n/a 0,771 0,762 0,865 0,842 n/a 0,778 0,69 0,829 0,853 n/a 0,773 n/a 0,509 0,636 n/a 0,549 0,792 0,16 0,651 n/a n/a 0,584 n/a 0,237 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,776 0,77
0,797 0,667 0,366 0,741 0,525 n/a 0,396 0,267 0,221 0,693 0,585 n/a 0,661 0,723 0,317 0,246 0,307 n/a 0,472 0,259 n/a 0,315 n/a 0,182 n/a n/a 0,487 0,233 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,312 n/a 0,786 0,884
0,909 0,247 0,601 0,443 0,591 0,433 0,488 n/a 0,771 -6,727 0,942 0,755 0,467 0,803 0,512 0,728 0,516 n/a n/a 0,773 n/a 5,398 n/a 0,905 n/a -2,083 1,602 1,447 n/a -0,232 n/a -0,085 n/a n/a -0,198 -0,116 -0,115 n/a -0,181 -0,105 -3,29 -1,369 0,992
1,069 -0,735 1,428 -1,022 -0,544 0,426 -2,226 n/a 1,269 1,66 1,112 n/a 4,229 1,448 1,2 1,101 1,144 n/a n/a n/a n/a -0,68 -1,305 n/a n/a -6,71 n/a -0,763 -0,212 n/a -0,098 -0,475 -0,695 -0,356 -0,188 -0,172 n/a -0,316 n/a -1,159 -0,299 3,301 0,561
n/a 0,781 0,762 0,804 1,243 0,805 0,328 n/a 0,775 0,693 0,453 0,21 0,38 0,525 0,551 0,721 0,319 0,504 n/a 0,771 n/a 0,194 0,665 0,742 n/a 0,679 n/a 0,995 -0,504 n/a n/a -1,168 n/a n/a -0,12 n/a n/a -0,673 -0,423 -0,183 0,921 n/a 0,764
-0,408 -0,927 -0,651 -0,917 -0,377 -0,623 -0,244 -0,849 -0,925 -0,902 -0,865 1,002 -1,194 -0,616 -1,034 0,6 1,803 1,426 1,034 1,373 1,314 -0,808 n/a 1,739 -0,531 -0,576 -0,944 2,446 -0,419 -0,532 -0,501 -0,483 -0,301 -0,644 -0,657 n/a -0,262 -0,839 -0,395 -0,194 -0,641 -0,873 1,011
1,078 1,06 1,051 1,062 1,015 1,052 1,038 1,013 1,018 1,019 1,023 1,005 1,035 1,032 1,028 1,02 n/a 1,156 n/a 1,145 n/a 1,212 1,135 1,105 n/a 1,031 n/a n/a -0,31 -0,083 n/a -0,307 -1,313 -1,055 2,819 -0,197 -0,57 -0,381 1,567 -0,161 1,709 1,28 1,014
-0,138 -0,966 1,067 -1,185 -1,086 0,927 -0,567 -3,672 -0,24 -0,739 2,535 0,591 0,717 -1,111 -1,009 0,94 0,205 1,185 0,293 1,201 n/a 0,903 0,898 0,973 n/a 0,449 n/a 1,303 -0,497 -0,725 3,654 -0,175 -0,59 -0,172 -0,114 -0,345 -0,436 -0,273 -0,347 -0,211 -0,435 1,051 0,963
-0,366 -0,845 -0,16 n/a -1,438 -2,428 -0,424 n/a n/a -0,465 n/a n/a -1,452 -0,597 -1,511 1 1,415 0,869 1,176 0,533 1,647 0,562 n/a 0,941 2,022 1,131 1,437 1,546 -0,739 1,331 -0,922 -0,153 -0,409 n/a -0,678 n/a -0,865 n/a -0,294 -0,294 -1,333 -0,737 1,56
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
-0,228 -0,023 n/a -0,511 -0,134 -0,252 -0,398 -0,446 -0,142 -0,099 -0,312 n/a -0,086 -0,261 -0,42 -0,191 -0,385 -0,183 n/a n/a n/a -0,366 -0,202 n/a n/a -0,306 n/a n/a -0,415 n/a -0,641 -0,108 -0,211 -0,088 n/a -0,074 -0,131 n/a -0,125 -0,173 -0,103 -0,183 -0,649
-0,555 -0,859 -0,344 -0,331 -0,219 -0,676 -0,374 n/a -0,224 -0,338 -0,522 1,272 -0,408 -0,345 -0,281 1,511 -1,368 -3,984 n/a n/a n/a -5,013 -0,709 n/a n/a -0,675 -4,341 -1,217 -0,202 n/a n/a -0,066 -0,062 -0,093 -0,272 -0,093 -0,245 -0,048 -0,153 -0,146 n/a -0,277 -0,289
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
-0,103 -0,133 -0,207 -0,179 -0,211 -0,208 -0,253 -0,628 -0,16 -0,099 -0,105 -0,214 -0,287 -0,087 -0,14 -0,169 -0,145 -0,136 -0,12 -0,256 -0,267 -0,143 -0,299 -0,132 -0,293 -0,293 -0,054 n/a -0,062 -1,061 -1,035 -0,247 -0,106 -0,217 -0,196 -0,073 -0,142 -0,384 -0,081 -0,685 -0,318 -0,183 -0,08
-0,649 -0,565 1,119 0,817 -0,284 -2,211 -0,405 -0,647 -0,554 -0,368 0,87 1 0,942 -0,419 1,333 -1,603 0,73 -0,589 n/a -0,505 n/a 0,987 0,618 2,146 n/a -3,394 n/a -0,708 -0,32 -0,112 -0,521 -0,336 -0,201 -0,459 -0,048 -0,321 -0,251 -0,626 -0,094 -0,233 -1,596 -0,74 -3,255
-0,654 -0,37 -0,388 -0,312 -0,07 -0,259 -0,244 -1,477 -0,732 -0,617 -0,952 1,186 -0,483 -1,106 -0,217 -0,234 -0,57 -0,153 n/a n/a -0,1 -0,525 -0,373 -0,351 -0,317 -0,319 n/a n/a -0,257 n/a n/a -0,103 -0,165 n/a -0,086 -0,179 -0,054 -0,129 -0,357 -0,297 -0,231 -0,305 -0,283
-0,498 -0,789 2,437 1,21 n/a -0,627 1,406 1,034 1,62 -2,058 9,684 0,864 0,927 1,838 -0,49 0,953 n/a 1,693 n/a 1,482 1,566 0,901 0,941 0,447 n/a 1,431 n/a 1,869 n/a -1,869 3,854 n/a -0,371 -0,295 n/a -0,551 -0,249 n/a n/a -0,301 2,797 -0,626 0,814
-0,219 -0,084 -0,243 -0,222 -0,184 -0,365 -0,281 -0,164 -0,165 -0,261 -0,225 -0,768 -0,346 -0,126 -0,332 -0,421 -0,327 -0,214 -0,285 -0,101 -0,063 -0,29 -0,344 -0,279 -0,2 -0,233 -0,366 -0,154 -0,229 -0,086 -0,228 -0,108 -0,066 -0,146 -0,38 -0,13 -0,064 -0,14 -0,28 -0,2 -0,781 -0,384 -0,247
1,306 -1,077 1,569 n/a -0,962 1,401 1,451 n/a -0,521 -0,278 -0,98 1,017 0,816 1,209 1,406 -0,913 -0,892 1,084 -0,679 n/a 1,008 n/a 3,803 1,432 n/a -0,139 n/a -0,929 -0,333 n/a -0,272 -0,319 2,153 n/a -0,235 -0,112 n/a -0,091 -0,315 n/a 1,526 -0,28 n/a
-0,689 0,868 0,949 0,56 -2,753 0,8 1,006 0,866 1,239 1,015 0,719 0,581 0,794 1,409 0,891 0,811 0,482 0,676 0,495 0,6 1,489 0,412 1,095 0,719 n/a 0,794 0,571 0,783 -0,53 -0,628 -2,43 -0,194 -1,206 n/a 2,103 -0,246 -0,279 n/a -0,249 -0,222 -0,545 1,489 n/a
-0,117 n/a n/a -0,151 n/a -0,261 -0,333 n/a -0,126 -0,127 -0,191 -0,155 -0,108 -0,151 n/a n/a n/a -0,158 n/a n/a n/a -0,096 -0,15 -0,049 n/a n/a n/a -0,089 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,244 n/a -0,074 -0,152
-2,599 -8,05 -1,192 -0,931 -1,278 n/a 1,54 1,048 1,737 2,263 2,667 1,211 1,275 -0,338 -1,429 1,232 2,05 n/a n/a n/a 1,181 1,058 n/a 1,013 1,864 -4,208 1,446 1,307 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,129 -0,388 n/a 1,17
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
0,638 0,576 0,542 0,877 n/a 0,542 n/a 0,55 0,689 0,073 0,515 0,485 0,407 n/a n/a 0,674 0,53 0,301 n/a 0,115 n/a 0,933 n/a n/a n/a 0,601 0,915 0,206 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,397 -0,578 0,691 0,81
1,668 -0,674 1,102 3,178 -0,244 0,272 -0,704 -1,456 -0,493 2,265 0,591 0,801 0,617 3,711 0,911 n/a 1,749 n/a -6,121 1,231 n/a n/a n/a n/a n/a -0,464 n/a n/a -0,399 n/a n/a -0,204 -0,333 -0,765 -0,088 -0,511 -0,416 -0,408 -0,691 -0,794 -0,417 -0,39 1,003
-0,176 -0,183 -0,255 -0,228 -0,096 -0,414 -0,246 -0,168 -0,132 -0,11 -0,173 -0,517 -0,31 -0,115 -0,32 -0,189 -0,39 -0,189 -0,238 -0,286 -0,255 -0,226 -0,186 -0,123 -0,319 -0,432 -0,143 -0,271 -0,244 n/a -0,618 -0,035 -0,138 -0,311 -0,106 -0,176 n/a -0,094 -0,116 -0,19 -0,252 -0,198 -0,171
-0,119 -0,123 n/a -0,152 -0,137 -0,279 -0,102 -0,066 -0,087 -0,076 -0,164 -0,257 -0,096 -0,106 -0,19 -0,116 -0,167 -0,165 -0,251 -0,185 -0,12 -0,167 -0,124 -0,094 -0,262 -0,104 -0,134 -0,136 -0,137 n/a -0,262 -0,047 -0,037 -0,032 -0,066 -0,109 -0,113 n/a -0,183 -0,155 -0,236 -0,335 -0,094
-0,335 -0,496 -0,515 -0,675 -0,352 -2,812 -0,703 2,2 -0,909 -0,574 -0,343 -2,875 -1,883 -1,576 -0,638 -4,421 -2,413 -0,164 -0,613 14,998 n/a -1,464 -0,325 -0,046 n/a -0,678 n/a -0,337 -0,031 -0,575 n/a -0,084 -0,092 -0,13 -0,103 -0,136 -0,189 -0,051 -0,084 -0,461 n/a -0,054 -0,578
-0,291 -0,119 -0,668 -0,507 -0,191 -4,846 -0,634 n/a -0,451 -0,656 -0,319 -1,422 -0,432 -0,354 -0,916 -0,357 -0,238 -0,287 -0,172 -0,462 -2,549 -0,198 -0,525 -0,645 n/a -0,877 -0,214 -0,156 -0,164 -0,217 -0,147 -0,278 -0,048 n/a -0,018 -0,482 -0,195 -0,068 -0,142 -0,308 5,583 -0,841 -4,931
-0,248 -0,592 -0,347 -0,188 n/a -0,291 -0,351 -0,514 -0,28 -0,253 -0,314 -0,569 -0,396 -0,239 -0,515 -0,354 -0,563 -0,653 -0,413 n/a n/a -0,255 -0,412 n/a n/a -0,239 -0,176 -0,524 -0,24 -1,678 -0,247 -0,066 -0,359 -0,273 -0,206 -0,22 -0,464 n/a -0,315 -0,104 -0,198 -0,148 -0,401
-0,152 -0,193 -0,27 -0,421 -0,272 -0,43 -0,254 -0,206 -0,262 -0,256 -0,323 -0,162 -0,214 -0,565 1,808 -0,334 -0,311 -0,493 -0,625 -0,329 -0,046 -0,372 -0,241 n/a -0,388 -0,066 -0,156 -0,098 -0,286 -0,338 -0,234 -0,354 -0,369 -0,418 -0,235 n/a -0,19 -0,453 -0,197 -0,442 -0,338 -0,289 -0,182
0,576 0,526 0,439 0,614 0,722 0,719 0,52 0,615 0,358 0,776 0,288 0,572 0,607 0,736 0,525 0,558 0,544 0,787 n/a 0,524 n/a n/a n/a 0,558 n/a n/a n/a n/a -0,22 -0,315 n/a n/a -0,412 -0,526 -0,269 -0,243 -0,217 -0,233 -0,143 -0,33 -0,074 1,498 0,261
0,613 0,552 0,241 0,635 0,328 n/a 0,587 n/a 0,366 0,196 n/a n/a n/a 0,372 0,085 0,256 0,605 0,691 0,557 n/a n/a 0,344 n/a 0,832 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,37 n/a n/a
-0,255 -0,256 -0,186 -0,236 -0,098 -0,134 -0,296 -0,405 -0,15 -0,21 -0,298 -0,443 -0,76 -0,424 -0,232 n/a -0,211 -0,395 n/a -0,328 n/a -0,209 -0,387 -0,267 n/a -0,186 -0,1 -0,229 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -1,012 -0,171 -0,659
-0,298 -0,183 -1,529 5,974 -0,816 n/a 1,673 0,738 -1,254 -2,521 -0,317 1,05 0,829 -0,7 -0,63 -1,584 n/a -0,338 n/a n/a n/a n/a -1,582 -0,895 n/a 2,531 -0,456 -0,352 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,221 -0,334 n/a 1,151
-0,093 -0,309 -0,559 -0,416 -0,24 n/a -0,573 -0,423 -0,683 -0,081 -0,072 -0,347 -0,406 -0,346 -0,481 -0,27 -0,362 n/a -0,336 -2,333 -0,534 -0,258 -0,269 n/a n/a n/a -0,355 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1,363
-0,408 -0,55 -0,479 -0,397 -0,176 -0,192 -0,281 -0,342 -0,304 -0,152 -0,323 -0,859 -0,792 -0,259 -0,179 -0,233 -0,208 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,332 -0,012 -0,154 -0,072
-0,321 -0,325 -0,288 -0,515 -0,232 -0,423 -0,286 -0,359 -0,106 n/a -1,109 1,545 -0,397 -0,495 -0,553 -0,308 -0,21 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,404 -0,193 -0,214 -0,232
-0,284 -0,29 -0,367 -0,403 -0,618 -0,509 -0,079 -0,409 -0,182 -0,264 -0,084 -8,457 -0,717 -0,408 -0,217 -0,104 -0,422 -0,203 -1,022 -0,488 -0,405 -0,213 -0,129 -0,307 -0,264 -0,21 -0,271 -0,185 -0,203 -0,076 -0,493 -0,084 -0,103 -0,134 -0,252 -0,069 -0,07 -0,529 -0,158 -1,804 -0,344 -0,327 -0,18
-0,148 -0,11 -0,105 -0,125 -0,162 -0,044 -0,15 -0,241 -0,229 -0,162 -0,164 -0,245 -0,163 -0,101 -0,148 -0,321 -0,121 -0,137 -0,055 -0,24 -0,214 -0,216 -0,13 -0,223 -0,111 -0,101 -0,152 -0,129 -0,258 n/a -1,109 -0,099 -0,057 -0,237 -0,557 -0,276 -0,198 -0,514 -0,235 -0,129 -0,372 -0,218 -0,828
-0,119 -0,077 -0,113 -0,104 -0,162 -0,232 -0,026 -0,152 -0,143 -0,262 -0,196 -0,263 -0,127 -0,264 -0,15 -0,171 -0,307 -0,281 -0,31 -0,184 -0,078 -0,16 -0,105 -0,193 -0,104 -0,306 -0,092 -0,116 -0,127 -0,247 -0,549 -0,064 -0,022 -0,186 -0,323 n/a -0,132 -0,275 -0,257 -0,242 -0,349 -0,123 n/a
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
-0,9 -0,456 -0,589 -0,638 -0,405 1,752 -2,283 -2,448 -1,843 -0,602 -1,288 1,183 1,079 -0,955 2,249 1,791 -1,838 0,987 -0,384 -0,531 -0,89 -4,142 1,985 1,231 -1,192 0,99 -0,564 1,835 -0,259 1,602 -0,112 -0,335 -0,033 -0,13 -0,184 -0,118 -0,127 -0,558 -0,212 -0,235 -0,275 -1,216 -1,968
1,06 0,762 2,913 -1,284 -0,431 0,798 1,122 0,82 0,482 -0,695 0,5 0,559 0,745 0,958 0,986 0,519 0,939 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,274 -0,13 -0,239 -0,306
0,706 1,101 0,558 0,751 -1,097 0,725 0,259 n/a 0,954 0,718 0,397 0,565 0,372 0,893 0,798 0,566 0,524 0,88 0,855 0,549 0,784 0,689 0,266 0,585 0,412 0,161 n/a 0,635 -0,512 1,352 -0,326 -0,64 -0,61 -0,365 -0,088 -1,294 1,282 -0,18 -0,436 -0,112 0,579 0,308 0,551
0,853 0,782 0,687 1,052 1,076 0,875 0,781 n/a 1,061 1,101 0,744 n/a 0,806 n/a 1,132 1,188 1,03 n/a 0,878 n/a n/a 1,04 0,726 1,111 n/a 1,102 n/a 1,098 0,273 1,085 3,121 -0,706 -0,642 n/a n/a 1,505 n/a -0,192 3,577 -0,569 1,541 2,625 0,824
0,328 0,279 0,709 0,65 0,894 1,024 0,715 n/a 0,921 0,805 0,44 0,643 0,405 1,512 0,586 1,203 0,417 n/a n/a 0,205 0,504 0,656 0,534 0,676 0,426 0,621 n/a 0,475 0,905 0,993 -0,555 1,308 1,007 1,054 -0,144 n/a 0,631 6,659 0,768 n/a -0,696 1,172 0,994
1,228 -0,779 1,209 1,111 -0,095 0,893 2,212 n/a 1,311 1,334 1,101 1,235 0,336 1,186 0,733 1,09 1,01 0,55 n/a 2,082 n/a 1 0,535 0,867 n/a n/a n/a n/a -0,388 -0,104 -0,331 -0,476 -0,399 -0,115 -0,23 n/a -1,129 -0,687 -0,12 -0,631 0,895 0,652 n/a
0,404 0,452 0,351 0,466 0,492 0,55 0,496 0,687 0,501 0,331 0,401 0,448 0,398 0,211 0,405 0,214 0,489 0,422 0,224 0,344 0,301 0,363 0,382 0,382 0,362 0,378 0,348 0,564 0,402 0,521 0,616 1,129 0,917 0,72 0,897 0,731 0,811 0,787 0,364 0,969 0,582 0,534 0,555
0,392 0,374 0,186 0,453 0,388 0,273 0,388 0,512 0,333 0,435 0,197 n/a 0,339 0,432 0,415 0,342 0,425 0,476 0,644 0,755 0,179 0,63 0,26 0,399 0,534 0,648 0,821 0,535 1,073 -0,625 -1,469 -0,991 0,93 -1,549 1,677 -0,618 -0,885 -5,418 0,636 -0,213 0,433 0,946 0,743
0,365 0,421 0,699 0,233 1,11 0,792 0,974 0,798 1,024 1,082 0,348 0,387 0,899 1,14 1,055 0,83 n/a 0,712 0,932 1,147 0,774 0,464 0,557 0,923 0,736 0,381 1,164 0,574 -0,474 -0,228 -0,146 -0,614 -0,698 -0,118 -0,108 n/a -0,963 -0,162 -0,076 -0,23 1,003 1,457 0,944
1,151 0,908 1,068 0,816 0,698 0,497 0,605 0,515 0,563 0,672 0,671 0,576 0,548 0,61 0,566 0,55 0,595 0,652 0,419 0,612 n/a 0,667 0,454 0,628 0,558 0,602 0,476 0,533 -0,347 -0,867 -0,229 -0,249 -0,771 -0,317 -0,189 -0,266 -0,717 -0,235 -0,589 -0,488 1,411 1,265 0,774
-2,225 1,117 n/a 1,05 1,048 1,43 1,283 1,116 1,207 n/a 1,326 0,681 1,131 1,3 n/a 1,133 n/a 0,414 n/a n/a 0,988 0,465 0,475 0,914 n/a 0,971 0,379 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,398 7,846 1,03 n/a
-1,048 1,794 1,115 -0,319 1,093 0,751 1,067 n/a 1,123 -3,085 1,065 n/a 1,789 1,084 n/a 1,061 2,982 0,2 -1,176 1,124 n/a 0,966 1,172 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,819 n/a n/a 1,02
-0,287 -0,255 -0,288 -0,391 0,212 0,576 -0,215 -0,28 -0,239 n/a -0,344 -0,545 -0,206 -0,24 -0,183 -0,263 -0,391 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0,781 n/a 0,726 0,576
1,16 1,278 1,062 -0,697 -0,29 1,09 -0,496 -1,081 -0,357 -0,367 -1,509 -0,973 1,59 -0,628 1,385 n/a -0,992 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -0,227 -0,239 -0,886 -0,485
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Table V.6: Table summarizing the 45 PH domains that were previously tested for their
lipid-binding properties. The first column gives the name of the PH domain as used in this
study. The second and third columns indicate if the interaction with lipid was detected
in previous studies (referred to with PMID) and in this study with high confidence (0
< TI < 2), respectively. The last column summarizes the match of our data with the
literature-based benchmark dataset.
Domains previously 
analysed
Previously known 
interaction (reference PMID)
Interaction with LiMA (0 < 
TI < 2)
False positive (fp)
True positives (tp)
False negative (fn)
True negative (tn)
Ask10 yes (15023338) yes tp
Atg26 yes (15023338) yes tp
Bem3 no (15023338) yes fp
Boi2 yes (15023338) yes tp
Bud4 yes (15023338) yes tp
Caf120N yes (15023338) yes tp
Cdc24 yes (15023338) yes tp
Cla4 yes (15023338) yes tp
Exo84 no (21119626) yes fp
Ira2_2 yes (21119626) yes tp
Num1 yes (15023338) yes tp
Nup2 yes (21119626) yes tp
Nvj2 no (15023338) yes fp
Opy1N yes (22562153) yes tp
Opy1C yes (22562153, 15023338) yes tp
Osh2 yes (15023338) yes tp
Osh3 yes (15023338) yes tp
Pkh2 yes (21119626) yes tp
Psy2 yes (21119626) yes tp
Sip3 yes (15023338) yes tp
Skg3N yes (15023338) yes tp
Skm1 yes (15023338) yes tp
Slm2 yes (15023338) yes tp
Spo71M yes (15023338) yes tp
Ste5 yes (21119626) yes tp
Swh1 yes (15023338) yes tp
Yrb2 yes (21119626) yes tp
Ysp1 no (15023338) yes fp
Bem2_1 yes (15023338) no fn
Boi1 yes (15023338) no fn
Dcp1 no (21119626) no tn
Las17 yes (21119626) no fn
Mdr1 yes (21119626) no fn
Rgc1 yes (15023338) no fn
Rom2 yes (12015967) no fn
Skg3C yes (15023338) no fn
Slm1 yes (21119626) no fn
Spo14 yes (15023338) no fn
Spo71C yes (15023338) no fn
Syt1 yes (15023338) no fn
Tfb1 yes (15909982) no fn
Tus1 no (15023338) no tn
Yel1 yes (15023338) no fn
Yhr131c yes (15023338) no fn
Ynl144c no (15023338) no tn
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Table V.7: Table summarizing current knowledge on PH domains preferred ligands. The
first column indicate the name of the PH domain as used in this study. The second
column indicate whether the PH domain was used in the context of its full protein or
alone in the litterature. The third column indicates the lipid ligand that was found to be
recruited by the PH domain in the litterature. The fourth column indicates the PMID
of the publication in which this interaction was found. Cells marked in green indicate
interactions that we reproduced and the red ones, interactions that we did not reproduce.
LBD name LBD/full length protein Lipid ligand Reference (PMID)
PI(3,4,5)P3 9079675 / 18954143 
PI(3,4)P2 9079675
PI(4,5)P2 9079675 / 18954143
PS 21402788
PI(3,4)P2 9765310
PI(4,5)P2 9765310
PI(3,4,5)P3 9765310
PI(3,4)P2 21971045 / 9895304
PI(3,4,5)P3 21971045  / 9895304 
PS 21971045
PI(4,5)P2 9895304
PI(3)P 9895304
PI(4,5)P2 18954143
PI(3,4,5)P3 18954143
Pleckstrin PH (C-term) PI(3,4)P2 15698571
PA 17486115
PI(4,5)P2 9135150
Boi1 PH PI(4,5)P2 12097146
PI(4,5)P2 15023338
PI(3,5)P2 15023338
PI(3)P 15023338
PI(4)P 15023338
PI(4,5)P2 15023338
PI(3,5)P2 15023338
PI(3,4,5)P3 21119626
PS 21119626
Num1 PH PI(4,5)P2 15023338
Opy1N PH PI(4,5)P2 22562153
Opy1C PH PI(4,5)P2 22562153
PI(4,5)P2 15023338
PI(3,5)P2 15023338
PI(3)P 15023338
PI(4)P 15023338
PI(4,5)P2 15023338
PI(3,5)P2 15023338
PI(3)P 15023338
PI(4)P 15023338
Ste5 PH PI(4,5)P2 16847350
PI(4,5)P2 15023338
PI(3,5)P2 15023338
PI(3)P 15023338
PI(4)P 15023338
EEA1 FYVE PI(3)P 9702203
PI(3)P 22704557
PI(3,5)P2 22704557
Lactadherin C2 PS 18160406 / 18187657
p40phox PX PI(3)P 11684018
PDK1
PH
AKT1 PH
PH
Dynamin1
Plcδ1
PH
PH
PH
PH
PHCla4
Boi2
SOS1
Ira2_2
Osh2
Hsv2
Swh1 PH
PROPPIN
PH
PH
Skm1
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Table V.8: Table summarizing the PH domains for which new high confident (0 < TI <
2) interactions were detected. Novel interaction indicates the 34 PH domains that were
not previously reported to interact with any membranes. New specificity/mechanism
indicates the 26 PH domains for which the interaction with lipids was previously reported
and for which we propose additional specificity and/or binding mechanism. The 30 PH
domains that did not interact with any liposomes with high confidence in this study are
in italics. (n/a: not available)
Domain name Novelty
Ask10 new specificity/mechanism
Atg26 new specificity/mechanism
Atg26Ct novel interaction
Avo1 novel interaction
Bem2_1
Bem2_2 novel interaction
Bem3 novel interaction
Bem3Ct novel interaction
Boi1
Boi2 new specificity/mechanism
Bud4 new specificity/mechanism
Bud4Ct novel interaction
Caf120N new specificity/mechanism
Caf120NCt n/a
Caf120C
Caf120CCt novel interaction
Caf120_tandem
Caf120Ct_tandem novel interaction
Cdc24 new specificity/mechanism
Cdc24Ct
Cla4 new specificity/mechanism
Cla4Ct novel interaction
Dcp1
Exo84 novel interaction
Exo84Ct novel interaction
Ira1
Ira1_CRAL-TRIO-PH novel interaction
Ira2_1
Ira2_2 new specificity/mechanism
Ira2Ct
Ira2_CRAL-TRIO-PH
Ira2Ct_CRAL-TRIO-PH
Las17
Mdr1
Mdr1Ct
Num1 new specificity/mechanism
Num1Ct novel interaction
Nup2 novel interaction
Nvj2 novel interaction
Opy1N new specificity/mechanism
Opy1C new specificity/mechanism
Osh2 new specificity/mechanism
Osh3 new specificity/mechanism
Osh3Ct novel interaction
Pkh2 novel interaction
Plc1 novel interaction
Plc1Ct novel interaction
Psy2 novel interaction
Rgc1 
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Rom1
Rom1Ct_A novel interaction
Rom1Ct_B
Rom2
Rtt106 novel interaction
Rtt106Ct novel interaction
Sec3 new specificity/mechanism
Sec3Ct
Sip3 new specificity/mechanism
Skg3N new specificity/mechanism
Skg3C
Skm1 new specificity/mechanism
Slm1
Slm1Ct novel interaction
Slm2 new specificity/mechanism
Spo14
Spo14Ct
Spo71N new specificity/mechanism
Spo71M novel interaction
Spo71C
Ste5 novel interaction
Swh1 new specificity/mechanism
Swh1Ct novel interaction
Syt1
Syt1Ct_A novel interaction
Syt1Ct_B novel interaction
Tfb1
Tfb1Ct novel interaction
Tus1
Yel1
Yhr131c
Ynl144c
Ynl144cCt novel interaction
Yrb2 novel interaction
Ysp1 novel interaction
Ysp1Ct novel interaction
AKT1 new specificity/mechanism
Dynamin1 new specificity/mechanism
PDK1 new specificity/mechanism
Plcδ1 new specificity/mechanism
Pleckstrin new specificity/mechanism
SOS1 new specificity/mechanism
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Table V.9: Table listing the PH domains used for the validation experiments. First column
indicates the PH domain name as used in this study. The second column indicates its
Uniprot ID. The third column the species it belongs to. The fourth column its amino acid
sequence. The columns 5 to 11 indicate the protein concentration used in the respective
experiments (mentioned by the column header).
Fig. 5b Fig. 5d,e Fig. 5f Fig. 3b/Fig. S3b Fig. 4b Fig. S1b,c Fig. S1i
OSBP1 P22059 Homo sapiens GSAREGWLFKWTNYIKGYQRRWFVLSNGLLSYYRSKAEMRHTCRGTINLATANITVED
SCNFIISNGGAQTYHLKASSEVERQRWVTALELAKA
1,71 - - - - - -
OSBP2 LDSFEGWLLKWTNYLKGYQRRWFVLGNGLLSYYRNQGEMAHTCRGTINLSTAHIDTED
SCGILLTSGARSYHLKASSEVDRQQWITALELAKA
1,87 2,19 - - - 6,15 -
OSBP2 R262L LDSFEGWLLKWTNYLKGYQRRWFVLGNGLLSYYRNQGEMAHTCRGTINLSTAHIDTED
SCGILLTSGARSYHLKASSEVDLQQWITALELAKA
- 2,09 - - - 5,90 -
OSBPL3 Q9H4L5 Homo sapiens PPVQKGFLLKKRKWPLKGWHKRFFYLDKGILKYAKSQTDIEREKLHGCIDVGLSVMSVK
KSSKCIDLDTEEHIYHLKVKSEEVFDEWVSKLRHHRM
1,70 - - - - - -
OSBPL5 Q9H0X9 Homo sapiens VVIMADSLKIRGTLKSWTKLWCVLKPGVLLIYKTPKVGQWVGTVLLHCCELIERPSKKDG
FCFKLFHPLDQSVWAVKGPKGESVGSITQPLPSSYLIFRAASESDGRCWLDALELALR
1,51 - - - - - -
OSBPL7 Q9BZF2 Homo sapiens RQEGHLLKKRKWPLKGWHKRYFVLEDGILHYATTRQDITKGKLHGSIDVRLSVMSINKK
AQRIDLDTEDNIYHLKIKSQDLFQSWVAQLRAHR
1,76 - - - - - -
OSBPL8 Q9BZF1 Homo sapiens VIVMADWLKIRGTLKSWTKLWCVLKPGVLLIYKTQKNGQWVGTVLLNACEIIERPSKKDG
FCFKLFHPLEQSIWAVKGPKGEAVGSITQPLPSSYLIIRATSESDGRCWMDALELALK
1,48 - - - - - -
OSBPL10 Q9BXB5 Homo sapiens PALEGVLSKYTNLLQGWQNRYFVLDFEAGILQYFVNEQSKHQKPRGVLSLSGAIVSLSD
EAPHMLVVYSANGEMFKLRAADAKEKQFWVTQLRACAK
1,87 - - - - - -
OSBPL11 Q9BXB4 Homo sapiens NVYGYLMKYTNLVTGWQYRFFVLNNEAGLLEYFVNEQSRNQKPRGTLQLAGAVISPSD
EDSHTFTVNAASGEQYKLRATDAKERQHWVSRLQICTQ
1,91 - - - - - -
CERT MSDNQSWNSSGSEEDPETESGPPVERCGVLSKWTNYIHGWQDRWVVLKNNALSYYK
SEDETEYGCRGSICLSKAVITPHDFDECRFDISVNDSVWYLRAQDPDHRQQWIDAIEQH
KTESGYG
1,42 1,42 - - - - -
CERT R98Q MSDNQSWNSSGSEEDPETESGPPVERCGVLSKWTNYIHGWQDRWVVLKNNALSYYK
SEDETEYGCRGSICLSKAVITPHDFDECRFDISVNDSVWYLQAQDPDHRQQWIDAIEQH
KTESGYG
- 1,41 - - - - -
FAPP1 MEGVLYKWTNYLTGWQPRWFVLDNGILSYYDSQDDVCKGSKGSIKMAVCEIKVHSADN
TRMELIIPGEQHFYMKAVNAAERQRWLVALGSSKACLTDT
1,60 1,60 2,07 - - - -
FAPP1 T9A MEGVLYKWANYLTGWQPRWFVLDNGILSYYDSQDDVCKGSKGSIKMAVCEIKVHSADN
TRMELIIPGEQHFYMKAVNAAERQRWLVALGSSKACLTDT
- - 2,11 - - - -
FAPP1 K74Q MEGVLYKWTNYLTGWQPRWFVLDNGILSYYDSQDDVCKGSKGSIKMAVCEIKVHSADN
TRMELIIPGEQHFYMQAVNAAERQRWLVALGSSKACLTDT
- 1,35 - - - - -
Swh1 LHEAPTYKGYLKKWTNFAQGYKLRWFILSSDGKLSYYIDQADTKNACRGSLNMSSCSL
HLDSSEKLKFEIIGGNNGVIRWHLKGNHPIETNRWVWAIQGAIRYAKDREILL
- 1,24 - 1,44 - 4,75 0.1-7.0
Swh1 K360Q LHEAPTYKGYLKKWTNFAQGYKLRWFILSSDGKLSYYIDQADTKNACRGSLNMSSCSL
HLDSSEKLKFEIIGGNNGVIRWHLQGNHPIETNRWVWAIQGAIRYAKDREILL
- 1,36 - - - 5,05 -
Num1 Q00402 Saccharomyces 
cerevisiae
NEPSIIPALTQTVIGEYLFKYYPRLGPFGFESRHERFFWVHPYTLTLYWSASNPILENPAN
TKTKGVAILGVESVTDPNPYPTGLYHKSIVVTTETRTIKFTCPTRQRHNIWYNSLRYLLQR
NMQGISLE
- - - 1,39 - 7,01 -
Opy1N MIAGATAPSSQHEILIASNLIKKPSTSQNKTPTAQSSSGNNGAADGAPQGYHHHHHHHR
HLWWPRTTDHQYWCVLRKNQFAYYKTRDEREAISVIPRFDILNFKISELDGILTVYTPSK
DLIFKFPRGQNEKVGMELMHNWKIALEKFLSSPSGN
- - - 9,10 - - -
Opy1C DPRNAEHQVCSGILYTKVKKKKLFNRAKWQKFNVELTNTSFNLYSFKTGKLKKSIKLDKII
DCIELDNNSKMKNDDTNFALITFDERLSFKAANDQDMVDWIINFKSGILIRKKLKAENI
- - - 11,10 - - -
Osh3 P38713 Saccharomyces 
cerevisiae
QDMLFRVGQGRYLQGYLLKKRRKRLQGFKKRFFTLDFRYGTLSYYLNDHNQTCRGEIV
ISLSSVSANKKDKIIIIDSGMEVWVLKATTKENWQSWVDALQTCFDDQFEDK
- - - 5,92 - - -
Plcδ1 P10688 Rattus norvegicus HGLQDDPDLQALLKGSQLLKVKSSSWRRERFYKLQEDCKTIWQESRKVMRSPESQLF
SIEDIQEVRMGHRTEGLEKFARDIPEDRCFSIVFKDQRNTLDLIAPSPADAQHWVQGLRK
IIHHSGSMDQRQK
- - - 1,86 - - -
SOS1 Q07889 Homo sapiens QQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLM
ICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSA
KSAEEKNNWMAALISLQYRSTLE
- - - 6,43 - - -
Yrb2 P40517 Saccharomyces 
cerevisiae
GEESEECIYQVNAKLYQLSNIKEGWKERGVGIIKINKSKDDVEKTRIVMRSRGILKVILNIQ
LVKGFTVQKGFTGSLQSEKFIRLLAVDDNGDPAQYAIKTGKKETTDELYNIIVKSVPK
- - - 2,10 - - -
Nup2 P32499 Saccharomyces 
cerevisiae
EEDEVALFSQKAKLMTFNAETKSYDSRGVGEMKLLKKKDDPSKVRLLCRSDGMGNVLL
NATVVDSFKYEPLAPGNDNLIKAPTVAADGKLVTYIVKFKQKEEGRSFTKAIEDAKKEMK
- - - 3,48 - - -
Avo1 Q08236 Saccharomyces 
cerevisiae
DNFQDLFTGAYHKYKVWRRQQMSFINKHERTLAIDGDYIYIVPPEGRIHWHDNVKTKSL
HISQVVLVKKSKRVPEHFKIFVRREGQDDIKRYYFEAVSGQECTEIVTRLQNLLSAYRMN
HK
- - - 9,34 - - -
Slm1Ct G0SAZ0 Chaetomium 
thermophilum
HYACQEIRAGLLERKSKYLKSYTPGWYVLSPTHLHEFKSADKTQAPVMSLYLPEQKLGS
HSEEGSSSNKFILKGRQTGHMHRGHTWVFRAESHDTMMAWYEDIKALTERTPEER
- - - 15,52 - - -
AKT1 E17K P31749 Homo sapiens MSDVAIVKEGWLHKRGKYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVA
QCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEE
MDF
- - - - 5,29 6,90 -
AKT1 P31749 Homo sapiens MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVA
QCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEE
MDF
- - - - - 6,73 0.05-6.0
Cdc24 P11433 Saccharomyces 
cerevisiae
ISKFGELLYFDKVFISTTNSSSEPEREFEVYLFEKIIILFSEVVTKKSASSLILKKKSSTSASI
SASNITDNNGSPHHSYHKRHSNSSSSNNIHLSSSSAAAIIHSSTNSSDNNSNNSSSSSLF
KLSANEPKLDLRGRIMIMNLNQIIPQNNRSLNITWESIKEQGNFLLKFKNEETRDNWSSC
LQQLIHDLKNEQFKARHHSST
- - - - - 4,55 -
Osh2 Q12451 Saccharomyces 
cerevisiae
ASSKPPTYKGFLKKWTNFAHGYKLRWFILSGDGNLSYYKDQSHVDRPRGTLKVSTCRL
HIDSSEKLNFELLGGITGTTRWRLKGNHPIETTRWVNAIQSAIRFAKDKEILNKKKAVP
- - - - - 5,21 -
Cla4 P48562 Saccharomyces 
cerevisiae
TSTSKKKSGWVSYKDDGILSFIWQKRYLMLHDSYVALYKNDKQNDDAILKIPLTSIISVSR
TQLKQYCFELVRCSDRNSVSSGSSSSLNVSSDSNSKKSIYIATKTESDLHSWLDAIFAKC
PLLSGVSSPTNFTHK
- - - - - 6,17 -
Bem3 P32873 Saccharomyces 
cerevisiae
MDDNVKDGSLLLRRPKTLTGNSTWRVRYGILRDDVLQLFDKNQLTETIKLRQSSIELIPNL
PEDRFGTRNGFLITEHKKSGLSTSTKYYICTETSKERELWLSAFSDYIDPSQS
- - - - - 5,45 -
Boi2 P39969 Saccharomyces 
cerevisiae
SISVKEAMKDADFSGWMSKKGSGAMSTWKTRFFTLHGTRLSYFSSTTDTRERGLIDITA
HRVVPAKEDDKLVSLYAASTGKGRYCFKLLPPQPGSKKGLTFTQPRTHYFAVDNKEEMR
GWMAALIKTTIDIDTSVP
- - - - - - 0.2-7.0
Q9HB20 Homo sapiens
Q9Y5P4 Homo sapiens
PH domain name PH domain sequence (AA)Uniprot ID Species
Q969R2 Homo sapiens
P38271 Saccharomyces 
cerevisiae
P35845 Saccharomyces 
cerevisiae
Protein concentration [µM]
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Figure 1: The PH domains are divided into three groups according to their cooperativity
class (class 1, 2a and 2b). The barplots show NBI values measured with liposome types
composed of single PIP liposomes (yellow bars), or mixtures liposomes (colour/white
bars). The colour bars represent predicted cooperative interactions - the combinations
composed of lipids physiological in S. cerevisiae in blue, the combinations composed of
at least one lipid non-physiological in S. cerevisiae in green, and the white bars indicate
non-cooperative interactions or no binding. The horizontal line represents the binding
threshold (NBI = 0.037). Only data of PH domains with at least one cooperativity event
of physiological lipids are shown. (§) indicates that the lipid is not physiological in S.
cerevisiae, # indicates di erent variants of DOPI35P2 lipid.
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Figure S4
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Figure 2: (A) Landscape of cooperating lipids in the targeting of mammalian PH domains
to liposomal membranes. (B) Validation of interactions of PH domains with cooperating
lipids using dose response experiments. The table gives the results of dose response
experiments (heatmaps) for 31 selected PH domain-lipids combination pairs and compares
them with the results obtained from the PH domain screen (barplots and TI values). The
results are divided into four groups: true positive, true negative, false positive and false
negative. Each cell in the heatmaps gives the NBI value (violet) measured for the PH
domain interaction with liposomes containing the indicated concentration of signalling
lipids. The grey colour indicates missing data. Values are mean (n Ø 2). The bar plots
show mean NBI values (+/- s.d.) measured in the PH domain screen for each liposome
type containing indicated signalling lipids or their combinations (black, NBI Ø 0.037;
white, NBI < 0.037). The concentration of signalling lipids in liposomes used in the PH
domain screen was 10 mol %, except the combination of DOPI45P2 and DHS1P, for which
data from liposomes containing 7 mol % of both lipids are shown. The TI values for each
experiment is given under the bar plots. In the group of false negative, the PH domains
recognizing cooperating lipids at lower lipid concentrations are marked with a star.
27
Part V Chapter 6 – Relative to Part II Chapter 6 – Relative to Part II
True positive
Yrb2
0.1
0.2
0.5
0.0
N
B
I 0.3
0.4
PHS1P
PI(4,5)P2 +
+
+
-
-
+
0 3 6 10
0
3
6
10
PHS1P [%]
P
I(4
,5
)P
2 
[%
]
0.00
0.06
0.03
NBIScreen data Dose response
Swh1
0 3 6 10
PHS1P [%]
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0.00
0.10
0.20
NBIDose response
PHS1P
PI(4,5)P2 +
+
+
-
-
+
0.2
0.4
0.6
0.0
N
B
I
Screen data
Opy1N
0 3 6 10
DHS1P [%]
0
3
6
P
I(4
,5
)P
2 
[%
]
0.00
0.04
0.08
NBI
Dose responseScreen data
DHS1P
PI(4,5)P2 +
+
+
-
-
+
0.1
0.2
0.3
0.0
N
B
I
Slm1Ct
DHS1P
PI(4,5)P2 +
+
+
-
-
+
0.05
0.10
0.00
N
B
I
Screen data
0 3 6 10
DHS1P [%]
0
3
6
P
I(4
,5
)P
2 
[%
]
0.00
0.05
0.10
NBI
Dose response
Opy1C
0.1
0.2
0.3
0.0
N
B
I
DHS1P
PI(4,5)P2 +
+
+
-
-
+
0 3 6 10
0
3
6
DHS1P [%]
P
I(4
,5
)P
2 
[%
]
0.00
0.05
0.15
0.10
NBI
Screen data Dose response
Swh1
0.05
0.10
0.00
0.15
N
B
I
DHS1P
PI(4,5)P2 +
+
+
-
-
+
0 3 6 10
0
3
6
DHS1P [%]
 P
I(4
,5
)P
2 
[%
]
0.00
0.09
0.18
NBI
Dose responseScreen data
Slm1Ct
PS
PI(4,5)P2 +
+
+
-
-
+
0.2
0.4
0.0
0.6
N
B
I
Screen data
0 10
PS [%]
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0.00
0.10
0.20
NBIDose response
Yrb2
PS
PI(4,5)P2 +
+
+
-
-
+
0.05
0.10
0.00
0.15
N
B
I
Screen data
10
0 10
PS [%]
0
3
6
P
I(4
,5
)P
2 
[%
]
0.00
0.02
0.04
NBI
Dose response
Figure S3
Osh3
0.10
0.15
0.20
0.00
N
B
I
0.05
PS
PI(4,5)P2 +
+
+
-
-
+
Screen data
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
PS [%]
0.00
0.03
0.06
NBI
Dose response
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
PHS [%]
0.1
0.2
0.3
NBI
0.0
0.1
0.2
0.3
0.0
N
B
I
PHS
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
Nup2 Avo1
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
PHS [%]
0.0
0.2
0.4
NBI
1
2
3
0
N
B
I
PHS
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
0.0
0.1
0.2
NBI
0.3
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
Phytocer [%]
Yrb2
0.04
0.06
0.00
N
B
I
0.02
Phytocer
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
Yrb2
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
PHS [%]
0.0
0.1
0.2
NBI
0.2
0.4
0.0
N
B
I
PHS
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
Yrb2
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
DHS [%]
0.0
0.05
0.10
NBI
0.02
0.04
0.06
0.00
N
B
I
DHS
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
A
B
AKT1
Dynamin1
PDK1
Pleckstrin
SOS1
3OFį
P
E
:P
A
_1
0:
10
P
I(4
)P
:S
1P
_1
0:
10
P
I(4
)P
:P
hy
to
ce
r_
10
:1
0
P
I(4
)P
:P
H
S
1P
_1
0:
10
P
I(4
)P
:P
S
_1
0:
10
P
I(4
)P
:D
ih
yd
ro
ce
r_
10
:1
0
P
I(4
,5
)P
2:
S
1P
_1
0:
10
P
I(4
,5
)P
2:
P
hy
to
ce
r_
10
:1
0
P
I(4
,5
)P
2:
P
H
S
_1
0:
10
P
I(4
,5
)P
2:
S
ph
in
go
si
ne
_1
0:
10
P
I(4
,5
)P
2:
D
H
S
1P
_7
:7
P
I(4
,5
)P
2:
D
ih
yd
ro
ce
r_
10
:1
0
P
I(4
,5
)P
2:
C
er
1P
_1
0:
10
P
I(4
,5
)P
2:
D
H
S
1P
_1
0:
10
P
I(4
,5
)P
2:
D
H
S
_1
0:
10
P
I(3
)P
:S
1P
_1
0:
10
P
I(3
)P
:P
hy
to
ce
r_
10
:1
0
P
I(3
)P
:P
S
_1
0:
10
P
I(3
)P
:D
ih
yd
ro
ce
r_
10
:1
0
P
I(3
,4
,5
)P
3:
S
1P
_1
0:
10
P
I(3
,4
,5
)P
3:
P
S
_1
0:
10
P
I(3
,4
,5
)P
3:
D
ih
yd
ro
ce
r_
10
:1
0
P
I(3
,4
,5
)P
3:
P
hy
to
ce
r_
10
:1
0
P
I(3
,4
,5
)P
3:
C
er
1P
_1
0:
10
P
I(3
,4
,5
)P
3:
D
H
S
1P
_1
0:
10
P
I(3
,4
,5
)P
3:
P
H
S
1P
_1
0:
10
P
I(3
,4
,5
)P
3:
D
H
S
_1
0:
10
P
I(3
,4
)P
2:
S
1P
_1
0:
10
P
I(3
,4
)P
2:
P
S
_1
0:
10
P
I(3
,4
)P
2:
D
ih
yd
ro
ce
r_
10
:1
0
P
I(3
,4
)P
2:
P
H
S
1P
_1
0:
10
P
I(3
,4
)P
2:
P
H
S
_1
0:
10
P
I(3
)P
:C
er
_1
0:
10
P
I(3
)P
:C
er
1P
_1
0:
10
P
I(3
)P
:D
H
S
_1
0:
10
P
I(3
)P
:P
H
S
_1
0:
10
P
I(3
)P
:S
ph
in
go
si
ne
_1
0:
10
P
I(4
)P
:D
H
S
1P
_1
0:
10
P
I(5
)P
:S
ph
in
go
si
ne
_1
0:
10
P
I(5
)P
:S
1P
_1
0:
10
P
I(5
)P
:P
hy
to
ce
r_
10
:1
0
P
I(5
)P
:P
H
S
_1
0:
10
P
I(5
)P
:P
S
_1
0:
10
P
I(5
)P
:D
H
S
_1
0:
10
P
I(5
)P
:C
er
_1
0:
10
P
I(5
)P
:C
er
1P
_1
0:
10 TI
Incomplete data
No cooperation/
no binding
Strong
Weak
Negative
Strong
Weak
Positive
TI  0.6 -0.6 -0.3 TI  0.6  0.6 -0.9 TI  0.8  0.9 -0.3
TI  0.8  0.8 -0.3 TI  0.1 -0.8 -0.5 TI  0.7  0.7 -0.3
TI  0.5  n/a  n/a TI  0.8 -0.6 -0.2 TI  0.4  1.5 -0.3
TI  1.0  3.1 -0.1 TI  0.9  0.6 -0.3 TI  0.5 -0.6 -0.2
TI  0.8 -0.6 -0.1 TI  1.1 -0.6 -0.2
28
Chapter 6 – Relative to Part II
Swh1
PS
PI(4,5)P2 +
+
+
-
-
+
0.1
0.2
0.3
0.0
0.4
0.5
N
B
I
Screen data Dose response
0 10
PS [%]
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0.00
0.10
0.20
NBI
False positive
Slm1Ct
0.2
0.4
0.0
N
B
I
PHS1P
PI(4,5)P2 +
+
+
-
-
+
Screen data
0 3 6 10
PHS1P [%]
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0.05
0.10
0.00
NBIDose response
Yrb2
0.025
0.050
0.075
0.000
N
B
I
DHS1P
PI(3,5)P2 +
+
+
-
-
+
Screen data
0
3
6
10
0 3 6 10
DHS1P [%]
0.002
0.004
0.000
NBI
P
I(3
,5
)P
2 
[%
]
Dose response
Osh3
0.025
0.050
0.075
0.000
N
B
I
0.100
0.125
DHS1P
PI(4,5)P2 +
+
+
-
-
+
Screen data
0
3
6
P
I(4
,5
)P
2 
[%
]
0 3 6 10
DHS1P [%]
0.005
0.015
0.00
0.010
NBI
Dose response
False negative
Opy1N
0.2
0.4
0.6
0.0
N
B
I
PHS1P
PI(4,5)P2 +
+
+
-
-
+
Screen data
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
PHS1P [%]
0.00
0.08
0.16
NBIDose response
Num1*
0.1
0.2
0.3
0.0
N
B
I
0.4
PS
PI(4,5)P2 +
+
+
-
-
+
Screen data
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
PS [%]
0.00
0.02
0.04
NBIDose response
Opy1N
0.02
0.04
0.06
0.00
N
B
I
PS
PI(4,5)P2 +
+
+
-
-
+
Screen data
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
PS [%]
0.00
0.04
0.12
NBI
Dose response
SOS1*
0.2
0.4
0.0
N
B
I
PS
PI(4,5)P2 +
+
+
-
-
+
Screen data
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
PS [%]
0.00
0.03
0.06
NBIDose response
* PH domains recognizing cooperating
   lipids at lower concentration
Legend:
Interaction No binding
SOS1
DHS1P
PI(4,5)P2 +
+
+
-
-
+
0.1
0.2
0.3
0.4
0.0
N
B
I
Screen data
0.00
0.03
0.06
0 3 6 10
DHS1P [%]
0
3
6
P
I(4
,5
)P
2 
[%
]
NBI
Dose response
Num1*
0.2
0.4
0.6
0.0
N
B
I
PHS1P
PI(4,5)P2 +
+
+
-
-
+
Screen data
0 3 6 10
PHS1P [%]
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0.00
0.03
0.06
NBI
Dose response
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
Phytocer [%]
0.0
0.1
0.2
NBI
Nup2
0.05
0.10
0.00
N
B
I
Phytocer
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
Phytocer [%]
0.1
0.3
0.5
NBI
1.0
1.5
0.0
N
B
I
0.5
Phytocer
PI(4,5)P2 +
+
+
-
-
+
Avo1
Screen data Dose response
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 3 6 10
PHS [%]
0.0
0.2
0.3
NBI
3OFį*
1
2
3
0
N
B
I
PHS
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
Avo1
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
DHS [%]
0.1
0.2
0.3
NBI
0.5
1.0
1.5
0.0
N
B
I
DHS
PI(4,5)P2 +
+
+
-
-
+
Screen data Dose response
Nup2
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
DHS [%]
0.00
0.02
0.04
NBIScreen data
0.05
0.10
0.00
N
B
I
DHS
PI(4,5)P2 +
+
+
-
-
+
Dose response
3OFį
0
3
6
10
P
I(4
,5
)P
2 
[%
]
0 10
DHS [%]
0.0
0.2
0.3
NBI
DHS
PI(4,5)P2 +
+
+
-
-
+
1.0
2.0
0.0
N
B
I
Screen data Dose response
True negative
Num1
0.15
0.20
0.25
0.00
N
B
I
0.10
0.05
DHS1P
PI(4,5)P2 +
+
+
-
-
+
Screen data
0
3
6
P
I(4
,5
)P
2 
[%
]
0 3 6 10
DHS1P [%]
0.02
0.04
0.00
NBI
Dose response
TI  0.5  n/a -0.1 TI  1.4 -0.2 -0.3 TI  1.7 -0.4 -0.3
TI  0.9  0.9 -0.8 TI  0.8  0.7 -0.3 TI  0.7  0.7 -0.3
TI  0.7  0.6 -0.2 TI  1.1  0.9 -0.5 TI  0.5  0.5 -0.4
TI  -0.1  3.1 -0.2 TI  0.9  0.6 -0.8 TI  0.5  0.4  1.1
TI  0.6  0.6  1.5 TI  0.8  0.7   n/a TI  -1.6  3.1 -0.2
TI  0.4  0.4 -0.9 TI  0.8  1.0 -0.7
29
Chapter 7
Relative to Part III
30
Chapter 7 – Relative to Part III
Table V.1: Table summarizing the arguments required by the name matching module.
The first column indicates the argument name, the second column indicates whether the
argument is mandatory, the third column gives an example of input value, the fourth
column mentions whether a default value is already included within the module and the
fifth column gives a short description of what kind of value is expected to be given.
Argument)name
!n YES fg_input No)default)value The)absolute)path)of)a)chemical)name)file)properly)formatted
!o YES) nm_fg_output No)default)value Name)matching)output)(corresponding)to)background)
!u OPTIONAL STITCH STITCH Universe)used)for)the)name)matching
!a OPTIONAL TRUE TRUE Fuzzy)name)matching)algorithm
!e OPTIONAL TRUE TRUE Heuristic)name)matching)algorithm
!s OPTIONAL TRUE FALSE Additional)synonym)output
!!verbose OPTIONAL 2 2 Verbose)level
REQUIRED? Example Default)value Description
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Table V.2: Table summarizing the arguments required by the enrichment module. The
first column indicates the argument name, the second column indicates whether the argu-
ment is mandatory, the third column gives an example of input value, the fourth column
mentions whether a default value is already included within the module and the fifth
column gives a short description of what kind of value is expected to be given.
Argument)name REQUIRED? Example Default)value Description
!f YES nm_fg_output No)default)value name)matching)output)corresponding)to)foreground)
!b OPTIONAL) ALL ALL Either)name)matching)output)corresponding)to)background,)or)“ALL”
!d YES drugJsideJeffects No)default)value Database)form)which)biological)terms)will)be)extracted
!o YES enrJenrJoutput No)default)value Enrichment)module)output)containing)the)enriched)biological)terms
!p YES enrJannJoutput No)default)value Enrichment)module)output))containing)the)chemical/biological)terms)annotations
!m OPTIONAL fisher fisher Method)used)to)perform)the)enrichment
!a OPTIONAL 0.05 0.05 Enrichment)significance)level
!c OPTIONAL FDR FDR FDR)correction)method
!!versbose OPTIONAL 2 2 Verbose)level
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Table V.3: Table summarizing the arguments required by the visualization module. The
first column indicates the argument name, the second column indicates whether the argu-
ment is mandatory, the third column gives an example of input value, the fourth column
mentions whether a default value is already included within the module and the fifth
column gives a short description of what kind of value is expected to be given.
Argument)name
!i YES enr.enr.output No)default)value The)enrichment)table)outputted)by)the)enrichment)module
!o YES res.viz.tab.html No)default)value File)name)(.html))where)the)table)containing)links)to)external)resources)will)be)generated
REQUIRED Example Default)value Description
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